<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.science.org/doi/10.1126/science.abl4784');</script>

        <script> var body_html = '<body > <div > <div > <div > <div > <div > <div > <div > <div > <div > <div > <span >Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header > <div ><div ><div ><div ><div ><div ><div ><a ><div >science</div></a></div></div><div ><div ><a ><div >science advances</div></a></div></div><div ><div ><a ><div >science immunology</div></a></div></div><div ><div ><a ><div >science robotics</div></a></div></div><div ><div ><a ><div >science signaling</div></a></div></div><div ><div ><a ><div >science translational medicine</div></a></div></div><div ><div ><a ><div >science partner journals</div></a></div></div></div></div></div></div></div> <div > <div > <div > <div > <div ><div ><div ><label >Searching:</label><div ><div ><div >AnywhereScienceScience AdvancesScience ImmunologyScience RoboticsScience SignalingScience Translational Medicine</div></div></div></div><div > <a ><u>Advanced Search</u></a> </div></div></div> </div> </div> </div> <div > <div > <div > <h6 >Trending Terms:</h6> <ul > <li > covid-19 </li> <li > climate </li> <li > science policy </li> <li > genome editing </li> <li > batteries </li> </ul> </div> </div> </div> </div> </header><div ><div ><div > <div > <div > <ul > <li > Current Issue </li> <li > First release papers </li> <li > Archive </li> <li > <div > About <div > About Science Mission Scope Editors Advisory Boards Editorial Policies Information for Authors Information for Reviewers Journal Metrics Staff Contact Us </div> </div> </li> </ul> </div> <div > <ul > <li > Submit manuscript </li> <li > <div > More </div> </li> </ul> </div> </div> GET OUR E-ALERTS </div></div></div> <main > <div ><div ><div ><div ><div > <div >HomeScienceVol. 374, No. 6575<span >An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19</span></div><div >Back To Vol. 374, No. 6575</div> </div> <article ><section ><header><div ><div ><div ><div >OPEN ACCESS</div><div >Research Article</div><div >CORONAVIRUS</div></div><div ><div > <div >Share on</div> </div></div></div><h1 >An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19</h1><div >Dafydd R. Owen https://orcid.org/0000-0003-3106-7809 [email protected], Charlotte M. N. Allerton https://orcid.org/0000-0001-8665-159X, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt https://orcid.org/0000-0001-5572-6771, Britton Boras https://orcid.org/0000-0003-3624-9177, … Show All … , Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman https://orcid.org/0000-0001-6164-7500, Alyssa Dantonio, Li Di https://orcid.org/0000-0001-6117-9022, Heather Eng https://orcid.org/0000-0002-2914-3967, RoseAnn Ferre https://orcid.org/0000-0001-7462-1879, Ketan S. Gajiwala, Scott A. Gibson, Samantha E. Greasley https://orcid.org/0000-0002-7978-6477, Brett L. Hurst https://orcid.org/0000-0003-1025-5878, Eugene P. Kadar https://orcid.org/0000-0003-3724-6517, Amit S. Kalgutkar https://orcid.org/0000-0001-9701-756X, Jack C. Lee, Jisun Lee https://orcid.org/0000-0003-1750-0063, Wei Liu, Stephen W. Mason, Stephen Noell https://orcid.org/0000-0003-3054-2575, Jonathan J. Novak https://orcid.org/0000-0002-3635-7955, R. Scott Obach https://orcid.org/0000-0002-6604-401X, Kevin Ogilvie, Nandini C. Patel https://orcid.org/0000-0002-2735-7662, Martin Pettersson https://orcid.org/0000-0001-8748-9539, Devendra K. Rai, Matthew R. Reese https://orcid.org/0000-0002-1066-2652, Matthew F. Sammons https://orcid.org/0000-0001-6472-0646, Jean G. Sathish, Ravi Shankar P. Singh https://orcid.org/0000-0001-6298-8219, Claire M. Steppan https://orcid.org/0000-0002-2609-7707, Al E. Stewart, Jamison B. Tuttle, Lawrence Updyke, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, and Yuao Zhu Show Fewer</div><div >Science • 2 Nov 2021 • Vol 374, Issue 6575 • pp. 1586-1593 • DOI: 10.1126/science.abl4784</div><div ><div > <div > <a ><div ><div ><h6>PREVIOUS ARTICLE</h6><div>Pol IV and RDR2: A two-RNA-polymerase machine that produces double-stranded RNA</div></div></div>Previous</a><a ><div ><div ><h6>NEXT ARTICLE</h6><div>Enhancement of lithium-mediated ammonia synthesis by addition of oxygen</div></div></div>Next</a> </div> </div></div></div></header><div ><div ><section ><h2 >Path to another drug against COVID-19</h2><div >The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs. Owen <i>et al</i>. report the discovery and characterization of a drug against the main protease involved in the cleavage of polyproteins involved in viral replication. The drug, PF-07321332, can be administered orally, has good selectivity and safety profiles, and protects against infection in a mouse model. In a phase 1 clinical trial, the drug reached concentrations expected to inhibit the virus based on in vitro studies. It also inhibited other coronaviruses, including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus, and could be in the armory against future viral threats. —VV</div></section><section ><h2 >Abstract</h2><div >The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.</div></section></div></div></section><section ><div ><div >Human coronavirus infections are common, with at least four examples (229E, NL63, OC43, and HKU1) now considered endemic (<a ><i>1</i></a>). However, the emergence within the past 20 years of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 as novel human coronaviruses has signaled the substantial threat potential of this viral class. The catastrophic SARS-CoV-2 outbreak of 2019 has resulted in 235 million confirmed cases of COVID-19 causing &gt;5.2 million deaths globally as of December 2021. SARS-CoV-2 is a highly infectious, RNA beta-coronavirus that can cause life-threatening viral pneumonia in the most serious cases. Although effective COVID-19 vaccines have been developed within unprecedented timelines, a large number of people are either unable due to preexisting medical conditions or unwilling to be vaccinated, and global access challenges remain. Limited therapeutic options are available to those who are infected. Oral SARS-CoV-2–specific therapeutics are urgently needed to prevent more severe disease, hospitalization, and death. Treatment may also reduce the period of infectivity. Repurposing of approved drugs in the search for small-molecule antiviral agents that target SARS-CoV-2 has thus far been minimally effective (<a ><i>2</i></a>, <a ><i>3</i></a>). Viral RNA–dependent RNA polymerase inhibitors such as molnupiravir and AT-527 are currently undergoing clinical trials for the treatment of COVID-19 (<a ><i>4</i></a>, <a ><i>5</i></a>).</div><div >The SARS-CoV-2 genome encodes two polyproteins, pp1a and pp1ab, and four structural proteins (<a ><i>6</i></a>, <a ><i>7</i></a>). The polyproteins are cleaved by the critical SARS-CoV-2 main protease (M<sup>pro</sup>, also referred to as 3CL protease) at 11 different sites to yield shorter, nonstructural proteins vital to viral replication (<a ><i>8</i></a>, <a ><i>9</i></a>). The coronavirus M<sup>pro</sup> is a three-domain cysteine protease that features a Cys145-His41 catalytic dyad located in the cleft between domains I and II. Several common features are shared among M<sup>pro</sup> substrates, including the presence of a Gln residue at P1 [using Schechter-Berger nomenclature (<a ><i>10</i></a>)]. No known human cysteine protease cleaves after Gln, thus offering potential selectivity for this viral target over the human proteome (<a ><i>11</i></a>–<a ><i>13</i></a>). Viral proteases are tractable targets for small-molecule oral therapies in the treatment of HIV and HCV (<a ><i>14</i></a>, <a ><i>15</i></a>). Moreover, a recent report has demonstrated oral activity of an M<sup>pro</sup> inhibitor in a transgenic mouse model of SARS-CoV-2 infection (<a ><i>16</i></a>). Given the pivotal role of SARS-CoV-2 M<sup>pro</sup> in viral replication, its potential for mechanistic safety, and the expected lack of spike protein variant resistance challenges, SARS-CoV-2 M<sup>pro</sup> inhibition represents an attractive small-molecule approach for an oral antiviral therapy to treat COVID-19.</div><div >An effort to identify inhibitors of the SARS-CoV-1 M<sup>pro</sup> in response to the 2002 SARS outbreak led to the identification of PF-00835231 (<b>1</b>; Fig. 1) as a potent inhibitor of recombinant SARS-CoV-1 M<sup>pro</sup> in a fluorescence resonance energy transfer (FRET)–based substrate cleavage assay (<a ><i>17</i></a>). PF-00835231 also demonstrated potent inhibition [inhibition constant (<i>K</i><sub>i</sub>) = 0.271 nM] of recombinant SARS-CoV-2 M<sup>pro</sup>, which is expected given that the SARS-CoV-1 and SARS-CoV-2 M<sup>pro</sup> share 100% sequence homology across their respective substrate-binding sites (<a ><i>18</i></a>). Antiviral activity against SARS-CoV-2 was also observed with PF-00835231 [half-maximal effective concentration (EC<sub>50</sub>) of 231 nM] by monitoring the cytopathic effect (CPE) in epithelial Vero E6 cells. Because Vero E6 cells express high levels of the efflux transporter P-glycoprotein, for which <b>1</b> is a substrate (<a ><i>17</i></a>, <a ><i>19</i></a>), antiviral assays in this cell line were conducted in the presence of the P-glycoprotein efflux inhibitor CP-100356 (<a ><i>20</i></a>). TMPRSS2 expression was not detected in the Vero E6 cells by quantitative reverse transcription polymerase chain reaction. PF-07304814, the phosphate prodrug form of PF-00835231, is currently under investigation as an intravenous treatment option for COVID-19 in hospitalized patients (<a ><i>20</i></a>).</div><div >To improve upon the low passive absorptive permeability (<i>P</i><sub>app</sub> &lt; 0.207 × 10<sup>−6</sup> cm/s) (<a ><i>21</i></a>) and poor oral absorption of <b>1</b> in animals, we aimed to remove the hydrogen bond donor (HBD) of the P1′ α-hydroxymethyl ketone moiety in <b>1</b> (Fig. 2A) because increased HBD count has been shown to be correlated with poor oral bioavailability (<a ><i>22</i></a>). To this end, we pursued two functional groups precedented as covalent warheads for cysteine proteases in parallel: nitriles (<a ><i>23</i></a>, <a ><i>24</i></a>) and benzothiazol-2-yl ketones (<a ><i>25</i></a>, <a ><i>26</i></a>). The nitrile compound <b>2</b> demonstrated an increase in rat oral absorption [oral bioavailability (<i>F</i>) = 7.6% and fraction of oral dose absorbed from the gastrointestinal tract (<i>F</i><sub>a</sub> × <i>F</i><sub>g</sub>) = 38%] (<a ><i>27</i></a>) while maintaining reasonable metabolic stability [intrinsic clearance (CL<sub>int</sub>)] against oxidative metabolism in human liver microsomes (HLMs) (<a ><i>28</i></a>) relative to <b>1</b> (Fig. 1). However, the in vitro FRET M<sup>pro</sup> potency (<i>K</i><sub>i</sub> = 27.7 nM) and SARS-CoV-2 antiviral activity (EC<sub>50</sub> = 1364 nM) of <b>2</b> was inferior to <b>1</b>. Introduction of a 6,6-dimethyl-3-azabicyclo[3.1.0]hexane as a cyclic leucine mimetic at P2 (Fig. 2B) removed the HBD from the P2/P3 amide linkage. Analog <b>3</b>, resulting from the combination of this cyclic P2 fragment with a P1′ benzothiazolyl ketone, displayed high <i>P</i><sub>app</sub> (10.3 × 10<sup>−6</sup> cm/s). The reduced biochemical SARS-CoV-2 M<sup>pro</sup> inhibitory potency of <b>3</b> (<i>K</i><sub>i</sub> = 230 nM) relative to other reported benzothiazole-2-yl SARS-CoV-2 M<sup>pro</sup> inhibitors (<a ><i>29</i></a>) containing leucine P2 groups can be rationalized from the binding mode observed for <b>3</b> (<a >Fig. 2C</a>). Although the 6,6-dimethyl-3-azabicyclo[3.1.0]hexane effectively fills the lipophilic S2 pocket formed by Met49, Met169, His41, and Gln189, productive hydrogen bonding of the ligand backbone to Gln189 is no longer possible (<a >Fig. 2C</a>). The inferior SARS-CoV-2 M<sup>pro</sup> potency and the high CL<sub>int</sub> (337 μl/min/mg) precluded further investments in compound <b>3</b>. Similar to <b>1</b>, the P3 indole of <b>3</b> does not protrude into the S3 pocket (<a >Fig. 2, A and C</a>). To better occupy the S3 pocket, we introduced branched, acyclic P3 groups. The methanesulfonamide in compound <b>4</b> extends underneath Gln189, productively engaging P3 pocket residues and achieving improved hydrogen-bonding interactions with the Glu166 backbone (<a >Fig. 2D</a>) relative to <b>1</b> and <b>3</b>. Compound <b>4</b> demonstrated improved SARS-CoV-2 M<sup>pro</sup> biochemical potency (<i>K</i><sub>i</sub> = 7.93 nM), Vero E6 antiviral activity (EC<sub>50</sub> = 909 nM), and HLM CL<sub>int</sub> (127 μl/min/mg) relative to <b>3</b> (<a >Fig. 1</a>). Examination of the rat pharmacokinetics of <b>4</b> also revealed improvements in oral absorption (<i>F</i> = 10%, <i>F</i><sub>a</sub> × <i>F</i><sub>g</sub> = 84%) (<a >Fig. 1</a>). An effort to identify alternate P3 capping groups to sulfonamide led to trifluoroacetamide <b>5</b>. Compound <b>5</b> exhibited comparable biochemical potency (<i>K</i><sub>i</sub> = 12.1 nM) to <b>4</b> but with greatly improved SARS-CoV-2 Vero E6 antiviral activity (EC<sub>50</sub> = 85.3 nM and <i>P</i><sub>app</sub> = 13.1 × 10<sup>−6</sup> cm/sec) as well as increased metabolic stability in HLMs (CL<sub>int</sub> = 30.3 μl/min/mg) (<a >Fig. 1</a>). <b>5</b> also shows greatly improved oral pharmacokinetics in both rats (<i>F</i> = 33%, <i>F</i><sub>a</sub> × <i>F</i><sub>g</sub> = 100%) (<a >Fig. 1</a>) and monkeys (<i>F</i> = 7.9%, <i>F</i><sub>a</sub> × <i>F</i><sub>g</sub> = 66%) (table S1). Introduction of the P1′ nitrile to this scaffold led to the identification of the clinical candidate PF-07321332 (<b>6</b>; <a >Fig. 1</a>). Compound <b>6</b> is a potent inhibitor of SARS-CoV-2 M<sup>pro</sup> biochemical activity (<i>K</i><sub>i</sub> = 3.11 nM) with improved Vero E6 antiviral activity (EC<sub>50</sub> = 74.5 nM) relative to compounds <b>2</b> to <b>4</b>. Compound <b>6</b> displays a similar binding mode (<a >Fig. 2E</a>) to compound <b>4</b>. The P1′ nitrile of <b>6</b> forms a reversible covalent thioimidate adduct with the catalytic Cys145 (<a >Fig. 2F</a>). Reversibility of M<sup>pro</sup> inhibition by <b>6</b> was demonstrated upon incubation of SARS-CoV-2 M<sup>pro</sup> (2 mM) with 2 mM of either <b>6</b> or an irreversible M<sup>pro</sup> inhibitor (compound <b>7</b>; <a >Fig. 3A</a>) (<a ><i>17</i></a>) for 30 min and monitoring M<sup>pro</sup> activity after 100-fold dilution of the incubation mixtures. No recovery of activity was observed after M<sup>pro</sup> incubation with <b>7</b>. The recovery of &gt;50% M<sup>pro</sup> activity after incubation with <b>6</b> indicates that inhibition of SARS-CoV-2 M<sup>pro</sup> is reversible (<a >Fig. 3A</a>). We selected the nitrile compound <b>6</b> (named PF-07321332) over compound <b>5</b> as the clinical candidate based on ease of synthetic scale-up, enhanced solubility that allowed for a simple formulation vehicle in support of preclinical toxicology, and reduced propensity for epimerization at the P1 stereocenter.</div><div >PF-07321332 demonstrated potent inhibition in FRET M<sup>pro</sup> assays representing M<sup>pro</sup> from all coronavirus types known to infect humans (<a ><i>6</i></a>, <a ><i>7</i></a>, <a ><i>30</i></a>), including beta-coronaviruses (SARS-CoV-2, SARS-CoV-1, HKU1, OC43, and MERS-CoV) as well as alpha-coronaviruses (229E and NL63) (<a >Fig. 3B</a> and table S2). No inhibitory effects were noted against several mammalian cysteine (caspase 2, cathepsin B, and cathepsin L), serine (chymotrypsin, elastase, and thrombin) and aspartyl (cathepsin D) proteases at the highest concentration tested (100 μM) of PF-07321332 (table S3). This was also the case for HIV-1 protease, a viral aspartyl protease (table S3).</div><div >The in vitro antiviral activity of PF-07321332 was also evaluated in two physiologically relevant cellular systems: human adenocarcinoma–derived alveolar basal epithelial (A549) cells constitutively expressing ACE2 (<a ><i>19</i></a>) and differentiated normal human bronchial epithelial (dNHBE) cells (<a ><i>31</i></a>). In contrast to Vero E6 cells, A549 and dNHBE cells do not overly express P-glycoprotein, and therefore co-dosing with a P-glycoprotein inhibitor was not necessary to gauge antiviral activity in these cell lines (<a ><i>19</i></a>). PF-07321332 inhibited SARS-CoV-2 replication as assessed using a nanoluciferase reporter virus in A549-ACE2 cells with EC<sub>50</sub> and EC<sub>90</sub> values of 77.9 and 215 nM, respectively, with no cytotoxicity detected at concentrations up to 3 μM (<a >Fig. 3C</a> and table S4). Treatment of dNHBE cells with varying concentrations of PF-07321332 for 3 days led to inhibition of SARS-CoV-2 viral replication, with EC<sub>50</sub> and EC<sub>90</sub> values of 61.8 and 181 nM, respectively (<a >Fig. 3C</a>), as monitored by titration of virus harvested from the apical compartment using a 50% cell culture infective dose (CCID<sub>50</sub>) assay in Vero76 cells. Increasing the duration of the dNHBE study to 5 days resulted in viral replication being inhibited, with EC<sub>50</sub> and EC<sub>90</sub> values of 32.6 and 56.1 nM, respectively (<a >Fig. 3C</a>). Because optimal therapeutic efficacy with marketed viral protease inhibitors and other antiviral agents is generally achieved when the minimum systemic unbound plasma concentration (<i>C</i><sub>min</sub>) of inhibitor is maintained above cellular antiviral EC<sub>90</sub> (<a ><i>32</i></a>), we selected the more conservative day 3 EC<sub>90</sub> value of 181 nM PF-07321332 in the dNHBE assay as the <i>C</i><sub>min</sub> to be maintained when predicting efficacy in animal models and in the clinical setting. We further evaluated the in vitro cellular antiviral activity of PF-07321332 against SARS-CoV-1, MERS-CoV, and human coronavirus 229E using CPE assays. PF-07321332 demonstrated potent antiviral activity against SARS-CoV-1 (EC<sub>90</sub> = 317 nM), MERS-CoV (EC<sub>90</sub> = 351 nM), and 229E (EC<sub>90</sub> = 620 nM) in their respective cellular assays (<a >Fig. 3D</a> and table S5).</div><div >We evaluated the in vivo antiviral activity of PF-07321332 in a mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA10) model (<a ><i>33</i></a>). Intranasal infection of BALB/c mice with SARS-CoV-2 MA10 led to ~10% body weight loss and minimal mortality in 10-week-old mice. As shown in <a >Fig. 4A</a>, after infection with SARS-CoV-2 MA10, mice treated twice daily with PF-07321332 (at both 300 and 1000 mg/kg doses) were protected from weight loss compared with vehicle-treated mice. At 4 days after infection, mice were sacrificed and lung viral titers were evaluated in CCID<sub>50</sub> assays. Infected animals in the placebo group (<i>n</i> = 12, two independent studies) had robust infection in the lungs (mean lung titer of log<sub>10</sub> 4.93 ± 0.140 CCID<sub>50</sub>/ml SARS-CoV-2 MA10) (<a >Fig. 4B</a>), whereas virus levels in mice treated with PF-07321332 were significantly reduced (mean lung titers of log<sub>10</sub> 3.53 ± 0.187 and log<sub>10</sub> 3.02 ± 0.423 CCID<sub>50</sub>/ml for the 300 and 1000 mg/kg PF-07321332-treated groups, respectively). In a satellite group of uninfected mice, the 300 mg/kg twice daily (BID) dose of PF-07321332 used in the mouse-adapted viral in vivo efficacy study maintained <i>C</i><sub>min</sub> unbound plasma concentrations above ~0.9 × EC<sub>90</sub> (<a >Fig. 4C</a>), as defined in the dNHBE primary cell assay. The 1000 mg/kg BID dose of PF-07321332 maintained a <i>C</i><sub>min</sub> unbound plasma concentrations of ~4 × EC<sub>90</sub> (<a >Fig. 4C</a>). This confirms that PF-07321332 is effective at reducing SARS-CoV-2 MA10 viral load in mouse lungs at concentrations consistent with the observed in vitro antiviral potency and those being targeted clinically.</div><div >Disease in this model is manifest by weight loss and pathological changes in the lungs of the infected mice (<a ><i>33</i></a>). Histopathological analysis and immunostaining of lungs from the SARS-CoV-2 MA10–infected mice showed that PF-07321332 limits cellular infiltration (<a >Fig. 4D</a> and fig. S2) and protects lung tissue from damage caused by virus replication (<a >Fig. 4E</a>). Immunohistochemical analysis using a viral nucleocapsid antibody to detect viral antigen levels in the lungs revealed that PF-07321332 inhibits virus replication in a dose-dependent manner (<a >Fig. 4E</a>). Lungs from vehicle-treated, infected mice showed the strongest staining, whereas mock-infected lungs were negative for nucleocapsid staining. Histopathological evaluation of lungs from the vehicle-treated mice demonstrated evidence of increased perivascular inflammation, bronchial or bronchiolar epithelial degeneration or necrosis, bronchial or bronchiolar inflammation, cellular debris in alveolar lumen, and alveolar inflammation and thickening of the alveolar septum compared with PF-07321332–treated mice and mock-infected mice (fig. S2). Most of the infected mice exhibited multifocal pulmonary lesions, which were significantly reduced in PF-07321332–treated mice.</div><div >PF-07321332 exhibited moderate plasma clearance (CL<sub>p</sub>) in rats and monkeys, with elimination half-lives (<i>t</i><sub>1/2</sub>) of 5 hours and &lt;1 hour, respectively, after intravenous dosing (table S6). After oral administration to rats, crystalline PF-07321332 (10 mg/kg) demonstrated <i>F</i><sub>a</sub> × <i>F</i><sub>g</sub> and <i>F</i> values ranging from 65 to 95% and 34 to 50%, respectively, depending on the crystalline form used (<a >Fig. 1</a> and table S6). Oral administration of PF-07321332 (10 mg/kg) to monkeys led to a relatively poor <i>F</i> of 8.5% (<i>F</i><sub>a</sub> × <i>F</i><sub>g</sub> = 20%) (table S6), which is attributed to first-pass metabolism along the gastrointestinal tract by cytochrome P450 (CYP) enzymes, consistent with a rapid (<i>t</i><sub>1/2</sub> = 20.5 min, CL<sub>int</sub> = 33.8 μl/min/mg), NADPH-dependent metabolic turnover of PF-07321332 in monkey intestinal microsomes (table S7). PF-07321332 was resistant (<i>t</i><sub>1/2</sub> &gt; 240 min, CL<sub>int</sub> &lt;2.89 μl/min/mg) to CYP-mediated metabolism in intestinal microsomes from rat and human. PF-07321332 (0.3 to 10 μM) exhibited concentration-independent plasma protein binding in rat [mean plasma unbound fraction (<i>f</i><sub>u,p</sub>) = 0.478], monkey (mean <i>f</i><sub>u,p</sub> = 0.434), and human (mean <i>f</i><sub>u,p</sub> = 0.310) under equilibrium dialysis conditions (<a ><i>34</i></a>).</div><div >Drug-metabolizing enzymes involved in the metabolism of PF-07321332 were also studied. In NADPH-supplemented HLMs, PF-07321332 demonstrated moderate CL<sub>int</sub> (24.5 μl/min/mg) (<a >Fig. 1</a> and table S7), which was significantly inhibited (≥82%) by the selective CYP3A4/5 inhibitor ketoconazole (<a ><i>28</i></a>) (table S8). Moreover, the oxidative metabolic profile of PF-07321332 in HLMs, which includes modifications on the P2 6,6-dimethyl-3-azabicyclo[3.1.0]hexane, the <i>tert</i>-butyl group at the P3 position, and the P1 pyrrolidinone ring, was reproduced in incubations of PF-07321332 with recombinant human CYP3A4 (fig. S1). These in vitro studies, which established a predominant role for CYP3A4 in the metabolism of PF-07321332, also presented an opportunity to boost therapeutic concentrations of PF-07321332 in the clinic by co-dosing with the potent CYP3A4 inactivator ritonavir (RTV), which is used as a pharmacokinetic enhancer of several marketed protease inhibitors (e.g., darunavir and lopinavir) that are subject to metabolic clearance through CYP3A4 (<a ><i>35</i></a>, <a ><i>36</i></a>).</div><div >PF-07321332 demonstrated a favorable off-target selectivity profile in a broad panel of G protein–coupled receptors, kinases, transporters, and phosphodiesterase enzyme inhibitor screens, and was devoid of activity against the cardiac ion channels K<sub>v</sub>1.1, Ca<sub>v</sub>1.2, and Na<sub>v</sub>1.5 (tables S9 and S10). PF-07321332 was not mutagenic or clastogenic in in vitro genetic toxicity studies and was negative in an in vivo rat micronucleus assay (table S11). Repeat oral dosing of PF-07321332 in 2-week regulatory toxicity studies in monkeys (60 to 600 mg/kg) and rats (40 to 1000 mg/kg) led to dose-dependent increases in both maximal plasma concentrations (<i>C</i><sub>max</sub>) and area-under-the-plasma concentration versus time curves (AUCs) (<a >Fig. 5, A and B</a>, and table S12). This resulted in unbound <i>C</i><sub>max</sub> and average concentrations (<i>C</i><sub>av</sub>) margins of 273-fold and 65-fold in rats, respectively (day 14, 1000 mg/kg), and 510-fold and 245-fold in monkeys, respectively (day 15, 600 mg/kg), over the measured unbound EC<sub>90</sub> value of PF-07321332 determined in the SARS-CoV-2 day 3 dNHBE cellular assay. PF-07321332 was well tolerated, with no adverse findings in either species; the corresponding no observed adverse effect levels (NOAELs) were the highest doses tested (600 mg/kg/day in monkeys and 1000 mg/kg/day in rats).</div><div >The safety, tolerability, and pharmacokinetics of PF-07321332 as a single agent and in combination with RTV are under investigation in a randomized, double-blind, placebo-controlled, single ascending dose study in healthy adult participants (table S13; <a >www.ClinicalTrials.gov</a> identifier: NCT04756531). At each dose tested, four participants were randomized to receive active treatment and two participants received placebo. In the PF-07321332/RTV co-administration dosing paradigm, each subject (active and placebo) received one tablet (100 mg) of RTV at –12 hours, 0 hours, and 12 hours. PF-07321332 was administered as an oral suspension under fasted conditions at 0 hours (minimum fast of ~10 hours before treatment). Preliminary plasma concentration versus time pharmacokinetic profiles achieved from two oral doses, PF-07321332 150 mg alone and PF-07321332 250 mg with RTV, are presented in <a >Fig. 5C</a>. PF-07321332 was safe and well tolerated and exhibited a significant boost in plasma concentrations when co-administered with RTV. Oral plasma concentrations of PF-07321332 250 mg with RTV were considerably above the SARS-COV-2 antiviral EC<sub>90</sub> value (total EC<sub>90</sub> = 292 ng/ml, unbound EC<sub>90</sub> = 90.5 ng/ml, 181 nM) at 12 hours after dose, thus increasing confidence in achieving robust pan-coronavirus antiviral activity clinically (<a >Fig. 5D</a>). On the basis of these observations and the high safety margins at the NOAEL doses in animals, the efficacy of PF-07321332 in COVID-19 patients will be assessed with a twice-daily dosing paradigm with the potential to increase the dose of PF-07321332 as a single agent and/or co-administered with RTV.</div><section ><h2>Acknowledgments</h2><div >The authors thank the participants of the first-in-human (FIH) study. We would also like to acknowledge the many Pfizer colleagues who have contributed to the COVID-19 oral protease program across a number of disciplines. In particular, we acknowledge S. Sakata, J. Arcari, and J. Zhang for external research resourcing; K. Farley for NMR studies; L. Lanyon for protease panel data; Y. Lian, E. LaChapelle, S. Wright, S. O’Neil, E. Yang, J. Humphrey, and B. Boscoe for compound synthesis; S. Jenkinson for safety pharmacology data; K. Ryan for structural biology support; E. Collins and C. Allais for FIH-enabling active pharmaceutical ingredient supply; F. Clark for bioanalysis; H. Shi for clinical assay support; G. Nucci and A. Bergman for first-in-human study design and clinical pharmacology; F. Hackman for clinical statistics; S. Toussi for medical monitoring; K. Bartsch for clinical study leadership; S. Pawlak for clinical trial leadership; C. Fredette for clinical trial project management; D. Ding for regulatory documentation support; and M. Dolsten for scientific discussion and advice. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. Extraordinary facility operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on the response to COVID-19, with funding provided by the Coronavirus CARES Act.</div><div ><b>Funding:</b> This study was sponsored by Pfizer, Inc.</div><div ><b>Author contributions:</b> Conceptualization: C.M.N.A., A.S.A., D.R.O., M.P.; Formal analysis: L.D., B.B., S.E.G., Q.Y., D.K.R., J.J.N., A.D., R.S.O., R.S.P.S.; Investigation: M.A., S.B., J.C.L., J.L., K.O., L.W., R.F., K.S.G., W.L., R.S.O., D.K.R., S.A.G., L.A., S.N., H.E.; Methodology: J.B.T., Q.Y., M.F.S., P.R.V., M.R.R., M.P., D.R.O., N.C.P., A.C., E.P.K., K.J.C., R.S.P.S.; Project administration: D.R.O., M.R.R., J.B.T., A.S.K., C.M.S., L.U., J.G.S., B.L.H., Y.Z., S.W.M., R.D.C., N.C.P.; Resources: A.D., J.J.N., K.J.C.; Supervision: M.R.R., C.E.S., A.E.S., B.L.H., P.R.V., R.D.C.; Visualization: S.W.M., D.K.R., S.N., B.B., L.A., H.E.; Writing – original draft: D.R.O., A.S.K., M.F.S., C.M.S., R.D.C., M.R.R., J.G.S., C.M.S., Y.Z.; Writing – review and editing: D.R.O., A.S.K., M.F.S., A.S.A., C.M.N.A.</div><div ><b>Competing interests:</b> D.R.O., C.M.N.A., A.S.A., L.A., M.A., S.B., B.B., R.D.C., A.C., K.J.C., A.D., L.D., H.E., R.F., K.S.G., S.E.G., E.P.K., A.S.K., J.C.L., J.L., W.L., S.N., R.S.O., K.O., N.C.P., D.K.R., M.R.R., M.F.S., J.G.S., R.P.S., C.M.S., A.S., J.B.T., L.U., P.R.V., L.W., Q.Y., and Y.Z. are employees of Pfizer and some of the authors are shareholders in Pfizer Inc. S.W.M., J.J.N., and M.P. were employees of Pfizer Inc. during part of this study.</div><div ><b>Data and materials availability:</b> All nonclinical data are available in the main text or the supplementary materials. X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under accession codes 7RFR, 7RFU, 7RFS, and 7RFW. Individualized <a >Fig. 5</a> data and the statistical analysis plan are available on <a >www.Figshare.com</a> with the following DOI: 10.25454/pfizer.figshare.16699669. Pfizer compound use requests are processed through the Pure Compound Grants program (see <a >https://www.cybergrants.com/pfizer/Research</a>). Pfizer Inc. has applied for patent applications covering PF-07321332 as well as related compounds. A phase 1 clinical trial has been registered at <a >www.ClinicalTrials.gov</a> under identifier NCT04756531. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section> </div></section><section ><div ><section ><h2>Supplementary Materials</h2><section ><h3>This PDF file includes:</h3><div ><div ><div>Materials and Methods</div><div>Figs. S1 and S2</div><div>Tables S1 to S13</div><div>References (<a ><i>37</i></a>–<a ><i>70</i></a>)</div></div><div ><a >Download (4.60 MB)</a></div></div></section><section ><h3>Other Supplementary Material for this manuscript includes the following:</h3><div ><div ><div>MDAR Reproducibility Checklist</div></div><div ><a >Download (128.44 KB)</a></div></div></section></section><div ><a >View/request a protocol for this paper from <i>Bio-protocol</i>.</a></div><section ><h2>References and Notes</h2><div ><div >1</div><div ><div ><div >V. M. Corman, D. Muth, D. Niemeyer, C. Drosten, Hosts and sources of endemic human coronaviruses. Adv. Virus Res. <b>100</b>, 163–188 (2018).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >2</div><div ><div ><div >WHO Solidarity Trial Consortium, Repurposed antiviral drugs for Covid-19 – Interim WHO Solidarity Trial results. N. Engl. J. Med. <b>384</b>, 497–511 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >3</div><div ><div ><div >L. Riva, S. Yuan, X. Yin, L. Martin-Sancho, N. Matsunaga, L. Pache, S. Burgstaller-Muehlbacher, P. D. De Jesus, P. Teriete, M. V. Hull, M. W. Chang, J. F. Chan, J. Cao, V. K. Poon, K. M. Herbert, K. Cheng, T. H. Nguyen, A. Rubanov, Y. Pu, C. Nguyen, A. Choi, R. Rathnasinghe, M. Schotsaert, L. Miorin, M. Dejosez, T. P. Zwaka, K. Y. Sit, L. Martinez-Sobrido, W. C. Liu, K. M. White, M. E. Chapman, E. K. Lendy, R. J. Glynne, R. Albrecht, E. Ruppin, A. D. Mesecar, J. R. Johnson, C. Benner, R. Sun, P. G. Schultz, A. I. Su, A. García-Sastre, A. K. Chatterjee, K. Y. Yuen, S. K. Chanda, Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature <b>586</b>, 113–119 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >4</div><div ><div ><div >A. Wahl, L. E. Gralinski, C. E. Johnson, W. Yao, M. Kovarova, K. H. Dinnon 3rd, H. Liu, V. J. Madden, H. M. Krzystek, C. De, K. K. White, K. Gully, A. Schäfer, T. Zaman, S. R. Leist, P. O. Grant, G. R. Bluemling, A. A. Kolykhalov, M. G. Natchus, F. B. Askin, G. Painter, E. P. Browne, C. D. Jones, R. J. Pickles, R. S. Baric, J. V. Garcia, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature <b>591</b>, 451–457 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >5</div><div ><div ><div >S. S. Good, J. Westover, K. H. Jung, X. J. Zhou, A. Moussa, P. La Colla, G. Collu, B. Canard, J. P. Sommadossi, AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob. Agents Chemother. <b>65</b>, e02479–e02420 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >6</div><div ><div ><div >F. Wu, S. Zhao, B. Yu, Y. M. Chen, W. Wang, Z. G. Song, Y. Hu, Z. W. Tao, J. H. Tian, Y. Y. Pei, M. L. Yuan, Y. L. Zhang, F. H. Dai, Y. Liu, Q. M. Wang, J. J. Zheng, L. Xu, E. C. Holmes, Y. Z. Zhang, A new coronavirus associated with human respiratory disease in China. Nature <b>579</b>, 265–269 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >7</div><div ><div ><div >P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L. Huang, H. D. Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng, K. Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, Z. L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature <b>579</b>, 270–273 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >8</div><div ><div ><div >T. Pillaiyar, M. Manickam, V. Namasivayam, Y. Hayashi, S. H. Jung, An overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. J. Med. Chem. <b>59</b>, 6595–6628 (2016).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >9</div><div ><div ><div >Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, J. Yu, L. Wang, K. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao, H. Yang, Structure of M<sup>pro</sup> from SARS-CoV-2 and discovery of its inhibitors. Nature <b>582</b>, 289–293 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >10</div><div ><div ><div >I. Schechter, A. Berger, On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. <b>27</b>, 157–162 (1967).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >11</div><div ><div ><div >W. Rut, K. Groborz, L. Zhang, X. Sun, M. Zmudzinski, B. Pawlik, X. Wang, D. Jochmans, J. Neyts, W. Młynarski, R. Hilgenfeld, M. Drag, SARS-CoV-2 M<sup>pro</sup> inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. <b>17</b>, 222–228 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >12</div><div ><div ><div >K. Anand, J. Ziebuhr, P. Wadhwani, J. R. Mesters, R. Hilgenfeld, Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science <b>300</b>, 1763–1767 (2003).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >13</div><div ><div ><div >L. Zhang, D. Lin, Y. Kusov, Y. Nian, Q. Ma, J. Wang, A. von Brunn, P. Leyssen, K. Lanko, J. Neyts, A. de Wilde, E. J. Snijder, H. Liu, R. Hilgenfeld, α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment. J. Med. Chem. <b>63</b>, 4562–4578 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >14</div><div ><div ><div >A. K. Ghosh, H. L. Osswald, G. Prato, Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med. Chem. <b>59</b>, 5172–5208 (2016).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >15</div><div ><div ><div >R. Cannalire, M. L. Barreca, G. Manfroni, V. Cecchetti, A journey around the medicinal chemistry of Hepatitis C virus inhibitors targeting NS4B: From target to preclinical drug candidates. J. Med. Chem. <b>59</b>, 16–41 (2016).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >16</div><div ><div ><div >J. Qiao, Y.-S. Li, R. Zeng, F.-L. Liu, R.-H. Luo, C. Huang, Y.-F. Wang, J. Zhang, B. Quan, C. Shen, X. Mao, X. Liu, W. Sun, W. Yang, X. Ni, K. Wang, L. Xu, Z.-L. Duan, Q.-C. Zou, H.-L. Zhang, W. Qu, Y.-H.-P. Long, M.-H. Li, R.-C. Yang, X. Liu, J. You, Y. Zhou, R. Yao, W.-P. Li, J.-M. Liu, P. Chen, Y. Liu, G.-F. Lin, X. Yang, J. Zou, L. Li, Y. Hu, G.-W. Lu, W.-M. Li, Y.-Q. Wei, Y.-T. Zheng, J. Lei, S. Yang, SARS-CoV-2 M<sup>pro</sup> inhibitors with antiviral activity in a transgenic mouse model. Science <b>371</b>, 1374–1378 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >17</div><div ><div ><div >R. L. Hoffman, R. S. Kania, M. A. Brothers, J. F. Davies, R. A. Ferre, K. S. Gajiwala, M. He, R. J. Hogan, K. Kozminski, L. Y. Li, J. W. Lockner, J. Lou, M. T. Marra, L. J. Mitchell Jr., B. W. Murray, J. A. Nieman, S. Noell, S. P. Planken, T. Rowe, K. Ryan, G. J. Smith 3rd, J. E. Solowiej, C. M. Steppan, B. Taggart, Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. <b>63</b>, 12725–12747 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >18</div><div ><div ><div >L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science <b>368</b>, 409–412 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >19</div><div ><div ><div >M. de Vries, A. S. Mohamed, R. A. Prescott, A. M. Valero-Jimenez, L. Desvignes, R. O’Connor, C. Steppan, J. C. Devlin, E. Ivanova, A. Herrera, A. Schinlever, P. Loose, K. Ruggles, S. B. Koralov, A. S. Anderson, J. Binder, M. Dittmann, A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL<sup>pro</sup> inhibitor PF-00835231 as a potential new treatment for COVID-19. J. Virol. <b>95</b>, e01819–e01820 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >20</div><div ><div ><div >B. Boras, R. M. Jones, B. J. Anson, D. Arenson, L. Aschenbrenner, M. A. Bakowski, N. Beutler, J. Binder, E. Chen, H. Eng, J. Hammond, R. Hoffman, E. P. Kadar, R. Kania, E. Kimoto, M. G. Kirkpatrick, L. Lanyon, E. K. Lendy, J. R. Lillis, S. A. Luthra, C. Ma, S. Noell, R. S. Obach, M. N. O’ Brien, R. O’Connor, K. Ogilvie, D. Owen, M. Pettersson, M. R. Reese, T. F. Rogers, M. I. Rossulek, J. G. Sathish, C. Steppan, M. Ticehurst, L. W. Updyke, Y. Zhu, J. Wang, A. K. Chatterjee, A. D. Mesecar, A. S. Anderson, C. Allerton, Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv 293498 [Preprint] (2020). <a >https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2</a>.</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >21</div><div ><div ><div >L. Di, C. Whitney-Pickett, J. P. Umland, H. Zhang, X. Zhang, D. F. Gebhard, Y. Lai, J. J. Federico 3rd, R. E. Davidson, R. Smith, E. L. Reyner, C. Lee, B. Feng, C. Rotter, M. V. Varma, S. Kempshall, K. Fenner, A. F. El-Kattan, T. E. Liston, M. D. Troutman, Development of a new permeability assay using low-efflux MDCKII cells. J. Pharm. Sci. <b>100</b>, 4974–4985 (2011).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >22</div><div ><div ><div >D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward, K. D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. <b>45</b>, 2615–2623 (2002).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >23</div><div ><div ><div >J. B. Moon, R. S. Coleman, R. P. Hanzlik, Reversible covalent inhibition of papain by a peptide nitrile. Carbon-13 NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc. <b>108</b>, 1350–1351 (2002).</div><div ><div><a >Crossref</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >24</div><div ><div ><div >C.-P. Chuck, C. Chen, Z. Ke, D. Chi-Cheong Wan, H.-F. Chow, K.-B. Wong, Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases. Eur. J. Med. Chem. <b>59</b>, 1–6 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >25</div><div ><div ><div >S. Konno, P. Thanigaimalai, T. Yamamoto, K. Nakada, R. Kakiuchi, K. Takayama, Y. Yamazaki, F. Yakushiji, K. Akaji, Y. Kiso, Y. Kawasaki, S. E. Chen, E. Freire, Y. Hayashi, Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety. Bioorg. Med. Chem. <b>21</b>, 412–424 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >26</div><div ><div ><div >P. S. Dragovich, R. Zhou, S. E. Webber, T. J. Prins, A. K. Kwok, K. Okano, S. A. Fuhrman, L. S. Zalman, F. C. Maldonado, E. L. Brown, J. W. Meador 3rd, A. K. Patick, C. E. Ford, M. A. Brothers, S. L. Binford, D. A. Matthews, R. A. Ferre, S. T. Worland, Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors. Bioorg. Med. Chem. Lett. <b>10</b>, 45–48 (2000).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >27</div><div ><div ><div >M. Kato, K. Chiba, A. Hisaka, M. Ishigami, M. Kayama, N. Mizuno, Y. Nagata, S. Takakuwa, Y. Tsukamoto, K. Ueda, H. Kusuhara, K. Ito, Y. Sugiyama, The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab. Pharmacokinet. <b>18</b>, 365–372 (2003).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >28</div><div ><div ><div >R. L. Walsky, R. S. Obach, Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. <b>32</b>, 647–660 (2004).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >29</div><div ><div ><div >S. I. Hattori, N. Higashi-Kuwata, H. Hayashi, S. R. Allu, J. Raghavaiah, H. Bulut, D. Das, B. J. Anson, E. K. Lendy, Y. Takamatsu, N. Takamune, N. Kishimoto, K. Murayama, K. Hasegawa, M. Li, D. A. Davis, E. N. Kodama, R. Yarchoan, A. Wlodawer, S. Misumi, A. D. Mesecar, A. K. Ghosh, H. Mitsuya, A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. <b>12</b>, 668 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >30</div><div ><div ><div >J. Cui, F. Li, Z. L. Shi, Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. <b>17</b>, 181–192 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >31</div><div ><div ><div >A. Barilli, R. Visigalli, F. Ferrari, M. Di Lascia, B. Riccardi, P. Puccini, V. Dall’Asta, B. M. Rotoli, Organic cation transporters (OCTs) in EpiAirway<sup>TM</sup>, a cellular model of normal human bronchial epithelium. Biomedicines <b>8</b>, 127 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >32</div><div ><div ><div >M. B. Reddy, P. N. Morcos, S. Le Pogam, Y. Ou, K. Frank, T. Lave, P. Smith, Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob. Agents Chemother. <b>56</b>, 3144–3156 (2012).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >33</div><div ><div ><div >S. R. Leist, K. H. Dinnon 3rd, A. Schäfer, L. V. Tse, K. Okuda, Y. J. Hou, A. West, C. E. Edwards, W. Sanders, E. J. Fritch, K. L. Gully, T. Scobey, A. J. Brown, T. P. Sheahan, N. J. Moorman, R. C. Boucher, L. E. Gralinski, S. A. Montgomery, R. S. Baric, A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell <b>183</b>, 1070–1085.e12 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >34</div><div ><div ><div >M. J. Banker, T. H. Clark, J. A. Williams, Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. <b>92</b>, 967–974 (2003).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >35</div><div ><div ><div >K. McKeage, C. M. Perry, S. J. Keam, Darunavir: A review of its use in the management of HIV infection in adults. Drugs <b>69</b>, 477–503 (2009).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >36</div><div ><div ><div >R. S. Cvetkovic, K. L. Goa, Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs <b>63</b>, 769–802 (2003).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >37</div><div ><div ><div >A. M. Prior, Y. Kim, S. Weerasekara, M. Moroze, K. R. Alliston, R. A. Uy, W. C. Groutas, K. O. Chang, D. H. Hua, Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors. Bioorg. Med. Chem. Lett. <b>23</b>, 6317–6320 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >38</div><div ><div ><div >P. Thanigaimalai, S. Konno, T. Yamamoto, Y. Koiwai, A. Taguchi, K. Takayama, F. Yakushiji, K. Akaji, S. E. Chen, A. Naser-Tavakolian, A. Schön, E. Freire, Y. Hayashi, Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies. Eur. J. Med. Chem. <b>68</b>, 372–384 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >39</div><div ><div ><div >Use of the IMCA-CAT beamline 17-ID (or 17-BM) at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute.</div></div></div></div><div ><div >40</div><div ><div ><div >This research used resources at the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) beamline 17-ID, supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute.</div></div></div></div><div ><div >41</div><div ><div ><div >This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357.</div></div></div></div><div ><div >42</div><div ><div ><div >C. Vonrhein, C. Flensburg, P. Keller, A. Sharff, O. Smart, W. Paciorek, T. Womack, G. Bricogne, Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. <b>67</b>, 293–302 (2011).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >43</div><div ><div ><div >I. J. Tickle, F. C. P. Keller, W. Paciorek, A. Sharff, C. Vonrhein, G. Bricogne, “STARANISO” (Global Phasing Ltd., 2018).</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >44</div><div ><div ><div >G. Bricogne, E. Blanc, M. Brandl, C. Flensburg, P. Keller, W. Paciorek, P. Roversi, A. Sharff, O. S. Smart, C. Vonrhein, T. O. Womack, “BUSTER version 2.11.4” (Global Phasing Ltd., 2016).</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >45</div><div ><div ><div >A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, <i>Phaser</i> crystallographic software. J. Appl. Cryst. <b>40</b>, 658–674 (2007).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >46</div><div ><div ><div >A. Vagin, A. Teplyakov, Molecular replacement with MOLREP. Acta Crystallogr. <b>66</b>, 22–25 (2010).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >47</div><div ><div ><div >M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin, K. S. Wilson, Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. <b>67</b>, 235–242 (2011).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >48</div><div ><div ><div >OpenEye Scientific, “AFITT 2.4.1.2: OpenEye Scientific Software” (OpenEye Scientific, 2021); <a >https://www.eyesopen.com/afitt</a>.</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >49</div><div ><div ><div >S. Wlodek, A. G. Skillman, A. Nicholls, Automated ligand placement and refinement with a combined force field and shape potential. Acta Crystallogr. D Biol. Crystallogr. <b>62</b>, 741–749 (2006).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >50</div><div ><div ><div >P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. <b>66</b>, 486–501 (2010).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >51</div><div ><div ><div >M. S. Weiss, R. Hilgenfeld, On the use of the merging R factor as a quality indicator for X-ray data. J. Appl. Cryst. <b>30</b>, 203–205 (1997).</div><div ><div><a >Crossref</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >52</div><div ><div ><div >P. A. Karplus, K. Diederichs, Linking crystallographic model and data quality. Science <b>336</b>, 1030–1033 (2012).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >53</div><div ><div ><div >A. T. Brünger, Free R value: Cross-validation in crystallography. Methods Enzymol. <b>277</b>, 366–396 (1997).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >54</div><div ><div ><div >V. Grum-Tokars, K. Ratia, A. Begaye, S. C. Baker, A. D. Mesecar, Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery. Virus Res. <b>133</b>, 63–73 (2008).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >55</div><div ><div ><div >Y. Kim, S. Lovell, K. C. Tiew, S. R. Mandadapu, K. R. Alliston, K. P. Battaile, W. C. Groutas, K. O. Chang, Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. <b>86</b>, 11754–11762 (2012).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >56</div><div ><div ><div >L. J. Reed, H. Muench, A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. <b>27</b>, 493–497 (1938).</div><div ><div><a >Crossref</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >57</div><div ><div ><div >R. S. Obach, J. G. Baxter, T. E. Liston, B. M. Silber, B. C. Jones, F. MacIntyre, D. J. Rance, P. Wastall, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. <b>283</b>, 46–58 (1997) doi.</div><div ><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >58</div><div ><div ><div >B. Davies, T. Morris, Physiological parameters in laboratory animals and humans. Pharm. Res. <b>10</b>, 1093–1095 (1993).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >59</div><div ><div ><div >S. Hamada, S. Sutou, T. Morita, A. Wakata, S. Asanami, S. Hosoya, S. Ozawa, K. Kondo, M. Nakajima, H. Shimada, K. Osawa, Y. Kondo, N. Asano, S. Sato, H. Tamura, N. Yajima, R. Marshall, C. Moore, D. H. Blakey, L. M. Schechtman, J. L. Weaver, D. K. Torous, R. Proudlock, S. Ito, C. Namiki, M. Hayashi, Evaluation of the rodent micronucleus assay by a 28-day treatment protocol: Summary of the 13th Collaborative Study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Environmental Mutagen Society of Japan (JEMS)-Mammalian Mutagenicity Study Group (MMS). Environ. Mol. Mutagen. <b>37</b>, 93–110 (2001).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >60</div><div ><div ><div >M. Hayashi, J. T. MacGregor, D. G. Gatehouse, I.-D. Adler, D. H. Blakey, S. D. Dertinger, G. Krishna, T. Morita, A. Russo, S. Sutou, In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring. Environ. Mol. Mutagen. <b>35</b>, 234–252 (2000).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >61</div><div ><div ><div >Organisation for Economic Co-operation and Development, “Test no. 474: Mammalian erythrocyte micronucleus test (OECD, 2016); <a >https://www.oecd.org/env/test-no-474-mammalian-erythrocyte-micronucleus-test-9789264264762-en.htm</a>.</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >62</div><div ><div ><div >International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, “Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use” (ICH, 2011); <a >https://database.ich.org/sites/default/files/S2%28R1%29%20Guideline.pdf</a>.</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >63</div><div ><div ><div >S. D. Dertinger, D. K. Torous, K. R. Tometsko, Simple and reliable enumeration of micronucleated reticulocytes with a single-laser flow cytometer. Mutat. Res. <b>371</b>, 283–292 (1996).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >64</div><div ><div ><div >M. H. L. Green, W. J. Muriel, Mutagen testing using TRP+ reversion in Escherichia coli. Mutat. Res. <b>38</b>, 3–32 (1976).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >65</div><div ><div ><div >D. M. Maron, B. N. Ames, Revised methods for the Salmonella mutagenicity test. Mutat. Res. <b>113</b>, 173–215 (1983).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >66</div><div ><div ><div >Organisation for Economic Co-operation and Development, “Test no. 471: Bacterial reverse mutation test” (OECD, 2020); <a >https://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en</a>.</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >67</div><div ><div ><div >M. Kirsch-Volders, T. Sofuni, M. Aardema, S. Albertini, D. Eastmond, M. Fenech, M. Ishidate Jr., E. Lorge, H. Norppa, J. Surrallés, W. von der Hude, A. Wakata, Report from the In Vitro Micronucleus Assay Working Group. Environ. Mol. Mutagen. <b>35</b>, 167–172 (2000).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >68</div><div ><div ><div >J. M. Parry, A. Sors, The detection and assessment of the aneugenic potential of environmental chemicals: The European Community Aneuploidy Project. Mutat. Res. <b>287</b>, 3–15 (1993).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >69</div><div ><div ><div >Organisation for Economic Co-operation and Development, “Test no. 487: In vitro mammalian cell micronucleus test” (OECD, 2016); <a >https://www.oecd.org/chemicalsafety/test-no-487-in-vitro-mammalian-cell-micronucleus-test-9789264264861-en.htm</a>.</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >70</div><div ><div ><div >Y. Cheng, W. H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. <b>22</b>, 3099–3108 (1973).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div></section></div></section><div ><div ><header><h2>Information Authors</h2></header><section ><h3>Information</h3><section ><h4>Published In</h4><div > <div ><div >Science</div><div >Volume 374 | Issue 657524 December 2021</div></div></div></section><section ><h4>Copyright</h4><div >Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</div><div >https://creativecommons.org/licenses/by/4.0/</div><div >This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></section><section ><h4>Article versions</h4><div>You are viewing the most recent version of this article.</div><div><a >2 November 2021: Previous PDF (Version 1)</a></div></section><section ><h4>Submission history</h4><div><b >Received</b>: 15 July 2021</div><div><b >Accepted</b>: 28 October 2021</div><div><b >Published in print</b>: 24 December 2021</div></section><section ><h4>Permissions</h4><div>Request permissions for this article.</div><div><a >Request Permissions</a></div></section><section ><h4>Acknowledgments</h4><div >The authors thank the participants of the first-in-human (FIH) study. We would also like to acknowledge the many Pfizer colleagues who have contributed to the COVID-19 oral protease program across a number of disciplines. In particular, we acknowledge S. Sakata, J. Arcari, and J. Zhang for external research resourcing; K. Farley for NMR studies; L. Lanyon for protease panel data; Y. Lian, E. LaChapelle, S. Wright, S. O’Neil, E. Yang, J. Humphrey, and B. Boscoe for compound synthesis; S. Jenkinson for safety pharmacology data; K. Ryan for structural biology support; E. Collins and C. Allais for FIH-enabling active pharmaceutical ingredient supply; F. Clark for bioanalysis; H. Shi for clinical assay support; G. Nucci and A. Bergman for first-in-human study design and clinical pharmacology; F. Hackman for clinical statistics; S. Toussi for medical monitoring; K. Bartsch for clinical study leadership; S. Pawlak for clinical trial leadership; C. Fredette for clinical trial project management; D. Ding for regulatory documentation support; and M. Dolsten for scientific discussion and advice. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. Extraordinary facility operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on the response to COVID-19, with funding provided by the Coronavirus CARES Act.</div><div ><b>Funding:</b> This study was sponsored by Pfizer, Inc.</div><div ><b>Author contributions:</b> Conceptualization: C.M.N.A., A.S.A., D.R.O., M.P.; Formal analysis: L.D., B.B., S.E.G., Q.Y., D.K.R., J.J.N., A.D., R.S.O., R.S.P.S.; Investigation: M.A., S.B., J.C.L., J.L., K.O., L.W., R.F., K.S.G., W.L., R.S.O., D.K.R., S.A.G., L.A., S.N., H.E.; Methodology: J.B.T., Q.Y., M.F.S., P.R.V., M.R.R., M.P., D.R.O., N.C.P., A.C., E.P.K., K.J.C., R.S.P.S.; Project administration: D.R.O., M.R.R., J.B.T., A.S.K., C.M.S., L.U., J.G.S., B.L.H., Y.Z., S.W.M., R.D.C., N.C.P.; Resources: A.D., J.J.N., K.J.C.; Supervision: M.R.R., C.E.S., A.E.S., B.L.H., P.R.V., R.D.C.; Visualization: S.W.M., D.K.R., S.N., B.B., L.A., H.E.; Writing – original draft: D.R.O., A.S.K., M.F.S., C.M.S., R.D.C., M.R.R., J.G.S., C.M.S., Y.Z.; Writing – review and editing: D.R.O., A.S.K., M.F.S., A.S.A., C.M.N.A.</div><div ><b>Competing interests:</b> D.R.O., C.M.N.A., A.S.A., L.A., M.A., S.B., B.B., R.D.C., A.C., K.J.C., A.D., L.D., H.E., R.F., K.S.G., S.E.G., E.P.K., A.S.K., J.C.L., J.L., W.L., S.N., R.S.O., K.O., N.C.P., D.K.R., M.R.R., M.F.S., J.G.S., R.P.S., C.M.S., A.S., J.B.T., L.U., P.R.V., L.W., Q.Y., and Y.Z. are employees of Pfizer and some of the authors are shareholders in Pfizer Inc. S.W.M., J.J.N., and M.P. were employees of Pfizer Inc. during part of this study.</div><div ><b>Data and materials availability:</b> All nonclinical data are available in the main text or the supplementary materials. X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under accession codes 7RFR, 7RFU, 7RFS, and 7RFW. Individualized <a >Fig. 5</a> data and the statistical analysis plan are available on <a >www.Figshare.com</a> with the following DOI: 10.25454/pfizer.figshare.16699669. Pfizer compound use requests are processed through the Pure Compound Grants program (see <a >https://www.cybergrants.com/pfizer/Research</a>). Pfizer Inc. has applied for patent applications covering PF-07321332 as well as related compounds. A phase 1 clinical trial has been registered at <a >www.ClinicalTrials.gov</a> under identifier NCT04756531. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section></section><section ><h3>Authors</h3><section ><h4>Affiliations</h4><div ><div >Dafydd R. Owen<sup >*</sup> <a >https://orcid.org/0000-0003-3106-7809</a> <a >[email protected]</a></div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Charlotte M. N. Allerton https://orcid.org/0000-0001-8665-159X</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Annaliesa S. Anderson</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Lisa Aschenbrenner</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Melissa Avery</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Simon Berritt https://orcid.org/0000-0001-5572-6771</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Britton Boras https://orcid.org/0000-0003-3624-9177</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Rhonda D. Cardin</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Anthony Carlo</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Karen J. Coffman https://orcid.org/0000-0001-6164-7500</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Alyssa Dantonio</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Li Di https://orcid.org/0000-0001-6117-9022</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Heather Eng https://orcid.org/0000-0002-2914-3967</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >RoseAnn Ferre https://orcid.org/0000-0001-7462-1879</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Ketan S. Gajiwala</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Scott A. Gibson</div><div ><div ><div >Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Samantha E. Greasley https://orcid.org/0000-0002-7978-6477</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Brett L. Hurst https://orcid.org/0000-0003-1025-5878</div><div ><div ><div >Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Eugene P. Kadar https://orcid.org/0000-0003-3724-6517</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Amit S. Kalgutkar https://orcid.org/0000-0001-9701-756X</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jack C. Lee</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jisun Lee https://orcid.org/0000-0003-1750-0063</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Wei Liu</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Stephen W. Mason</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div ><div >Present address: Janssen Biopharma; South San Francisco, CA 94080, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Stephen Noell https://orcid.org/0000-0003-3054-2575</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jonathan J. Novak https://orcid.org/0000-0002-3635-7955</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div ><div >Present address: Praxis Precision Medicines; Cambridge, MA 02142, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >R. Scott Obach https://orcid.org/0000-0002-6604-401X</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Kevin Ogilvie</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Nandini C. Patel https://orcid.org/0000-0002-2735-7662</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Martin Pettersson https://orcid.org/0000-0001-8748-9539</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div ><div >Present address: GRT Therapeutics; Cambridge, MA 02142, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Devendra K. Rai</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Matthew R. Reese https://orcid.org/0000-0002-1066-2652</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Matthew F. Sammons https://orcid.org/0000-0001-6472-0646</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jean G. Sathish</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Ravi Shankar P. Singh https://orcid.org/0000-0001-6298-8219</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Claire M. Steppan https://orcid.org/0000-0002-2609-7707</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Al E. Stewart</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jamison B. Tuttle</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Lawrence Updyke</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Patrick R. Verhoest</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Liuqing Wei</div><div ><div ><div >Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Qingyi Yang</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Yuao Zhu</div><div ><div ><div >Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div >View all articles by this author</div></div></div></section><section ><h4>Notes</h4><div >*Corresponding author. Email: [email protected]</div></section></section></div><div ><header><h2>Metrics Citations</h2></header><section ><h3>Metrics</h3><section > <h5 > Article Usage </h5> </section><section > <h5 > Altmetrics </h5> </section></section><section ><h3>Citations</h3><section > <div > <h5 >Export citation</h5> <p>Select the format you want to export the citation of this publication.</p> </div> <div > <h5 > Cited by </h5> <section ><div ><div ><ol ><li ><ul ><li >Yong Ni, </li><li >Jinbiao Liao, </li><li >Zhenlong Qian, </li><li >Chunxiu Wu, </li><li >Xiangyu Zhang, </li><li >Ji Zhang, </li><li >Youhua Xie, </li><li >Sheng Jiang, </li></ul>Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro, Bioorganic Medicinal Chemistry, 53, (116523), (2022).https://doi.org/10.1016/j.bmc.2021.116523<div >Crossref</div></li><li ><ul ><li >Chunlong Ma, </li><li >Zilei Xia, </li><li >Michael Dominic Sacco, </li><li >Yanmei Hu, </li><li >Julia Alma Townsend, </li><li >Xiangzhi Meng, </li><li >Juliana Choza, </li><li >Haozhou Tan, </li><li >Janice Jang, </li><li >Maura V. Gongora, </li><li >Xiujun Zhang, </li><li >Fushun Zhang, </li><li >Yan Xiang, </li><li >Michael Thomas Marty, </li><li >Yu Chen, </li><li >Jun Wang, </li></ul>Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity, Journal of the American Chemical Society, 143, 49, (20697-20709), (2021).https://doi.org/10.1021/jacs.1c08060<div >Crossref</div></li><li ><ul ><li >Chunlong Ma, </li><li >Haozhou Tan, </li><li >Juliana Choza, </li><li >Yuyin Wang, </li><li >Jun Wang, </li></ul>Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays, Acta Pharmaceutica Sinica B, (2021).https://doi.org/10.1016/j.apsb.2021.10.026<div >Crossref</div></li><li ><ul ><li >Yuanlin Song, </li><li >Fujita Masaki, </li></ul>Preparation for the challenge of heavily mutated Omicron variant, Clinical and Translational Medicine, 11, 12, (2021).https://doi.org/10.1002/ctm2.679<div >Crossref</div></li><li ><ul ><li >Judith M. White, </li><li >Joshua T. Schiffer, </li><li >Rachel A. Bender Ignacio, </li><li >Shuang Xu, </li><li >Denis Kainov, </li><li >Aleksandr Ianevski, </li><li >Tero Aittokallio, </li><li >Matthew Frieman, </li><li >Gene G. Olinger, </li><li >Stephen J. Polyak, </li></ul>Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses, mBio, 12, 6, (2021).https://doi.org/10.1128/mbio.03347-21<div >Crossref</div></li><li ><ul ><li >Maria Yu. Zakharova, </li><li >Alexandra A. Kuznetsova, </li><li >Victoria I. Uvarova, </li><li >Anastasiia D. Fomina, </li><li >Liubov I. Kozlovskaya, </li><li >Elena N. Kaliberda, </li><li >Inna N. Kurbatskaia, </li><li >Ivan V. Smirnov, </li><li >Anatoly A. Bulygin, </li><li >Vera D. Knorre, </li><li >Olga S. Fedorova, </li><li >Alexandre Varnek, </li><li >Dmitry I. Osolodkin, </li><li >Aydar A. Ishmukhametov, </li><li >Alexey M. Egorov, </li><li >Alexander G. Gabibov, </li><li >Nikita A. Kuznetsov, </li></ul>Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery, Frontiers in Pharmacology, 12, (2021).https://doi.org/10.3389/fphar.2021.773198<div >Crossref</div></li></ol></div><div ><div >Loading...</div></div></div></section> </div> </section></section></div><div ><header><h2>View Options</h2></header><div ><h3>View options</h3><section ><h4>PDF format</h4><p>Download this article as a PDF file</p>Download PDF</section></div><div ><h3>Get Access</h3><section > <div ><h5>Log in to view the full text</h5> <p>AAAS Log in</p> <p>AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul > <li >Become a AAAS Member</li> <li >Activate your Account</li> <li >Purchase Access to Other Journals in the Science Family</li> <li><a >Account Help</a></li> </ul> <div > <div >Log in via OpenAthens. <div ><a >via OpenAthens</a></div> </div> <div >Log in via Shibboleth. <div ><a >via Shibboleth</a></div> </div> </div> </div> <div ><h5>More options</h5><p><a >Purchase digital access to this article</a></p><p >Download and print this article for your personal scholarly, research, and educational use.</p><p><a >Purchase this issue in print</a></p><p>Buy a single issue of Science for just $15 USD.</p></div> </section></div></div><div ><header><h2>Media</h2></header><section ><h3>Figures</h3></section><section ><h3>Multimedia</h3></section></div><div ><header><h2>Tables</h2></header></div><div ><header><h2>Share</h2></header><h3>Share</h3><div ><section ><h4>Share article link</h4><div ><a >Copy Link</a><div ><p >Copied!</p><p >Copying failed.</p></div></div></section><section ><h4>Share on social media</h4><div ><a >facebook</a><a >twitter</a><a >linkedin</a><a >email</a></div></section></div></div></div></article><section ><div ><div ><div ><div ><h3 >Submit a Response to This Article</h3></div></div></div></div> <div > <div > <h2 >(0)eLetters</h2> </div> <p >eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> Log In to Submit a Response <p >No eLetters have been published for this article yet.</p> </div> </section> <div ><a >View Full Text</a><a >Download PDF</a></div> </div></div></div></div><div ><div ><div ><div ><section><div ><h4 > Current Issue </h4><div ><div > <div ><div><article ><div ><div ><h3 ><a >Cell-by-cell dissection of phloem development links a maturation gradient to cell specialization</a></h3><ul ><li >By<ul > <li >Pawel Roszak</li> <li >Jung-ok Heo</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >The energetics of uniquely human subsistence strategies</h3><ul ><li >By<ul > <li >Thomas S. Kraft</li> <li >Vivek V. Venkataraman</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >Early giant reveals faster evolution of large body size in ichthyosaurs than in cetaceans</h3><ul ><li >By<ul > <li >P. Martin Sander</li> <li >Eva Maria Griebeler</li> <li >et al.</li> </ul> </li></ul></div></div></article></div><div ><a >Table of Contents</a></div></div> </div></div></div></section><section > <h4 >LATEST NEWS</h4> <div > <div ><div > <article > <div > <div > News<time >30 Dec 2021</time> </div> <div > Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article > <div > <div > ScienceInsider<time >29 Dec 2021</time> </div> <div > Once a ‘crazy idea,’ patent-pooling nonprofit will help bring COVID-19 pills to world’s poor </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > The natural world loses two of its biggest advocates </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > <a > What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article > <div > <div > ScienceInsider<time >25 Dec 2021</time> </div> <div > NASA’s Webb telescope takes flight—a Christmas gift to astronomers everywhere </div> </div> </article> <article > <div > <div > News<time >23 Dec 2021</time> </div> <div > <a > More than a virus: Science’s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, tag: body, level: 1" node_number="1"> <div class="valid" valid="valid" title="valid: True, node: 2, tag: div, level: 2" node_number="2"> <div class="valid" valid="valid" title="valid: True, node: 3, tag: div, level: 3" node_number="3"> <div class="valid" valid="valid" title="valid: True, node: 4, tag: div, level: 4" node_number="4"> <div class="valid" valid="valid" title="valid: True, node: 5, tag: div, level: 5" node_number="5"> <div class="valid" valid="valid" title="valid: True, node: 6, tag: div, level: 6" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, tag: div, level: 7" node_number="7"> <div class="valid" valid="valid" title="valid: True, node: 8, tag: div, level: 8" node_number="8"> <div class="valid" valid="valid" title="valid: True, node: 9, tag: div, level: 9" node_number="9"> <div class="valid" valid="valid" title="valid: True, node: 10, tag: div, level: 10" node_number="10"> <div class="valid" valid="valid" title="valid: True, node: 11, tag: div, level: 11" node_number="11"> <span class="valid" valid="valid" title="valid: True, node: 12, tag: span, level: 12" node_number="12">Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header class="valid" valid="valid" title="valid: True, node: 13, tag: header, level: 5" node_number="13"> <div class="valid" valid="valid" title="valid: True, node: 14, tag: div, level: 6" node_number="14"><div class="valid" valid="valid" title="valid: True, node: 15, tag: div, level: 7" node_number="15"><div class="valid" valid="valid" title="valid: True, node: 16, tag: div, level: 8" node_number="16"><div class="valid" valid="valid" title="valid: True, node: 17, tag: div, level: 9" node_number="17"><div class="valid" valid="valid" title="valid: True, node: 18, tag: div, level: 10" node_number="18"><div class="valid" valid="valid" title="valid: True, node: 19, tag: div, level: 11" node_number="19"><div class="valid" valid="valid" title="valid: True, node: 20, tag: div, level: 12" node_number="20"><a class="valid" valid="valid" title="valid: True, node: 21, tag: a, level: 13" node_number="21"><div class="valid" valid="valid" title="valid: True, node: 22, tag: div, level: 14" node_number="22">science</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 23, tag: div, level: 11" node_number="23"><div class="valid" valid="valid" title="valid: True, node: 24, tag: div, level: 12" node_number="24"><a class="valid" valid="valid" title="valid: True, node: 25, tag: a, level: 13" node_number="25"><div class="valid" valid="valid" title="valid: True, node: 26, tag: div, level: 14" node_number="26">science advances</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 27, tag: div, level: 11" node_number="27"><div class="valid" valid="valid" title="valid: True, node: 28, tag: div, level: 12" node_number="28"><a class="valid" valid="valid" title="valid: True, node: 29, tag: a, level: 13" node_number="29"><div class="valid" valid="valid" title="valid: True, node: 30, tag: div, level: 14" node_number="30">science immunology</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 31, tag: div, level: 11" node_number="31"><div class="valid" valid="valid" title="valid: True, node: 32, tag: div, level: 12" node_number="32"><a class="valid" valid="valid" title="valid: True, node: 33, tag: a, level: 13" node_number="33"><div class="valid" valid="valid" title="valid: True, node: 34, tag: div, level: 14" node_number="34">science robotics</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 35, tag: div, level: 11" node_number="35"><div class="valid" valid="valid" title="valid: True, node: 36, tag: div, level: 12" node_number="36"><a class="valid" valid="valid" title="valid: True, node: 37, tag: a, level: 13" node_number="37"><div class="valid" valid="valid" title="valid: True, node: 38, tag: div, level: 14" node_number="38">science signaling</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 39, tag: div, level: 11" node_number="39"><div class="valid" valid="valid" title="valid: True, node: 40, tag: div, level: 12" node_number="40"><a class="valid" valid="valid" title="valid: True, node: 41, tag: a, level: 13" node_number="41"><div class="valid" valid="valid" title="valid: True, node: 42, tag: div, level: 14" node_number="42">science translational medicine</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 43, tag: div, level: 11" node_number="43"><div class="valid" valid="valid" title="valid: True, node: 44, tag: div, level: 12" node_number="44"><a class="valid" valid="valid" title="valid: True, node: 45, tag: a, level: 13" node_number="45"><div class="valid" valid="valid" title="valid: True, node: 46, tag: div, level: 14" node_number="46">science partner journals</div></a></div></div></div></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 47, tag: div, level: 6" node_number="47"> <div class="valid" valid="valid" title="valid: True, node: 48, tag: div, level: 7" node_number="48"> <div class="valid" valid="valid" title="valid: True, node: 49, tag: div, level: 8" node_number="49"> <div class="valid" valid="valid" title="valid: True, node: 50, tag: div, level: 9" node_number="50"> <div class="valid" valid="valid" title="valid: True, node: 51, tag: div, level: 10" node_number="51"><div class="valid" valid="valid" title="valid: True, node: 52, tag: div, level: 11" node_number="52"><div class="valid" valid="valid" title="valid: True, node: 53, tag: div, level: 12" node_number="53"><label class="valid" valid="valid" title="valid: True, node: 54, tag: label, level: 13" node_number="54">Searching:</label><div class="valid" valid="valid" title="valid: True, node: 55, tag: div, level: 13" node_number="55"><div class="valid" valid="valid" title="valid: True, node: 56, tag: div, level: 14" node_number="56"><div title="valid: False, node: 57, tag: div, level: 15" node_number="57">AnywhereScienceScience AdvancesScience ImmunologyScience RoboticsScience SignalingScience Translational Medicine</div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 58, tag: div, level: 12" node_number="58"> <a class="valid" valid="valid" title="valid: True, node: 59, tag: a, level: 13" node_number="59"><u class="valid" valid="valid" title="valid: True, node: 60, tag: u, level: 14" node_number="60">Advanced Search</u></a> </div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 61, tag: div, level: 7" node_number="61"> <div class="valid" valid="valid" title="valid: True, node: 62, tag: div, level: 8" node_number="62"> <div class="valid" valid="valid" title="valid: True, node: 63, tag: div, level: 9" node_number="63"> <h6 class="valid" valid="valid" title="valid: True, node: 64, tag: h6, level: 10" node_number="64">Trending Terms:</h6> <ul class="valid" valid="valid" title="valid: True, node: 65, tag: ul, level: 10" node_number="65"> <li class="valid" valid="valid" title="valid: True, node: 66, tag: li, level: 11" node_number="66"> covid-19 </li> <li class="valid" valid="valid" title="valid: True, node: 67, tag: li, level: 11" node_number="67"> climate </li> <li class="valid" valid="valid" title="valid: True, node: 68, tag: li, level: 11" node_number="68"> science policy </li> <li class="valid" valid="valid" title="valid: True, node: 69, tag: li, level: 11" node_number="69"> genome editing </li> <li class="valid" valid="valid" title="valid: True, node: 70, tag: li, level: 11" node_number="70"> batteries </li> </ul> </div> </div> </div> </div> </header><div class="valid" valid="valid" title="valid: True, node: 71, tag: div, level: 5" node_number="71"><div class="valid" valid="valid" title="valid: True, node: 72, tag: div, level: 6" node_number="72"><div class="valid" valid="valid" title="valid: True, node: 73, tag: div, level: 7" node_number="73"> <div class="valid" valid="valid" title="valid: True, node: 74, tag: div, level: 8" node_number="74"> <div class="valid" valid="valid" title="valid: True, node: 75, tag: div, level: 9" node_number="75"> <ul class="valid" valid="valid" title="valid: True, node: 76, tag: ul, level: 10" node_number="76"> <li class="valid" valid="valid" title="valid: True, node: 77, tag: li, level: 11" node_number="77"> Current Issue </li> <li class="valid" valid="valid" title="valid: True, node: 78, tag: li, level: 11" node_number="78"> First release papers </li> <li class="valid" valid="valid" title="valid: True, node: 79, tag: li, level: 11" node_number="79"> Archive </li> <li class="valid" valid="valid" title="valid: True, node: 80, tag: li, level: 11" node_number="80"> <div class="valid" valid="valid" title="valid: True, node: 81, tag: div, level: 12" node_number="81"> About <div class="valid" valid="valid" title="valid: True, node: 82, tag: div, level: 13" node_number="82"> About Science Mission Scope Editors Advisory Boards Editorial Policies Information for Authors Information for Reviewers Journal Metrics Staff Contact Us </div> </div> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 83, tag: div, level: 9" node_number="83"> <ul class="valid" valid="valid" title="valid: True, node: 84, tag: ul, level: 10" node_number="84"> <li class="valid" valid="valid" title="valid: True, node: 85, tag: li, level: 11" node_number="85"> Submit manuscript </li> <li class="valid" valid="valid" title="valid: True, node: 86, tag: li, level: 11" node_number="86"> <div class="valid" valid="valid" title="valid: True, node: 87, tag: div, level: 12" node_number="87"> More </div> </li> </ul> </div> </div> GET OUR E-ALERTS </div></div></div> <main class="valid" valid="valid" title="valid: True, node: 88, tag: main, level: 5" node_number="88"> <div class="valid" valid="valid" title="valid: True, node: 89, tag: div, level: 6" node_number="89"><div class="valid" valid="valid" title="valid: True, node: 90, tag: div, level: 7" node_number="90"><div class="valid" valid="valid" title="valid: True, node: 91, tag: div, level: 8" node_number="91"><div class="valid" valid="valid" title="valid: True, node: 92, tag: div, level: 9" node_number="92"><div class="valid" valid="valid" title="valid: True, node: 93, tag: div, level: 10" node_number="93"> <div class="valid" valid="valid" title="valid: True, node: 94, tag: div, level: 11" node_number="94">HomeScienceVol. 374, No. 6575<span class="valid" valid="valid" title="valid: True, node: 95, tag: span, level: 12" node_number="95">An oral SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 96, tag: sup, level: 13" node_number="96">pro</sup> inhibitor clinical candidate for the treatment of COVID-19</span></div><div class="valid" valid="valid" title="valid: True, node: 97, tag: div, level: 11" node_number="97">Back To Vol. 374, No. 6575</div> </div> <article class="valid" valid="valid" title="valid: True, node: 98, tag: article, level: 10" node_number="98"><section class="valid" valid="valid" title="valid: True, node: 99, tag: section, level: 11" node_number="99"><header class="valid" valid="valid" title="valid: True, node: 100, tag: header, level: 12" node_number="100"><div class="valid" valid="valid" title="valid: True, node: 101, tag: div, level: 13" node_number="101"><div class="valid" valid="valid" title="valid: True, node: 102, tag: div, level: 14" node_number="102"><div title="valid: False, node: 103, tag: div, level: 15" node_number="103"><div title="valid: False, node: 104, tag: div, level: 16" node_number="104">OPEN ACCESS</div><div title="valid: False, node: 105, tag: div, level: 16" node_number="105">Research Article</div><div title="valid: False, node: 106, tag: div, level: 16" node_number="106">CORONAVIRUS</div></div><div title="valid: False, node: 107, tag: div, level: 15" node_number="107"><div title="valid: False, node: 108, tag: div, level: 16" node_number="108"> <div title="valid: False, node: 109, tag: div, level: 17" node_number="109">Share on</div> </div></div></div><h1 class="valid" valid="valid" title="valid: True, node: 110, tag: h1, level: 14" node_number="110">An oral SARS-CoV-2 M<sup title="valid: False, node: 111, tag: sup, level: 15" node_number="111">pro</sup> inhibitor clinical candidate for the treatment of COVID-19</h1><div class="valid" valid="valid" title="valid: True, node: 112, tag: div, level: 14" node_number="112">Dafydd R. Owen https://orcid.org/0000-0003-3106-7809 [email&#160;protected], Charlotte M. N. Allerton https://orcid.org/0000-0001-8665-159X, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt https://orcid.org/0000-0001-5572-6771, Britton Boras https://orcid.org/0000-0003-3624-9177, &#8230; Show All &#8230; , Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman https://orcid.org/0000-0001-6164-7500, Alyssa Dantonio, Li Di https://orcid.org/0000-0001-6117-9022, Heather Eng https://orcid.org/0000-0002-2914-3967, RoseAnn Ferre https://orcid.org/0000-0001-7462-1879, Ketan S. Gajiwala, Scott A. Gibson, Samantha E. Greasley https://orcid.org/0000-0002-7978-6477, Brett L. Hurst https://orcid.org/0000-0003-1025-5878, Eugene P. Kadar https://orcid.org/0000-0003-3724-6517, Amit S. Kalgutkar https://orcid.org/0000-0001-9701-756X, Jack C. Lee, Jisun Lee https://orcid.org/0000-0003-1750-0063, Wei Liu, Stephen W. Mason, Stephen Noell https://orcid.org/0000-0003-3054-2575, Jonathan J. Novak https://orcid.org/0000-0002-3635-7955, R. Scott Obach https://orcid.org/0000-0002-6604-401X, Kevin Ogilvie, Nandini C. Patel https://orcid.org/0000-0002-2735-7662, Martin Pettersson https://orcid.org/0000-0001-8748-9539, Devendra K. Rai, Matthew R. Reese https://orcid.org/0000-0002-1066-2652, Matthew F. Sammons https://orcid.org/0000-0001-6472-0646, Jean G. Sathish, Ravi Shankar P. Singh https://orcid.org/0000-0001-6298-8219, Claire M. Steppan https://orcid.org/0000-0002-2609-7707, Al E. Stewart, Jamison B. Tuttle, Lawrence Updyke, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, and Yuao Zhu Show Fewer</div><div class="valid" valid="valid" title="valid: True, node: 113, tag: div, level: 14" node_number="113">Science &#8226; 2 Nov 2021 &#8226; Vol 374, Issue 6575 &#8226; pp. 1586-1593 &#8226; DOI: 10.1126/science.abl4784</div><div class="valid" valid="valid" title="valid: True, node: 114, tag: div, level: 14" node_number="114"><div title="valid: False, node: 115, tag: div, level: 15" node_number="115"> <div title="valid: False, node: 116, tag: div, level: 16" node_number="116"> <a title="valid: False, node: 117, tag: a, level: 17" node_number="117"><div title="valid: False, node: 118, tag: div, level: 18" node_number="118"><div title="valid: False, node: 119, tag: div, level: 19" node_number="119"><h6 title="valid: False, node: 120, tag: h6, level: 20" node_number="120">PREVIOUS ARTICLE</h6><div title="valid: False, node: 121, tag: div, level: 20" node_number="121">Pol IV and RDR2: A two-RNA-polymerase machine that produces double-stranded RNA</div></div></div>Previous</a><a title="valid: False, node: 122, tag: a, level: 17" node_number="122"><div title="valid: False, node: 123, tag: div, level: 18" node_number="123"><div title="valid: False, node: 124, tag: div, level: 19" node_number="124"><h6 title="valid: False, node: 125, tag: h6, level: 20" node_number="125">NEXT ARTICLE</h6><div title="valid: False, node: 126, tag: div, level: 20" node_number="126">Enhancement of lithium-mediated ammonia synthesis by addition of oxygen</div></div></div>Next</a> </div> </div></div></div></header><div class="valid" valid="valid" title="valid: True, node: 127, tag: div, level: 12" node_number="127"><div class="valid" valid="valid" title="valid: True, node: 128, tag: div, level: 13" node_number="128"><section class="valid" valid="valid" title="valid: True, node: 129, tag: section, level: 14" node_number="129"><h2 title="valid: False, node: 130, tag: h2, level: 15" node_number="130">Path to another drug against COVID-19</h2><div title="valid: False, node: 131, tag: div, level: 15" node_number="131">The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs. Owen <i title="valid: False, node: 132, tag: i, level: 16" node_number="132">et al</i>. report the discovery and characterization of a drug against the main protease involved in the cleavage of polyproteins involved in viral replication. The drug, PF-07321332, can be administered orally, has good selectivity and safety profiles, and protects against infection in a mouse model. In a phase 1 clinical trial, the drug reached concentrations expected to inhibit the virus based on in vitro studies. It also inhibited other coronaviruses, including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus, and could be in the armory against future viral threats. &#8212;VV</div></section><section class="valid" valid="valid" title="valid: True, node: 133, tag: section, level: 14" node_number="133"><h2 title="valid: False, node: 134, tag: h2, level: 15" node_number="134">Abstract</h2><div title="valid: False, node: 135, tag: div, level: 15" node_number="135">The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.</div></section></div></div></section><section class="valid" valid="valid" title="valid: True, node: 136, tag: section, level: 11" node_number="136"><div class="valid" valid="valid" title="valid: True, node: 137, tag: div, level: 12" node_number="137"><div class="valid" valid="valid" title="valid: True, node: 138, tag: div, level: 13" node_number="138">Human coronavirus infections are common, with at least four examples (229E, NL63, OC43, and HKU1) now considered endemic (<a class="valid" valid="valid" title="valid: True, node: 139, tag: a, level: 14" node_number="139"><i title="valid: False, node: 140, tag: i, level: 15" node_number="140">1</i></a>). However, the emergence within the past 20 years of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 as novel human coronaviruses has signaled the substantial threat potential of this viral class. The catastrophic SARS-CoV-2 outbreak of 2019 has resulted in 235 million confirmed cases of COVID-19 causing &gt;5.2 million deaths globally as of December 2021. SARS-CoV-2 is a highly infectious, RNA beta-coronavirus that can cause life-threatening viral pneumonia in the most serious cases. Although effective COVID-19 vaccines have been developed within unprecedented timelines, a large number of people are either unable due to preexisting medical conditions or unwilling to be vaccinated, and global access challenges remain. Limited therapeutic options are available to those who are infected. Oral SARS-CoV-2&#8211;specific therapeutics are urgently needed to prevent more severe disease, hospitalization, and death. Treatment may also reduce the period of infectivity. Repurposing of approved drugs in the search for small-molecule antiviral agents that target SARS-CoV-2 has thus far been minimally effective (<a class="valid" valid="valid" title="valid: True, node: 141, tag: a, level: 14" node_number="141"><i title="valid: False, node: 142, tag: i, level: 15" node_number="142">2</i></a>, <a class="valid" valid="valid" title="valid: True, node: 143, tag: a, level: 14" node_number="143"><i title="valid: False, node: 144, tag: i, level: 15" node_number="144">3</i></a>). Viral RNA&#8211;dependent RNA polymerase inhibitors such as molnupiravir and AT-527 are currently undergoing clinical trials for the treatment of COVID-19 (<a class="valid" valid="valid" title="valid: True, node: 145, tag: a, level: 14" node_number="145"><i title="valid: False, node: 146, tag: i, level: 15" node_number="146">4</i></a>, <a class="valid" valid="valid" title="valid: True, node: 147, tag: a, level: 14" node_number="147"><i title="valid: False, node: 148, tag: i, level: 15" node_number="148">5</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 149, tag: div, level: 13" node_number="149">The SARS-CoV-2 genome encodes two polyproteins, pp1a and pp1ab, and four structural proteins (<a class="valid" valid="valid" title="valid: True, node: 150, tag: a, level: 14" node_number="150"><i title="valid: False, node: 151, tag: i, level: 15" node_number="151">6</i></a>, <a class="valid" valid="valid" title="valid: True, node: 152, tag: a, level: 14" node_number="152"><i title="valid: False, node: 153, tag: i, level: 15" node_number="153">7</i></a>). The polyproteins are cleaved by the critical SARS-CoV-2 main protease (M<sup class="valid" valid="valid" title="valid: True, node: 154, tag: sup, level: 14" node_number="154">pro</sup>, also referred to as 3CL protease) at 11 different sites to yield shorter, nonstructural proteins vital to viral replication (<a class="valid" valid="valid" title="valid: True, node: 155, tag: a, level: 14" node_number="155"><i title="valid: False, node: 156, tag: i, level: 15" node_number="156">8</i></a>, <a class="valid" valid="valid" title="valid: True, node: 157, tag: a, level: 14" node_number="157"><i title="valid: False, node: 158, tag: i, level: 15" node_number="158">9</i></a>). The coronavirus M<sup class="valid" valid="valid" title="valid: True, node: 159, tag: sup, level: 14" node_number="159">pro</sup> is a three-domain cysteine protease that features a Cys145-His41 catalytic dyad located in the cleft between domains I and II. Several common features are shared among M<sup class="valid" valid="valid" title="valid: True, node: 160, tag: sup, level: 14" node_number="160">pro</sup> substrates, including the presence of a Gln residue at P1 [using Schechter-Berger nomenclature (<a class="valid" valid="valid" title="valid: True, node: 161, tag: a, level: 14" node_number="161"><i title="valid: False, node: 162, tag: i, level: 15" node_number="162">10</i></a>)]. No known human cysteine protease cleaves after Gln, thus offering potential selectivity for this viral target over the human proteome (<a class="valid" valid="valid" title="valid: True, node: 163, tag: a, level: 14" node_number="163"><i title="valid: False, node: 164, tag: i, level: 15" node_number="164">11</i></a>&#8211;<a class="valid" valid="valid" title="valid: True, node: 165, tag: a, level: 14" node_number="165"><i title="valid: False, node: 166, tag: i, level: 15" node_number="166">13</i></a>). Viral proteases are tractable targets for small-molecule oral therapies in the treatment of HIV and HCV (<a class="valid" valid="valid" title="valid: True, node: 167, tag: a, level: 14" node_number="167"><i title="valid: False, node: 168, tag: i, level: 15" node_number="168">14</i></a>, <a class="valid" valid="valid" title="valid: True, node: 169, tag: a, level: 14" node_number="169"><i title="valid: False, node: 170, tag: i, level: 15" node_number="170">15</i></a>). Moreover, a recent report has demonstrated oral activity of an M<sup class="valid" valid="valid" title="valid: True, node: 171, tag: sup, level: 14" node_number="171">pro</sup> inhibitor in a transgenic mouse model of SARS-CoV-2 infection (<a class="valid" valid="valid" title="valid: True, node: 172, tag: a, level: 14" node_number="172"><i title="valid: False, node: 173, tag: i, level: 15" node_number="173">16</i></a>). Given the pivotal role of SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 174, tag: sup, level: 14" node_number="174">pro</sup> in viral replication, its potential for mechanistic safety, and the expected lack of spike protein variant resistance challenges, SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 175, tag: sup, level: 14" node_number="175">pro</sup> inhibition represents an attractive small-molecule approach for an oral antiviral therapy to treat COVID-19.</div><div class="valid" valid="valid" title="valid: True, node: 176, tag: div, level: 13" node_number="176">An effort to identify inhibitors of the SARS-CoV-1 M<sup class="valid" valid="valid" title="valid: True, node: 177, tag: sup, level: 14" node_number="177">pro</sup> in response to the 2002 SARS outbreak led to the identification of PF-00835231 (<b class="valid" valid="valid" title="valid: True, node: 178, tag: b, level: 14" node_number="178">1</b>; Fig. 1) as a potent inhibitor of recombinant SARS-CoV-1 M<sup class="valid" valid="valid" title="valid: True, node: 179, tag: sup, level: 14" node_number="179">pro</sup> in a fluorescence resonance energy transfer (FRET)&#8211;based substrate cleavage assay (<a class="valid" valid="valid" title="valid: True, node: 180, tag: a, level: 14" node_number="180"><i title="valid: False, node: 181, tag: i, level: 15" node_number="181">17</i></a>). PF-00835231 also demonstrated potent inhibition [inhibition constant (<i class="valid" valid="valid" title="valid: True, node: 182, tag: i, level: 14" node_number="182">K</i><sub class="valid" valid="valid" title="valid: True, node: 183, tag: sub, level: 14" node_number="183">i</sub>) = 0.271 nM] of recombinant SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 184, tag: sup, level: 14" node_number="184">pro</sup>, which is expected given that the SARS-CoV-1 and SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 185, tag: sup, level: 14" node_number="185">pro</sup> share 100% sequence homology across their respective substrate-binding sites (<a class="valid" valid="valid" title="valid: True, node: 186, tag: a, level: 14" node_number="186"><i title="valid: False, node: 187, tag: i, level: 15" node_number="187">18</i></a>). Antiviral activity against SARS-CoV-2 was also observed with PF-00835231 [half-maximal effective concentration (EC<sub class="valid" valid="valid" title="valid: True, node: 188, tag: sub, level: 14" node_number="188">50</sub>) of 231 nM] by monitoring the cytopathic effect (CPE) in epithelial Vero E6 cells. Because Vero E6 cells express high levels of the efflux transporter P-glycoprotein, for which <b class="valid" valid="valid" title="valid: True, node: 189, tag: b, level: 14" node_number="189">1</b> is a substrate (<a class="valid" valid="valid" title="valid: True, node: 190, tag: a, level: 14" node_number="190"><i title="valid: False, node: 191, tag: i, level: 15" node_number="191">17</i></a>, <a class="valid" valid="valid" title="valid: True, node: 192, tag: a, level: 14" node_number="192"><i title="valid: False, node: 193, tag: i, level: 15" node_number="193">19</i></a>), antiviral assays in this cell line were conducted in the presence of the P-glycoprotein efflux inhibitor CP-100356 (<a class="valid" valid="valid" title="valid: True, node: 194, tag: a, level: 14" node_number="194"><i title="valid: False, node: 195, tag: i, level: 15" node_number="195">20</i></a>). TMPRSS2 expression was not detected in the Vero E6 cells by quantitative reverse transcription polymerase chain reaction. PF-07304814, the phosphate prodrug form of PF-00835231, is currently under investigation as an intravenous treatment option for COVID-19 in hospitalized patients (<a class="valid" valid="valid" title="valid: True, node: 196, tag: a, level: 14" node_number="196"><i title="valid: False, node: 197, tag: i, level: 15" node_number="197">20</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 198, tag: div, level: 13" node_number="198">To improve upon the low passive absorptive permeability (<i class="valid" valid="valid" title="valid: True, node: 199, tag: i, level: 14" node_number="199">P</i><sub class="valid" valid="valid" title="valid: True, node: 200, tag: sub, level: 14" node_number="200">app</sub> &lt; 0.207 &#215; 10<sup class="valid" valid="valid" title="valid: True, node: 201, tag: sup, level: 14" node_number="201">&#8722;6</sup> cm/s) (<a class="valid" valid="valid" title="valid: True, node: 202, tag: a, level: 14" node_number="202"><i title="valid: False, node: 203, tag: i, level: 15" node_number="203">21</i></a>) and poor oral absorption of <b class="valid" valid="valid" title="valid: True, node: 204, tag: b, level: 14" node_number="204">1</b> in animals, we aimed to remove the hydrogen bond donor (HBD) of the P1&#8242; &#945;-hydroxymethyl ketone moiety in <b class="valid" valid="valid" title="valid: True, node: 205, tag: b, level: 14" node_number="205">1</b> (Fig. 2A) because increased HBD count has been shown to be correlated with poor oral bioavailability (<a class="valid" valid="valid" title="valid: True, node: 206, tag: a, level: 14" node_number="206"><i title="valid: False, node: 207, tag: i, level: 15" node_number="207">22</i></a>). To this end, we pursued two functional groups precedented as covalent warheads for cysteine proteases in parallel: nitriles (<a class="valid" valid="valid" title="valid: True, node: 208, tag: a, level: 14" node_number="208"><i title="valid: False, node: 209, tag: i, level: 15" node_number="209">23</i></a>, <a class="valid" valid="valid" title="valid: True, node: 210, tag: a, level: 14" node_number="210"><i title="valid: False, node: 211, tag: i, level: 15" node_number="211">24</i></a>) and benzothiazol-2-yl ketones (<a class="valid" valid="valid" title="valid: True, node: 212, tag: a, level: 14" node_number="212"><i title="valid: False, node: 213, tag: i, level: 15" node_number="213">25</i></a>, <a class="valid" valid="valid" title="valid: True, node: 214, tag: a, level: 14" node_number="214"><i title="valid: False, node: 215, tag: i, level: 15" node_number="215">26</i></a>). The nitrile compound <b class="valid" valid="valid" title="valid: True, node: 216, tag: b, level: 14" node_number="216">2</b> demonstrated an increase in rat oral absorption [oral bioavailability (<i class="valid" valid="valid" title="valid: True, node: 217, tag: i, level: 14" node_number="217">F</i>) = 7.6% and fraction of oral dose absorbed from the gastrointestinal tract (<i class="valid" valid="valid" title="valid: True, node: 218, tag: i, level: 14" node_number="218">F</i><sub class="valid" valid="valid" title="valid: True, node: 219, tag: sub, level: 14" node_number="219">a</sub> &#215; <i class="valid" valid="valid" title="valid: True, node: 220, tag: i, level: 14" node_number="220">F</i><sub class="valid" valid="valid" title="valid: True, node: 221, tag: sub, level: 14" node_number="221">g</sub>) = 38%] (<a class="valid" valid="valid" title="valid: True, node: 222, tag: a, level: 14" node_number="222"><i title="valid: False, node: 223, tag: i, level: 15" node_number="223">27</i></a>) while maintaining reasonable metabolic stability [intrinsic clearance (CL<sub class="valid" valid="valid" title="valid: True, node: 224, tag: sub, level: 14" node_number="224">int</sub>)] against oxidative metabolism in human liver microsomes (HLMs) (<a class="valid" valid="valid" title="valid: True, node: 225, tag: a, level: 14" node_number="225"><i title="valid: False, node: 226, tag: i, level: 15" node_number="226">28</i></a>) relative to <b class="valid" valid="valid" title="valid: True, node: 227, tag: b, level: 14" node_number="227">1</b> (Fig. 1). However, the in vitro FRET M<sup class="valid" valid="valid" title="valid: True, node: 228, tag: sup, level: 14" node_number="228">pro</sup> potency (<i class="valid" valid="valid" title="valid: True, node: 229, tag: i, level: 14" node_number="229">K</i><sub class="valid" valid="valid" title="valid: True, node: 230, tag: sub, level: 14" node_number="230">i</sub> = 27.7 nM) and SARS-CoV-2 antiviral activity (EC<sub class="valid" valid="valid" title="valid: True, node: 231, tag: sub, level: 14" node_number="231">50</sub> = 1364 nM) of <b class="valid" valid="valid" title="valid: True, node: 232, tag: b, level: 14" node_number="232">2</b> was inferior to <b class="valid" valid="valid" title="valid: True, node: 233, tag: b, level: 14" node_number="233">1</b>. Introduction of a 6,6-dimethyl-3-azabicyclo[3.1.0]hexane as a cyclic leucine mimetic at P2 (Fig. 2B) removed the HBD from the P2/P3 amide linkage. Analog <b class="valid" valid="valid" title="valid: True, node: 234, tag: b, level: 14" node_number="234">3</b>, resulting from the combination of this cyclic P2 fragment with a P1&#8242; benzothiazolyl ketone, displayed high <i class="valid" valid="valid" title="valid: True, node: 235, tag: i, level: 14" node_number="235">P</i><sub class="valid" valid="valid" title="valid: True, node: 236, tag: sub, level: 14" node_number="236">app</sub> (10.3 &#215; 10<sup class="valid" valid="valid" title="valid: True, node: 237, tag: sup, level: 14" node_number="237">&#8722;6</sup> cm/s). The reduced biochemical SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 238, tag: sup, level: 14" node_number="238">pro</sup> inhibitory potency of <b class="valid" valid="valid" title="valid: True, node: 239, tag: b, level: 14" node_number="239">3</b> (<i class="valid" valid="valid" title="valid: True, node: 240, tag: i, level: 14" node_number="240">K</i><sub class="valid" valid="valid" title="valid: True, node: 241, tag: sub, level: 14" node_number="241">i</sub> = 230 nM) relative to other reported benzothiazole-2-yl SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 242, tag: sup, level: 14" node_number="242">pro</sup> inhibitors (<a class="valid" valid="valid" title="valid: True, node: 243, tag: a, level: 14" node_number="243"><i title="valid: False, node: 244, tag: i, level: 15" node_number="244">29</i></a>) containing leucine P2 groups can be rationalized from the binding mode observed for <b class="valid" valid="valid" title="valid: True, node: 245, tag: b, level: 14" node_number="245">3</b> (<a class="valid" valid="valid" title="valid: True, node: 246, tag: a, level: 14" node_number="246">Fig. 2C</a>). Although the 6,6-dimethyl-3-azabicyclo[3.1.0]hexane effectively fills the lipophilic S2 pocket formed by Met49, Met169, His41, and Gln189, productive hydrogen bonding of the ligand backbone to Gln189 is no longer possible (<a class="valid" valid="valid" title="valid: True, node: 247, tag: a, level: 14" node_number="247">Fig. 2C</a>). The inferior SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 248, tag: sup, level: 14" node_number="248">pro</sup> potency and the high CL<sub class="valid" valid="valid" title="valid: True, node: 249, tag: sub, level: 14" node_number="249">int</sub> (337 &#956;l/min/mg) precluded further investments in compound <b class="valid" valid="valid" title="valid: True, node: 250, tag: b, level: 14" node_number="250">3</b>. Similar to <b class="valid" valid="valid" title="valid: True, node: 251, tag: b, level: 14" node_number="251">1</b>, the P3 indole of <b class="valid" valid="valid" title="valid: True, node: 252, tag: b, level: 14" node_number="252">3</b> does not protrude into the S3 pocket (<a class="valid" valid="valid" title="valid: True, node: 253, tag: a, level: 14" node_number="253">Fig. 2, A and C</a>). To better occupy the S3 pocket, we introduced branched, acyclic P3 groups. The methanesulfonamide in compound <b class="valid" valid="valid" title="valid: True, node: 254, tag: b, level: 14" node_number="254">4</b> extends underneath Gln189, productively engaging P3 pocket residues and achieving improved hydrogen-bonding interactions with the Glu166 backbone (<a class="valid" valid="valid" title="valid: True, node: 255, tag: a, level: 14" node_number="255">Fig. 2D</a>) relative to <b class="valid" valid="valid" title="valid: True, node: 256, tag: b, level: 14" node_number="256">1</b> and <b class="valid" valid="valid" title="valid: True, node: 257, tag: b, level: 14" node_number="257">3</b>. Compound <b class="valid" valid="valid" title="valid: True, node: 258, tag: b, level: 14" node_number="258">4</b> demonstrated improved SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 259, tag: sup, level: 14" node_number="259">pro</sup> biochemical potency (<i class="valid" valid="valid" title="valid: True, node: 260, tag: i, level: 14" node_number="260">K</i><sub class="valid" valid="valid" title="valid: True, node: 261, tag: sub, level: 14" node_number="261">i</sub> = 7.93 nM), Vero E6 antiviral activity (EC<sub class="valid" valid="valid" title="valid: True, node: 262, tag: sub, level: 14" node_number="262">50</sub> = 909 nM), and HLM CL<sub class="valid" valid="valid" title="valid: True, node: 263, tag: sub, level: 14" node_number="263">int</sub> (127 &#956;l/min/mg) relative to <b class="valid" valid="valid" title="valid: True, node: 264, tag: b, level: 14" node_number="264">3</b> (<a class="valid" valid="valid" title="valid: True, node: 265, tag: a, level: 14" node_number="265">Fig. 1</a>). Examination of the rat pharmacokinetics of <b class="valid" valid="valid" title="valid: True, node: 266, tag: b, level: 14" node_number="266">4</b> also revealed improvements in oral absorption (<i class="valid" valid="valid" title="valid: True, node: 267, tag: i, level: 14" node_number="267">F</i> = 10%, <i class="valid" valid="valid" title="valid: True, node: 268, tag: i, level: 14" node_number="268">F</i><sub class="valid" valid="valid" title="valid: True, node: 269, tag: sub, level: 14" node_number="269">a</sub> &#215; <i class="valid" valid="valid" title="valid: True, node: 270, tag: i, level: 14" node_number="270">F</i><sub class="valid" valid="valid" title="valid: True, node: 271, tag: sub, level: 14" node_number="271">g</sub> = 84%) (<a class="valid" valid="valid" title="valid: True, node: 272, tag: a, level: 14" node_number="272">Fig. 1</a>). An effort to identify alternate P3 capping groups to sulfonamide led to trifluoroacetamide <b class="valid" valid="valid" title="valid: True, node: 273, tag: b, level: 14" node_number="273">5</b>. Compound <b class="valid" valid="valid" title="valid: True, node: 274, tag: b, level: 14" node_number="274">5</b> exhibited comparable biochemical potency (<i class="valid" valid="valid" title="valid: True, node: 275, tag: i, level: 14" node_number="275">K</i><sub class="valid" valid="valid" title="valid: True, node: 276, tag: sub, level: 14" node_number="276">i</sub> = 12.1 nM) to <b class="valid" valid="valid" title="valid: True, node: 277, tag: b, level: 14" node_number="277">4</b> but with greatly improved SARS-CoV-2 Vero E6 antiviral activity (EC<sub class="valid" valid="valid" title="valid: True, node: 278, tag: sub, level: 14" node_number="278">50</sub> = 85.3 nM and <i class="valid" valid="valid" title="valid: True, node: 279, tag: i, level: 14" node_number="279">P</i><sub class="valid" valid="valid" title="valid: True, node: 280, tag: sub, level: 14" node_number="280">app</sub> = 13.1 &#215; 10<sup class="valid" valid="valid" title="valid: True, node: 281, tag: sup, level: 14" node_number="281">&#8722;6</sup> cm/sec) as well as increased metabolic stability in HLMs (CL<sub class="valid" valid="valid" title="valid: True, node: 282, tag: sub, level: 14" node_number="282">int</sub> = 30.3 &#956;l/min/mg) (<a class="valid" valid="valid" title="valid: True, node: 283, tag: a, level: 14" node_number="283">Fig. 1</a>). <b class="valid" valid="valid" title="valid: True, node: 284, tag: b, level: 14" node_number="284">5</b> also shows greatly improved oral pharmacokinetics in both rats (<i class="valid" valid="valid" title="valid: True, node: 285, tag: i, level: 14" node_number="285">F</i> = 33%, <i class="valid" valid="valid" title="valid: True, node: 286, tag: i, level: 14" node_number="286">F</i><sub class="valid" valid="valid" title="valid: True, node: 287, tag: sub, level: 14" node_number="287">a</sub> &#215; <i class="valid" valid="valid" title="valid: True, node: 288, tag: i, level: 14" node_number="288">F</i><sub class="valid" valid="valid" title="valid: True, node: 289, tag: sub, level: 14" node_number="289">g</sub> = 100%) (<a class="valid" valid="valid" title="valid: True, node: 290, tag: a, level: 14" node_number="290">Fig. 1</a>) and monkeys (<i class="valid" valid="valid" title="valid: True, node: 291, tag: i, level: 14" node_number="291">F</i> = 7.9%, <i class="valid" valid="valid" title="valid: True, node: 292, tag: i, level: 14" node_number="292">F</i><sub class="valid" valid="valid" title="valid: True, node: 293, tag: sub, level: 14" node_number="293">a</sub> &#215; <i class="valid" valid="valid" title="valid: True, node: 294, tag: i, level: 14" node_number="294">F</i><sub class="valid" valid="valid" title="valid: True, node: 295, tag: sub, level: 14" node_number="295">g</sub> = 66%) (table S1). Introduction of the P1&#8242; nitrile to this scaffold led to the identification of the clinical candidate PF-07321332 (<b class="valid" valid="valid" title="valid: True, node: 296, tag: b, level: 14" node_number="296">6</b>; <a class="valid" valid="valid" title="valid: True, node: 297, tag: a, level: 14" node_number="297">Fig. 1</a>). Compound <b class="valid" valid="valid" title="valid: True, node: 298, tag: b, level: 14" node_number="298">6</b> is a potent inhibitor of SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 299, tag: sup, level: 14" node_number="299">pro</sup> biochemical activity (<i class="valid" valid="valid" title="valid: True, node: 300, tag: i, level: 14" node_number="300">K</i><sub class="valid" valid="valid" title="valid: True, node: 301, tag: sub, level: 14" node_number="301">i</sub> = 3.11 nM) with improved Vero E6 antiviral activity (EC<sub class="valid" valid="valid" title="valid: True, node: 302, tag: sub, level: 14" node_number="302">50</sub> = 74.5 nM) relative to compounds <b class="valid" valid="valid" title="valid: True, node: 303, tag: b, level: 14" node_number="303">2</b> to <b class="valid" valid="valid" title="valid: True, node: 304, tag: b, level: 14" node_number="304">4</b>. Compound <b class="valid" valid="valid" title="valid: True, node: 305, tag: b, level: 14" node_number="305">6</b> displays a similar binding mode (<a class="valid" valid="valid" title="valid: True, node: 306, tag: a, level: 14" node_number="306">Fig. 2E</a>) to compound <b class="valid" valid="valid" title="valid: True, node: 307, tag: b, level: 14" node_number="307">4</b>. The P1&#8242; nitrile of <b class="valid" valid="valid" title="valid: True, node: 308, tag: b, level: 14" node_number="308">6</b> forms a reversible covalent thioimidate adduct with the catalytic Cys145 (<a class="valid" valid="valid" title="valid: True, node: 309, tag: a, level: 14" node_number="309">Fig. 2F</a>). Reversibility of M<sup class="valid" valid="valid" title="valid: True, node: 310, tag: sup, level: 14" node_number="310">pro</sup> inhibition by <b class="valid" valid="valid" title="valid: True, node: 311, tag: b, level: 14" node_number="311">6</b> was demonstrated upon incubation of SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 312, tag: sup, level: 14" node_number="312">pro</sup> (2 mM) with 2 mM of either <b class="valid" valid="valid" title="valid: True, node: 313, tag: b, level: 14" node_number="313">6</b> or an irreversible M<sup class="valid" valid="valid" title="valid: True, node: 314, tag: sup, level: 14" node_number="314">pro</sup> inhibitor (compound <b class="valid" valid="valid" title="valid: True, node: 315, tag: b, level: 14" node_number="315">7</b>; <a class="valid" valid="valid" title="valid: True, node: 316, tag: a, level: 14" node_number="316">Fig. 3A</a>) (<a class="valid" valid="valid" title="valid: True, node: 317, tag: a, level: 14" node_number="317"><i title="valid: False, node: 318, tag: i, level: 15" node_number="318">17</i></a>) for 30 min and monitoring M<sup class="valid" valid="valid" title="valid: True, node: 319, tag: sup, level: 14" node_number="319">pro</sup> activity after 100-fold dilution of the incubation mixtures. No recovery of activity was observed after M<sup class="valid" valid="valid" title="valid: True, node: 320, tag: sup, level: 14" node_number="320">pro</sup> incubation with <b class="valid" valid="valid" title="valid: True, node: 321, tag: b, level: 14" node_number="321">7</b>. The recovery of &gt;50% M<sup class="valid" valid="valid" title="valid: True, node: 322, tag: sup, level: 14" node_number="322">pro</sup> activity after incubation with <b class="valid" valid="valid" title="valid: True, node: 323, tag: b, level: 14" node_number="323">6</b> indicates that inhibition of SARS-CoV-2 M<sup class="valid" valid="valid" title="valid: True, node: 324, tag: sup, level: 14" node_number="324">pro</sup> is reversible (<a class="valid" valid="valid" title="valid: True, node: 325, tag: a, level: 14" node_number="325">Fig. 3A</a>). We selected the nitrile compound <b class="valid" valid="valid" title="valid: True, node: 326, tag: b, level: 14" node_number="326">6</b> (named PF-07321332) over compound <b class="valid" valid="valid" title="valid: True, node: 327, tag: b, level: 14" node_number="327">5</b> as the clinical candidate based on ease of synthetic scale-up, enhanced solubility that allowed for a simple formulation vehicle in support of preclinical toxicology, and reduced propensity for epimerization at the P1 stereocenter.</div><div class="valid" valid="valid" title="valid: True, node: 328, tag: div, level: 13" node_number="328">PF-07321332 demonstrated potent inhibition in FRET M<sup class="valid" valid="valid" title="valid: True, node: 329, tag: sup, level: 14" node_number="329">pro</sup> assays representing M<sup class="valid" valid="valid" title="valid: True, node: 330, tag: sup, level: 14" node_number="330">pro</sup> from all coronavirus types known to infect humans (<a class="valid" valid="valid" title="valid: True, node: 331, tag: a, level: 14" node_number="331"><i title="valid: False, node: 332, tag: i, level: 15" node_number="332">6</i></a>, <a class="valid" valid="valid" title="valid: True, node: 333, tag: a, level: 14" node_number="333"><i title="valid: False, node: 334, tag: i, level: 15" node_number="334">7</i></a>, <a class="valid" valid="valid" title="valid: True, node: 335, tag: a, level: 14" node_number="335"><i title="valid: False, node: 336, tag: i, level: 15" node_number="336">30</i></a>), including beta-coronaviruses (SARS-CoV-2, SARS-CoV-1, HKU1, OC43, and MERS-CoV) as well as alpha-coronaviruses (229E and NL63) (<a class="valid" valid="valid" title="valid: True, node: 337, tag: a, level: 14" node_number="337">Fig. 3B</a> and table S2). No inhibitory effects were noted against several mammalian cysteine (caspase 2, cathepsin B, and cathepsin L), serine (chymotrypsin, elastase, and thrombin) and aspartyl (cathepsin D) proteases at the highest concentration tested (100 &#956;M) of PF-07321332 (table S3). This was also the case for HIV-1 protease, a viral aspartyl protease (table S3).</div><div class="valid" valid="valid" title="valid: True, node: 338, tag: div, level: 13" node_number="338">The in vitro antiviral activity of PF-07321332 was also evaluated in two physiologically relevant cellular systems: human adenocarcinoma&#8211;derived alveolar basal epithelial (A549) cells constitutively expressing ACE2 (<a class="valid" valid="valid" title="valid: True, node: 339, tag: a, level: 14" node_number="339"><i title="valid: False, node: 340, tag: i, level: 15" node_number="340">19</i></a>) and differentiated normal human bronchial epithelial (dNHBE) cells (<a class="valid" valid="valid" title="valid: True, node: 341, tag: a, level: 14" node_number="341"><i title="valid: False, node: 342, tag: i, level: 15" node_number="342">31</i></a>). In contrast to Vero E6 cells, A549 and dNHBE cells do not overly express P-glycoprotein, and therefore co-dosing with a P-glycoprotein inhibitor was not necessary to gauge antiviral activity in these cell lines (<a class="valid" valid="valid" title="valid: True, node: 343, tag: a, level: 14" node_number="343"><i title="valid: False, node: 344, tag: i, level: 15" node_number="344">19</i></a>). PF-07321332 inhibited SARS-CoV-2 replication as assessed using a nanoluciferase reporter virus in A549-ACE2 cells with EC<sub class="valid" valid="valid" title="valid: True, node: 345, tag: sub, level: 14" node_number="345">50</sub> and EC<sub class="valid" valid="valid" title="valid: True, node: 346, tag: sub, level: 14" node_number="346">90</sub> values of 77.9 and 215 nM, respectively, with no cytotoxicity detected at concentrations up to 3 &#956;M (<a class="valid" valid="valid" title="valid: True, node: 347, tag: a, level: 14" node_number="347">Fig. 3C</a> and table S4). Treatment of dNHBE cells with varying concentrations of PF-07321332 for 3 days led to inhibition of SARS-CoV-2 viral replication, with EC<sub class="valid" valid="valid" title="valid: True, node: 348, tag: sub, level: 14" node_number="348">50</sub> and EC<sub class="valid" valid="valid" title="valid: True, node: 349, tag: sub, level: 14" node_number="349">90</sub> values of 61.8 and 181 nM, respectively (<a class="valid" valid="valid" title="valid: True, node: 350, tag: a, level: 14" node_number="350">Fig. 3C</a>), as monitored by titration of virus harvested from the apical compartment using a 50% cell culture infective dose (CCID<sub class="valid" valid="valid" title="valid: True, node: 351, tag: sub, level: 14" node_number="351">50</sub>) assay in Vero76 cells. Increasing the duration of the dNHBE study to 5 days resulted in viral replication being inhibited, with EC<sub class="valid" valid="valid" title="valid: True, node: 352, tag: sub, level: 14" node_number="352">50</sub> and EC<sub class="valid" valid="valid" title="valid: True, node: 353, tag: sub, level: 14" node_number="353">90</sub> values of 32.6 and 56.1 nM, respectively (<a class="valid" valid="valid" title="valid: True, node: 354, tag: a, level: 14" node_number="354">Fig. 3C</a>). Because optimal therapeutic efficacy with marketed viral protease inhibitors and other antiviral agents is generally achieved when the minimum systemic unbound plasma concentration (<i class="valid" valid="valid" title="valid: True, node: 355, tag: i, level: 14" node_number="355">C</i><sub class="valid" valid="valid" title="valid: True, node: 356, tag: sub, level: 14" node_number="356">min</sub>) of inhibitor is maintained above cellular antiviral EC<sub class="valid" valid="valid" title="valid: True, node: 357, tag: sub, level: 14" node_number="357">90</sub> (<a class="valid" valid="valid" title="valid: True, node: 358, tag: a, level: 14" node_number="358"><i title="valid: False, node: 359, tag: i, level: 15" node_number="359">32</i></a>), we selected the more conservative day 3 EC<sub class="valid" valid="valid" title="valid: True, node: 360, tag: sub, level: 14" node_number="360">90</sub> value of 181 nM PF-07321332 in the dNHBE assay as the <i class="valid" valid="valid" title="valid: True, node: 361, tag: i, level: 14" node_number="361">C</i><sub class="valid" valid="valid" title="valid: True, node: 362, tag: sub, level: 14" node_number="362">min</sub> to be maintained when predicting efficacy in animal models and in the clinical setting. We further evaluated the in vitro cellular antiviral activity of PF-07321332 against SARS-CoV-1, MERS-CoV, and human coronavirus 229E using CPE assays. PF-07321332 demonstrated potent antiviral activity against SARS-CoV-1 (EC<sub class="valid" valid="valid" title="valid: True, node: 363, tag: sub, level: 14" node_number="363">90</sub> = 317 nM), MERS-CoV (EC<sub class="valid" valid="valid" title="valid: True, node: 364, tag: sub, level: 14" node_number="364">90</sub> = 351 nM), and 229E (EC<sub class="valid" valid="valid" title="valid: True, node: 365, tag: sub, level: 14" node_number="365">90</sub> = 620 nM) in their respective cellular assays (<a class="valid" valid="valid" title="valid: True, node: 366, tag: a, level: 14" node_number="366">Fig. 3D</a> and table S5).</div><div class="valid" valid="valid" title="valid: True, node: 367, tag: div, level: 13" node_number="367">We evaluated the in vivo antiviral activity of PF-07321332 in a mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA10) model (<a class="valid" valid="valid" title="valid: True, node: 368, tag: a, level: 14" node_number="368"><i title="valid: False, node: 369, tag: i, level: 15" node_number="369">33</i></a>). Intranasal infection of BALB/c mice with SARS-CoV-2 MA10 led to ~10% body weight loss and minimal mortality in 10-week-old mice. As shown in <a class="valid" valid="valid" title="valid: True, node: 370, tag: a, level: 14" node_number="370">Fig. 4A</a>, after infection with SARS-CoV-2 MA10, mice treated twice daily with PF-07321332 (at both 300 and 1000 mg/kg doses) were protected from weight loss compared with vehicle-treated mice. At 4 days after infection, mice were sacrificed and lung viral titers were evaluated in CCID<sub class="valid" valid="valid" title="valid: True, node: 371, tag: sub, level: 14" node_number="371">50</sub> assays. Infected animals in the placebo group (<i class="valid" valid="valid" title="valid: True, node: 372, tag: i, level: 14" node_number="372">n</i> = 12, two independent studies) had robust infection in the lungs (mean lung titer of log<sub class="valid" valid="valid" title="valid: True, node: 373, tag: sub, level: 14" node_number="373">10</sub> 4.93 &#177; 0.140 CCID<sub class="valid" valid="valid" title="valid: True, node: 374, tag: sub, level: 14" node_number="374">50</sub>/ml SARS-CoV-2 MA10) (<a class="valid" valid="valid" title="valid: True, node: 375, tag: a, level: 14" node_number="375">Fig. 4B</a>), whereas virus levels in mice treated with PF-07321332 were significantly reduced (mean lung titers of log<sub class="valid" valid="valid" title="valid: True, node: 376, tag: sub, level: 14" node_number="376">10</sub> 3.53 &#177; 0.187 and log<sub class="valid" valid="valid" title="valid: True, node: 377, tag: sub, level: 14" node_number="377">10</sub> 3.02 &#177; 0.423 CCID<sub class="valid" valid="valid" title="valid: True, node: 378, tag: sub, level: 14" node_number="378">50</sub>/ml for the 300 and 1000 mg/kg PF-07321332-treated groups, respectively). In a satellite group of uninfected mice, the 300 mg/kg twice daily (BID) dose of PF-07321332 used in the mouse-adapted viral in vivo efficacy study maintained <i class="valid" valid="valid" title="valid: True, node: 379, tag: i, level: 14" node_number="379">C</i><sub class="valid" valid="valid" title="valid: True, node: 380, tag: sub, level: 14" node_number="380">min</sub> unbound plasma concentrations above ~0.9 &#215; EC<sub class="valid" valid="valid" title="valid: True, node: 381, tag: sub, level: 14" node_number="381">90</sub> (<a class="valid" valid="valid" title="valid: True, node: 382, tag: a, level: 14" node_number="382">Fig. 4C</a>), as defined in the dNHBE primary cell assay. The 1000 mg/kg BID dose of PF-07321332 maintained a <i class="valid" valid="valid" title="valid: True, node: 383, tag: i, level: 14" node_number="383">C</i><sub class="valid" valid="valid" title="valid: True, node: 384, tag: sub, level: 14" node_number="384">min</sub> unbound plasma concentrations of ~4 &#215; EC<sub class="valid" valid="valid" title="valid: True, node: 385, tag: sub, level: 14" node_number="385">90</sub> (<a class="valid" valid="valid" title="valid: True, node: 386, tag: a, level: 14" node_number="386">Fig. 4C</a>). This confirms that PF-07321332 is effective at reducing SARS-CoV-2 MA10 viral load in mouse lungs at concentrations consistent with the observed in vitro antiviral potency and those being targeted clinically.</div><div class="valid" valid="valid" title="valid: True, node: 387, tag: div, level: 13" node_number="387">Disease in this model is manifest by weight loss and pathological changes in the lungs of the infected mice (<a class="valid" valid="valid" title="valid: True, node: 388, tag: a, level: 14" node_number="388"><i title="valid: False, node: 389, tag: i, level: 15" node_number="389">33</i></a>). Histopathological analysis and immunostaining of lungs from the SARS-CoV-2 MA10&#8211;infected mice showed that PF-07321332 limits cellular infiltration (<a class="valid" valid="valid" title="valid: True, node: 390, tag: a, level: 14" node_number="390">Fig. 4D</a> and fig. S2) and protects lung tissue from damage caused by virus replication (<a class="valid" valid="valid" title="valid: True, node: 391, tag: a, level: 14" node_number="391">Fig. 4E</a>). Immunohistochemical analysis using a viral nucleocapsid antibody to detect viral antigen levels in the lungs revealed that PF-07321332 inhibits virus replication in a dose-dependent manner (<a class="valid" valid="valid" title="valid: True, node: 392, tag: a, level: 14" node_number="392">Fig. 4E</a>). Lungs from vehicle-treated, infected mice showed the strongest staining, whereas mock-infected lungs were negative for nucleocapsid staining. Histopathological evaluation of lungs from the vehicle-treated mice demonstrated evidence of increased perivascular inflammation, bronchial or bronchiolar epithelial degeneration or necrosis, bronchial or bronchiolar inflammation, cellular debris in alveolar lumen, and alveolar inflammation and thickening of the alveolar septum compared with PF-07321332&#8211;treated mice and mock-infected mice (fig. S2). Most of the infected mice exhibited multifocal pulmonary lesions, which were significantly reduced in PF-07321332&#8211;treated mice.</div><div class="valid" valid="valid" title="valid: True, node: 393, tag: div, level: 13" node_number="393">PF-07321332 exhibited moderate plasma clearance (CL<sub class="valid" valid="valid" title="valid: True, node: 394, tag: sub, level: 14" node_number="394">p</sub>) in rats and monkeys, with elimination half-lives (<i class="valid" valid="valid" title="valid: True, node: 395, tag: i, level: 14" node_number="395">t</i><sub class="valid" valid="valid" title="valid: True, node: 396, tag: sub, level: 14" node_number="396">1/2</sub>) of 5 hours and &lt;1 hour, respectively, after intravenous dosing (table S6). After oral administration to rats, crystalline PF-07321332 (10 mg/kg) demonstrated <i class="valid" valid="valid" title="valid: True, node: 397, tag: i, level: 14" node_number="397">F</i><sub class="valid" valid="valid" title="valid: True, node: 398, tag: sub, level: 14" node_number="398">a</sub> &#215; <i class="valid" valid="valid" title="valid: True, node: 399, tag: i, level: 14" node_number="399">F</i><sub class="valid" valid="valid" title="valid: True, node: 400, tag: sub, level: 14" node_number="400">g</sub> and <i class="valid" valid="valid" title="valid: True, node: 401, tag: i, level: 14" node_number="401">F</i> values ranging from 65 to 95% and 34 to 50%, respectively, depending on the crystalline form used (<a class="valid" valid="valid" title="valid: True, node: 402, tag: a, level: 14" node_number="402">Fig. 1</a> and table S6). Oral administration of PF-07321332 (10 mg/kg) to monkeys led to a relatively poor <i class="valid" valid="valid" title="valid: True, node: 403, tag: i, level: 14" node_number="403">F</i> of 8.5% (<i class="valid" valid="valid" title="valid: True, node: 404, tag: i, level: 14" node_number="404">F</i><sub class="valid" valid="valid" title="valid: True, node: 405, tag: sub, level: 14" node_number="405">a</sub> &#215; <i class="valid" valid="valid" title="valid: True, node: 406, tag: i, level: 14" node_number="406">F</i><sub class="valid" valid="valid" title="valid: True, node: 407, tag: sub, level: 14" node_number="407">g</sub> = 20%) (table S6), which is attributed to first-pass metabolism along the gastrointestinal tract by cytochrome P450 (CYP) enzymes, consistent with a rapid (<i class="valid" valid="valid" title="valid: True, node: 408, tag: i, level: 14" node_number="408">t</i><sub class="valid" valid="valid" title="valid: True, node: 409, tag: sub, level: 14" node_number="409">1/2</sub> = 20.5 min, CL<sub class="valid" valid="valid" title="valid: True, node: 410, tag: sub, level: 14" node_number="410">int</sub> = 33.8 &#956;l/min/mg), NADPH-dependent metabolic turnover of PF-07321332 in monkey intestinal microsomes (table S7). PF-07321332 was resistant (<i class="valid" valid="valid" title="valid: True, node: 411, tag: i, level: 14" node_number="411">t</i><sub class="valid" valid="valid" title="valid: True, node: 412, tag: sub, level: 14" node_number="412">1/2</sub> &gt; 240 min, CL<sub class="valid" valid="valid" title="valid: True, node: 413, tag: sub, level: 14" node_number="413">int</sub> &lt;2.89 &#956;l/min/mg) to CYP-mediated metabolism in intestinal microsomes from rat and human. PF-07321332 (0.3 to 10 &#956;M) exhibited concentration-independent plasma protein binding in rat [mean plasma unbound fraction (<i class="valid" valid="valid" title="valid: True, node: 414, tag: i, level: 14" node_number="414">f</i><sub class="valid" valid="valid" title="valid: True, node: 415, tag: sub, level: 14" node_number="415">u,p</sub>) = 0.478], monkey (mean <i class="valid" valid="valid" title="valid: True, node: 416, tag: i, level: 14" node_number="416">f</i><sub class="valid" valid="valid" title="valid: True, node: 417, tag: sub, level: 14" node_number="417">u,p</sub> = 0.434), and human (mean <i class="valid" valid="valid" title="valid: True, node: 418, tag: i, level: 14" node_number="418">f</i><sub class="valid" valid="valid" title="valid: True, node: 419, tag: sub, level: 14" node_number="419">u,p</sub> = 0.310) under equilibrium dialysis conditions (<a class="valid" valid="valid" title="valid: True, node: 420, tag: a, level: 14" node_number="420"><i title="valid: False, node: 421, tag: i, level: 15" node_number="421">34</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 422, tag: div, level: 13" node_number="422">Drug-metabolizing enzymes involved in the metabolism of PF-07321332 were also studied. In NADPH-supplemented HLMs, PF-07321332 demonstrated moderate CL<sub class="valid" valid="valid" title="valid: True, node: 423, tag: sub, level: 14" node_number="423">int</sub> (24.5 &#956;l/min/mg) (<a class="valid" valid="valid" title="valid: True, node: 424, tag: a, level: 14" node_number="424">Fig. 1</a> and table S7), which was significantly inhibited (&#8805;82%) by the selective CYP3A4/5 inhibitor ketoconazole (<a class="valid" valid="valid" title="valid: True, node: 425, tag: a, level: 14" node_number="425"><i title="valid: False, node: 426, tag: i, level: 15" node_number="426">28</i></a>) (table S8). Moreover, the oxidative metabolic profile of PF-07321332 in HLMs, which includes modifications on the P2 6,6-dimethyl-3-azabicyclo[3.1.0]hexane, the <i class="valid" valid="valid" title="valid: True, node: 427, tag: i, level: 14" node_number="427">tert</i>-butyl group at the P3 position, and the P1 pyrrolidinone ring, was reproduced in incubations of PF-07321332 with recombinant human CYP3A4 (fig. S1). These in vitro studies, which established a predominant role for CYP3A4 in the metabolism of PF-07321332, also presented an opportunity to boost therapeutic concentrations of PF-07321332 in the clinic by co-dosing with the potent CYP3A4 inactivator ritonavir (RTV), which is used as a pharmacokinetic enhancer of several marketed protease inhibitors (e.g., darunavir and lopinavir) that are subject to metabolic clearance through CYP3A4 (<a class="valid" valid="valid" title="valid: True, node: 428, tag: a, level: 14" node_number="428"><i title="valid: False, node: 429, tag: i, level: 15" node_number="429">35</i></a>, <a class="valid" valid="valid" title="valid: True, node: 430, tag: a, level: 14" node_number="430"><i title="valid: False, node: 431, tag: i, level: 15" node_number="431">36</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 432, tag: div, level: 13" node_number="432">PF-07321332 demonstrated a favorable off-target selectivity profile in a broad panel of G protein&#8211;coupled receptors, kinases, transporters, and phosphodiesterase enzyme inhibitor screens, and was devoid of activity against the cardiac ion channels K<sub class="valid" valid="valid" title="valid: True, node: 433, tag: sub, level: 14" node_number="433">v</sub>1.1, Ca<sub class="valid" valid="valid" title="valid: True, node: 434, tag: sub, level: 14" node_number="434">v</sub>1.2, and Na<sub class="valid" valid="valid" title="valid: True, node: 435, tag: sub, level: 14" node_number="435">v</sub>1.5 (tables S9 and S10). PF-07321332 was not mutagenic or clastogenic in in vitro genetic toxicity studies and was negative in an in vivo rat micronucleus assay (table S11). Repeat oral dosing of PF-07321332 in 2-week regulatory toxicity studies in monkeys (60 to 600 mg/kg) and rats (40 to 1000 mg/kg) led to dose-dependent increases in both maximal plasma concentrations (<i class="valid" valid="valid" title="valid: True, node: 436, tag: i, level: 14" node_number="436">C</i><sub class="valid" valid="valid" title="valid: True, node: 437, tag: sub, level: 14" node_number="437">max</sub>) and area-under-the-plasma concentration versus time curves (AUCs) (<a class="valid" valid="valid" title="valid: True, node: 438, tag: a, level: 14" node_number="438">Fig. 5, A and B</a>, and table S12). This resulted in unbound <i class="valid" valid="valid" title="valid: True, node: 439, tag: i, level: 14" node_number="439">C</i><sub class="valid" valid="valid" title="valid: True, node: 440, tag: sub, level: 14" node_number="440">max</sub> and average concentrations (<i class="valid" valid="valid" title="valid: True, node: 441, tag: i, level: 14" node_number="441">C</i><sub class="valid" valid="valid" title="valid: True, node: 442, tag: sub, level: 14" node_number="442">av</sub>) margins of 273-fold and 65-fold in rats, respectively (day 14, 1000 mg/kg), and 510-fold and 245-fold in monkeys, respectively (day 15, 600 mg/kg), over the measured unbound EC<sub class="valid" valid="valid" title="valid: True, node: 443, tag: sub, level: 14" node_number="443">90</sub> value of PF-07321332 determined in the SARS-CoV-2 day 3 dNHBE cellular assay. PF-07321332 was well tolerated, with no adverse findings in either species; the corresponding no observed adverse effect levels (NOAELs) were the highest doses tested (600 mg/kg/day in monkeys and 1000 mg/kg/day in rats).</div><div class="valid" valid="valid" title="valid: True, node: 444, tag: div, level: 13" node_number="444">The safety, tolerability, and pharmacokinetics of PF-07321332 as a single agent and in combination with RTV are under investigation in a randomized, double-blind, placebo-controlled, single ascending dose study in healthy adult participants (table S13; <a class="valid" valid="valid" title="valid: True, node: 445, tag: a, level: 14" node_number="445">www.ClinicalTrials.gov</a> identifier: NCT04756531). At each dose tested, four participants were randomized to receive active treatment and two participants received placebo. In the PF-07321332/RTV co-administration dosing paradigm, each subject (active and placebo) received one tablet (100 mg) of RTV at &#8211;12 hours, 0 hours, and 12 hours. PF-07321332 was administered as an oral suspension under fasted conditions at 0 hours (minimum fast of ~10 hours before treatment). Preliminary plasma concentration versus time pharmacokinetic profiles achieved from two oral doses, PF-07321332 150 mg alone and PF-07321332 250 mg with RTV, are presented in <a class="valid" valid="valid" title="valid: True, node: 446, tag: a, level: 14" node_number="446">Fig. 5C</a>. PF-07321332 was safe and well tolerated and exhibited a significant boost in plasma concentrations when co-administered with RTV. Oral plasma concentrations of PF-07321332 250 mg with RTV were considerably above the SARS-COV-2 antiviral EC<sub class="valid" valid="valid" title="valid: True, node: 447, tag: sub, level: 14" node_number="447">90</sub> value (total EC<sub class="valid" valid="valid" title="valid: True, node: 448, tag: sub, level: 14" node_number="448">90</sub> = 292 ng/ml, unbound EC<sub class="valid" valid="valid" title="valid: True, node: 449, tag: sub, level: 14" node_number="449">90</sub> = 90.5 ng/ml, 181 nM) at 12 hours after dose, thus increasing confidence in achieving robust pan-coronavirus antiviral activity clinically (<a class="valid" valid="valid" title="valid: True, node: 450, tag: a, level: 14" node_number="450">Fig. 5D</a>). On the basis of these observations and the high safety margins at the NOAEL doses in animals, the efficacy of PF-07321332 in COVID-19 patients will be assessed with a twice-daily dosing paradigm with the potential to increase the dose of PF-07321332 as a single agent and/or co-administered with RTV.</div><section class="valid" valid="valid" title="valid: True, node: 451, tag: section, level: 13" node_number="451"><h2 class="valid" valid="valid" title="valid: True, node: 452, tag: h2, level: 14" node_number="452">Acknowledgments</h2><div class="valid" valid="valid" title="valid: True, node: 453, tag: div, level: 14" node_number="453">The authors thank the participants of the first-in-human (FIH) study. We would also like to acknowledge the many Pfizer colleagues who have contributed to the COVID-19 oral protease program across a number of disciplines. In particular, we acknowledge S. Sakata, J. Arcari, and J. Zhang for external research resourcing; K. Farley for NMR studies; L. Lanyon for protease panel data; Y. Lian, E. LaChapelle, S. Wright, S. O&#8217;Neil, E. Yang, J. Humphrey, and B. Boscoe for compound synthesis; S. Jenkinson for safety pharmacology data; K. Ryan for structural biology support; E. Collins and C. Allais for FIH-enabling active pharmaceutical ingredient supply; F. Clark for bioanalysis; H. Shi for clinical assay support; G. Nucci and A. Bergman for first-in-human study design and clinical pharmacology; F. Hackman for clinical statistics; S. Toussi for medical monitoring; K. Bartsch for clinical study leadership; S. Pawlak for clinical trial leadership; C. Fredette for clinical trial project management; D. Ding for regulatory documentation support; and M. Dolsten for scientific discussion and advice. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. Extraordinary facility operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on the response to COVID-19, with funding provided by the Coronavirus CARES Act.</div><div class="valid" valid="valid" title="valid: True, node: 454, tag: div, level: 14" node_number="454"><b title="valid: False, node: 455, tag: b, level: 15" node_number="455">Funding:</b> This study was sponsored by Pfizer, Inc.</div><div class="valid" valid="valid" title="valid: True, node: 456, tag: div, level: 14" node_number="456"><b title="valid: False, node: 457, tag: b, level: 15" node_number="457">Author contributions:</b> Conceptualization: C.M.N.A., A.S.A., D.R.O., M.P.; Formal analysis: L.D., B.B., S.E.G., Q.Y., D.K.R., J.J.N., A.D., R.S.O., R.S.P.S.; Investigation: M.A., S.B., J.C.L., J.L., K.O., L.W., R.F., K.S.G., W.L., R.S.O., D.K.R., S.A.G., L.A., S.N., H.E.; Methodology: J.B.T., Q.Y., M.F.S., P.R.V., M.R.R., M.P., D.R.O., N.C.P., A.C., E.P.K., K.J.C., R.S.P.S.; Project administration: D.R.O., M.R.R., J.B.T., A.S.K., C.M.S., L.U., J.G.S., B.L.H., Y.Z., S.W.M., R.D.C., N.C.P.; Resources: A.D., J.J.N., K.J.C.; Supervision: M.R.R., C.E.S., A.E.S., B.L.H., P.R.V., R.D.C.; Visualization: S.W.M., D.K.R., S.N., B.B., L.A., H.E.; Writing &#8211; original draft: D.R.O., A.S.K., M.F.S., C.M.S., R.D.C., M.R.R., J.G.S., C.M.S., Y.Z.; Writing &#8211; review and editing: D.R.O., A.S.K., M.F.S., A.S.A., C.M.N.A.</div><div class="valid" valid="valid" title="valid: True, node: 458, tag: div, level: 14" node_number="458"><b title="valid: False, node: 459, tag: b, level: 15" node_number="459">Competing interests:</b> D.R.O., C.M.N.A., A.S.A., L.A., M.A., S.B., B.B., R.D.C., A.C., K.J.C., A.D., L.D., H.E., R.F., K.S.G., S.E.G., E.P.K., A.S.K., J.C.L., J.L., W.L., S.N., R.S.O., K.O., N.C.P., D.K.R., M.R.R., M.F.S., J.G.S., R.P.S., C.M.S., A.S., J.B.T., L.U., P.R.V., L.W., Q.Y., and Y.Z. are employees of Pfizer and some of the authors are shareholders in Pfizer Inc. S.W.M., J.J.N., and M.P. were employees of Pfizer Inc. during part of this study.</div><div class="valid" valid="valid" title="valid: True, node: 460, tag: div, level: 14" node_number="460"><b title="valid: False, node: 461, tag: b, level: 15" node_number="461">Data and materials availability:</b> All nonclinical data are available in the main text or the supplementary materials. X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under accession codes 7RFR, 7RFU, 7RFS, and 7RFW. Individualized <a title="valid: False, node: 462, tag: a, level: 15" node_number="462">Fig. 5</a> data and the statistical analysis plan are available on <a title="valid: False, node: 463, tag: a, level: 15" node_number="463">www.Figshare.com</a> with the following DOI: 10.25454/pfizer.figshare.16699669. Pfizer compound use requests are processed through the Pure Compound Grants program (see <a title="valid: False, node: 464, tag: a, level: 15" node_number="464">https://www.cybergrants.com/pfizer/Research</a>). Pfizer Inc. has applied for patent applications covering PF-07321332 as well as related compounds. A phase 1 clinical trial has been registered at <a title="valid: False, node: 465, tag: a, level: 15" node_number="465">www.ClinicalTrials.gov</a> under identifier NCT04756531. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 466, tag: a, level: 15" node_number="466">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section> </div></section><section class="valid" valid="valid" title="valid: True, node: 467, tag: section, level: 11" node_number="467"><div class="valid" valid="valid" title="valid: True, node: 468, tag: div, level: 12" node_number="468"><section class="valid" valid="valid" title="valid: True, node: 469, tag: section, level: 13" node_number="469"><h2 class="valid" valid="valid" title="valid: True, node: 470, tag: h2, level: 14" node_number="470">Supplementary Materials</h2><section class="valid" valid="valid" title="valid: True, node: 471, tag: section, level: 14" node_number="471"><h3 title="valid: False, node: 472, tag: h3, level: 15" node_number="472">This PDF file includes:</h3><div title="valid: False, node: 473, tag: div, level: 15" node_number="473"><div title="valid: False, node: 474, tag: div, level: 16" node_number="474"><div title="valid: False, node: 475, tag: div, level: 17" node_number="475">Materials and Methods</div><div title="valid: False, node: 476, tag: div, level: 17" node_number="476">Figs. S1 and S2</div><div title="valid: False, node: 477, tag: div, level: 17" node_number="477">Tables S1 to S13</div><div title="valid: False, node: 478, tag: div, level: 17" node_number="478">References (<a title="valid: False, node: 479, tag: a, level: 18" node_number="479"><i title="valid: False, node: 480, tag: i, level: 19" node_number="480">37</i></a>&#8211;<a title="valid: False, node: 481, tag: a, level: 18" node_number="481"><i title="valid: False, node: 482, tag: i, level: 19" node_number="482">70</i></a>)</div></div><div title="valid: False, node: 483, tag: div, level: 16" node_number="483"><a title="valid: False, node: 484, tag: a, level: 17" node_number="484">Download (4.60 MB)</a></div></div></section><section class="valid" valid="valid" title="valid: True, node: 485, tag: section, level: 14" node_number="485"><h3 title="valid: False, node: 486, tag: h3, level: 15" node_number="486">Other Supplementary Material for this manuscript includes the following:</h3><div title="valid: False, node: 487, tag: div, level: 15" node_number="487"><div title="valid: False, node: 488, tag: div, level: 16" node_number="488"><div title="valid: False, node: 489, tag: div, level: 17" node_number="489">MDAR Reproducibility Checklist</div></div><div title="valid: False, node: 490, tag: div, level: 16" node_number="490"><a title="valid: False, node: 491, tag: a, level: 17" node_number="491">Download (128.44 KB)</a></div></div></section></section><div class="valid" valid="valid" title="valid: True, node: 492, tag: div, level: 13" node_number="492"><a class="valid" valid="valid" title="valid: True, node: 493, tag: a, level: 14" node_number="493">View/request a protocol for this paper from <i title="valid: False, node: 494, tag: i, level: 15" node_number="494">Bio-protocol</i>.</a></div><section class="valid" valid="valid" title="valid: True, node: 495, tag: section, level: 13" node_number="495"><h2 class="valid" valid="valid" title="valid: True, node: 496, tag: h2, level: 14" node_number="496">References and Notes</h2><div class="valid" valid="valid" title="valid: True, node: 497, tag: div, level: 14" node_number="497"><div title="valid: False, node: 498, tag: div, level: 15" node_number="498">1</div><div title="valid: False, node: 499, tag: div, level: 15" node_number="499"><div title="valid: False, node: 500, tag: div, level: 16" node_number="500"><div title="valid: False, node: 501, tag: div, level: 17" node_number="501">V. M. Corman, D. Muth, D. Niemeyer, C. Drosten, Hosts and sources of endemic human coronaviruses. Adv. Virus Res. <b title="valid: False, node: 502, tag: b, level: 18" node_number="502">100</b>, 163&#8211;188 (2018).</div><div title="valid: False, node: 503, tag: div, level: 17" node_number="503"><div title="valid: False, node: 504, tag: div, level: 18" node_number="504"><a title="valid: False, node: 505, tag: a, level: 19" node_number="505">Crossref</a></div><div title="valid: False, node: 506, tag: div, level: 18" node_number="506"><a title="valid: False, node: 507, tag: a, level: 19" node_number="507">PubMed</a></div><div title="valid: False, node: 508, tag: div, level: 18" node_number="508"><a title="valid: False, node: 509, tag: a, level: 19" node_number="509">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 510, tag: div, level: 14" node_number="510"><div title="valid: False, node: 511, tag: div, level: 15" node_number="511">2</div><div title="valid: False, node: 512, tag: div, level: 15" node_number="512"><div title="valid: False, node: 513, tag: div, level: 16" node_number="513"><div title="valid: False, node: 514, tag: div, level: 17" node_number="514">WHO Solidarity Trial Consortium, Repurposed antiviral drugs for Covid-19 &#8211; Interim WHO Solidarity Trial results. N. Engl. J. Med. <b title="valid: False, node: 515, tag: b, level: 18" node_number="515">384</b>, 497&#8211;511 (2021).</div><div title="valid: False, node: 516, tag: div, level: 17" node_number="516"><div title="valid: False, node: 517, tag: div, level: 18" node_number="517"><a title="valid: False, node: 518, tag: a, level: 19" node_number="518">Crossref</a></div><div title="valid: False, node: 519, tag: div, level: 18" node_number="519"><a title="valid: False, node: 520, tag: a, level: 19" node_number="520">PubMed</a></div><div title="valid: False, node: 521, tag: div, level: 18" node_number="521"><a title="valid: False, node: 522, tag: a, level: 19" node_number="522">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 523, tag: div, level: 14" node_number="523"><div title="valid: False, node: 524, tag: div, level: 15" node_number="524">3</div><div title="valid: False, node: 525, tag: div, level: 15" node_number="525"><div title="valid: False, node: 526, tag: div, level: 16" node_number="526"><div title="valid: False, node: 527, tag: div, level: 17" node_number="527">L. Riva, S. Yuan, X. Yin, L. Martin-Sancho, N. Matsunaga, L. Pache, S. Burgstaller-Muehlbacher, P. D. De Jesus, P. Teriete, M. V. Hull, M. W. Chang, J. F. Chan, J. Cao, V. K. Poon, K. M. Herbert, K. Cheng, T. H. Nguyen, A. Rubanov, Y. Pu, C. Nguyen, A. Choi, R. Rathnasinghe, M. Schotsaert, L. Miorin, M. Dejosez, T. P. Zwaka, K. Y. Sit, L. Martinez-Sobrido, W. C. Liu, K. M. White, M. E. Chapman, E. K. Lendy, R. J. Glynne, R. Albrecht, E. Ruppin, A. D. Mesecar, J. R. Johnson, C. Benner, R. Sun, P. G. Schultz, A. I. Su, A. Garc&#237;a-Sastre, A. K. Chatterjee, K. Y. Yuen, S. K. Chanda, Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature <b title="valid: False, node: 528, tag: b, level: 18" node_number="528">586</b>, 113&#8211;119 (2020).</div><div title="valid: False, node: 529, tag: div, level: 17" node_number="529"><div title="valid: False, node: 530, tag: div, level: 18" node_number="530"><a title="valid: False, node: 531, tag: a, level: 19" node_number="531">Crossref</a></div><div title="valid: False, node: 532, tag: div, level: 18" node_number="532"><a title="valid: False, node: 533, tag: a, level: 19" node_number="533">PubMed</a></div><div title="valid: False, node: 534, tag: div, level: 18" node_number="534"><a title="valid: False, node: 535, tag: a, level: 19" node_number="535">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 536, tag: div, level: 14" node_number="536"><div title="valid: False, node: 537, tag: div, level: 15" node_number="537">4</div><div title="valid: False, node: 538, tag: div, level: 15" node_number="538"><div title="valid: False, node: 539, tag: div, level: 16" node_number="539"><div title="valid: False, node: 540, tag: div, level: 17" node_number="540">A. Wahl, L. E. Gralinski, C. E. Johnson, W. Yao, M. Kovarova, K. H. Dinnon 3rd, H. Liu, V. J. Madden, H. M. Krzystek, C. De, K. K. White, K. Gully, A. Sch&#228;fer, T. Zaman, S. R. Leist, P. O. Grant, G. R. Bluemling, A. A. Kolykhalov, M. G. Natchus, F. B. Askin, G. Painter, E. P. Browne, C. D. Jones, R. J. Pickles, R. S. Baric, J. V. Garcia, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature <b title="valid: False, node: 541, tag: b, level: 18" node_number="541">591</b>, 451&#8211;457 (2021).</div><div title="valid: False, node: 542, tag: div, level: 17" node_number="542"><div title="valid: False, node: 543, tag: div, level: 18" node_number="543"><a title="valid: False, node: 544, tag: a, level: 19" node_number="544">Crossref</a></div><div title="valid: False, node: 545, tag: div, level: 18" node_number="545"><a title="valid: False, node: 546, tag: a, level: 19" node_number="546">PubMed</a></div><div title="valid: False, node: 547, tag: div, level: 18" node_number="547"><a title="valid: False, node: 548, tag: a, level: 19" node_number="548">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 549, tag: div, level: 14" node_number="549"><div title="valid: False, node: 550, tag: div, level: 15" node_number="550">5</div><div title="valid: False, node: 551, tag: div, level: 15" node_number="551"><div title="valid: False, node: 552, tag: div, level: 16" node_number="552"><div title="valid: False, node: 553, tag: div, level: 17" node_number="553">S. S. Good, J. Westover, K. H. Jung, X. J. Zhou, A. Moussa, P. La Colla, G. Collu, B. Canard, J. P. Sommadossi, AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob. Agents Chemother. <b title="valid: False, node: 554, tag: b, level: 18" node_number="554">65</b>, e02479&#8211;e02420 (2021).</div><div title="valid: False, node: 555, tag: div, level: 17" node_number="555"><div title="valid: False, node: 556, tag: div, level: 18" node_number="556"><a title="valid: False, node: 557, tag: a, level: 19" node_number="557">Crossref</a></div><div title="valid: False, node: 558, tag: div, level: 18" node_number="558"><a title="valid: False, node: 559, tag: a, level: 19" node_number="559">PubMed</a></div><div title="valid: False, node: 560, tag: div, level: 18" node_number="560"><a title="valid: False, node: 561, tag: a, level: 19" node_number="561">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 562, tag: div, level: 14" node_number="562"><div title="valid: False, node: 563, tag: div, level: 15" node_number="563">6</div><div title="valid: False, node: 564, tag: div, level: 15" node_number="564"><div title="valid: False, node: 565, tag: div, level: 16" node_number="565"><div title="valid: False, node: 566, tag: div, level: 17" node_number="566">F. Wu, S. Zhao, B. Yu, Y. M. Chen, W. Wang, Z. G. Song, Y. Hu, Z. W. Tao, J. H. Tian, Y. Y. Pei, M. L. Yuan, Y. L. Zhang, F. H. Dai, Y. Liu, Q. M. Wang, J. J. Zheng, L. Xu, E. C. Holmes, Y. Z. Zhang, A new coronavirus associated with human respiratory disease in China. Nature <b title="valid: False, node: 567, tag: b, level: 18" node_number="567">579</b>, 265&#8211;269 (2020).</div><div title="valid: False, node: 568, tag: div, level: 17" node_number="568"><div title="valid: False, node: 569, tag: div, level: 18" node_number="569"><a title="valid: False, node: 570, tag: a, level: 19" node_number="570">Crossref</a></div><div title="valid: False, node: 571, tag: div, level: 18" node_number="571"><a title="valid: False, node: 572, tag: a, level: 19" node_number="572">PubMed</a></div><div title="valid: False, node: 573, tag: div, level: 18" node_number="573"><a title="valid: False, node: 574, tag: a, level: 19" node_number="574">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 575, tag: div, level: 14" node_number="575"><div title="valid: False, node: 576, tag: div, level: 15" node_number="576">7</div><div title="valid: False, node: 577, tag: div, level: 15" node_number="577"><div title="valid: False, node: 578, tag: div, level: 16" node_number="578"><div title="valid: False, node: 579, tag: div, level: 17" node_number="579">P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L. Huang, H. D. Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng, K. Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, Z. L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature <b title="valid: False, node: 580, tag: b, level: 18" node_number="580">579</b>, 270&#8211;273 (2020).</div><div title="valid: False, node: 581, tag: div, level: 17" node_number="581"><div title="valid: False, node: 582, tag: div, level: 18" node_number="582"><a title="valid: False, node: 583, tag: a, level: 19" node_number="583">Crossref</a></div><div title="valid: False, node: 584, tag: div, level: 18" node_number="584"><a title="valid: False, node: 585, tag: a, level: 19" node_number="585">PubMed</a></div><div title="valid: False, node: 586, tag: div, level: 18" node_number="586"><a title="valid: False, node: 587, tag: a, level: 19" node_number="587">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 588, tag: div, level: 14" node_number="588"><div title="valid: False, node: 589, tag: div, level: 15" node_number="589">8</div><div title="valid: False, node: 590, tag: div, level: 15" node_number="590"><div title="valid: False, node: 591, tag: div, level: 16" node_number="591"><div title="valid: False, node: 592, tag: div, level: 17" node_number="592">T. Pillaiyar, M. Manickam, V. Namasivayam, Y. Hayashi, S. H. Jung, An overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. J. Med. Chem. <b title="valid: False, node: 593, tag: b, level: 18" node_number="593">59</b>, 6595&#8211;6628 (2016).</div><div title="valid: False, node: 594, tag: div, level: 17" node_number="594"><div title="valid: False, node: 595, tag: div, level: 18" node_number="595"><a title="valid: False, node: 596, tag: a, level: 19" node_number="596">Crossref</a></div><div title="valid: False, node: 597, tag: div, level: 18" node_number="597"><a title="valid: False, node: 598, tag: a, level: 19" node_number="598">PubMed</a></div><div title="valid: False, node: 599, tag: div, level: 18" node_number="599"><a title="valid: False, node: 600, tag: a, level: 19" node_number="600">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 601, tag: div, level: 14" node_number="601"><div title="valid: False, node: 602, tag: div, level: 15" node_number="602">9</div><div title="valid: False, node: 603, tag: div, level: 15" node_number="603"><div title="valid: False, node: 604, tag: div, level: 16" node_number="604"><div title="valid: False, node: 605, tag: div, level: 17" node_number="605">Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, J. Yu, L. Wang, K. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao, H. Yang, Structure of M<sup title="valid: False, node: 606, tag: sup, level: 18" node_number="606">pro</sup> from SARS-CoV-2 and discovery of its inhibitors. Nature <b title="valid: False, node: 607, tag: b, level: 18" node_number="607">582</b>, 289&#8211;293 (2020).</div><div title="valid: False, node: 608, tag: div, level: 17" node_number="608"><div title="valid: False, node: 609, tag: div, level: 18" node_number="609"><a title="valid: False, node: 610, tag: a, level: 19" node_number="610">Crossref</a></div><div title="valid: False, node: 611, tag: div, level: 18" node_number="611"><a title="valid: False, node: 612, tag: a, level: 19" node_number="612">PubMed</a></div><div title="valid: False, node: 613, tag: div, level: 18" node_number="613"><a title="valid: False, node: 614, tag: a, level: 19" node_number="614">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 615, tag: div, level: 14" node_number="615"><div title="valid: False, node: 616, tag: div, level: 15" node_number="616">10</div><div title="valid: False, node: 617, tag: div, level: 15" node_number="617"><div title="valid: False, node: 618, tag: div, level: 16" node_number="618"><div title="valid: False, node: 619, tag: div, level: 17" node_number="619">I. Schechter, A. Berger, On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. <b title="valid: False, node: 620, tag: b, level: 18" node_number="620">27</b>, 157&#8211;162 (1967).</div><div title="valid: False, node: 621, tag: div, level: 17" node_number="621"><div title="valid: False, node: 622, tag: div, level: 18" node_number="622"><a title="valid: False, node: 623, tag: a, level: 19" node_number="623">Crossref</a></div><div title="valid: False, node: 624, tag: div, level: 18" node_number="624"><a title="valid: False, node: 625, tag: a, level: 19" node_number="625">PubMed</a></div><div title="valid: False, node: 626, tag: div, level: 18" node_number="626"><a title="valid: False, node: 627, tag: a, level: 19" node_number="627">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 628, tag: div, level: 14" node_number="628"><div title="valid: False, node: 629, tag: div, level: 15" node_number="629">11</div><div title="valid: False, node: 630, tag: div, level: 15" node_number="630"><div title="valid: False, node: 631, tag: div, level: 16" node_number="631"><div title="valid: False, node: 632, tag: div, level: 17" node_number="632">W. Rut, K. Groborz, L. Zhang, X. Sun, M. Zmudzinski, B. Pawlik, X. Wang, D. Jochmans, J. Neyts, W. M&#322;ynarski, R. Hilgenfeld, M. Drag, SARS-CoV-2 M<sup title="valid: False, node: 633, tag: sup, level: 18" node_number="633">pro</sup> inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. <b title="valid: False, node: 634, tag: b, level: 18" node_number="634">17</b>, 222&#8211;228 (2021).</div><div title="valid: False, node: 635, tag: div, level: 17" node_number="635"><div title="valid: False, node: 636, tag: div, level: 18" node_number="636"><a title="valid: False, node: 637, tag: a, level: 19" node_number="637">Crossref</a></div><div title="valid: False, node: 638, tag: div, level: 18" node_number="638"><a title="valid: False, node: 639, tag: a, level: 19" node_number="639">PubMed</a></div><div title="valid: False, node: 640, tag: div, level: 18" node_number="640"><a title="valid: False, node: 641, tag: a, level: 19" node_number="641">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 642, tag: div, level: 14" node_number="642"><div title="valid: False, node: 643, tag: div, level: 15" node_number="643">12</div><div title="valid: False, node: 644, tag: div, level: 15" node_number="644"><div title="valid: False, node: 645, tag: div, level: 16" node_number="645"><div title="valid: False, node: 646, tag: div, level: 17" node_number="646">K. Anand, J. Ziebuhr, P. Wadhwani, J. R. Mesters, R. Hilgenfeld, Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science <b title="valid: False, node: 647, tag: b, level: 18" node_number="647">300</b>, 1763&#8211;1767 (2003).</div><div title="valid: False, node: 648, tag: div, level: 17" node_number="648"><div title="valid: False, node: 649, tag: div, level: 18" node_number="649"><a title="valid: False, node: 650, tag: a, level: 19" node_number="650">Crossref</a></div><div title="valid: False, node: 651, tag: div, level: 18" node_number="651"><a title="valid: False, node: 652, tag: a, level: 19" node_number="652">PubMed</a></div><div title="valid: False, node: 653, tag: div, level: 18" node_number="653"><a title="valid: False, node: 654, tag: a, level: 19" node_number="654">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 655, tag: div, level: 14" node_number="655"><div title="valid: False, node: 656, tag: div, level: 15" node_number="656">13</div><div title="valid: False, node: 657, tag: div, level: 15" node_number="657"><div title="valid: False, node: 658, tag: div, level: 16" node_number="658"><div title="valid: False, node: 659, tag: div, level: 17" node_number="659">L. Zhang, D. Lin, Y. Kusov, Y. Nian, Q. Ma, J. Wang, A. von Brunn, P. Leyssen, K. Lanko, J. Neyts, A. de Wilde, E. J. Snijder, H. Liu, R. Hilgenfeld, &#945;-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment. J. Med. Chem. <b title="valid: False, node: 660, tag: b, level: 18" node_number="660">63</b>, 4562&#8211;4578 (2020).</div><div title="valid: False, node: 661, tag: div, level: 17" node_number="661"><div title="valid: False, node: 662, tag: div, level: 18" node_number="662"><a title="valid: False, node: 663, tag: a, level: 19" node_number="663">Crossref</a></div><div title="valid: False, node: 664, tag: div, level: 18" node_number="664"><a title="valid: False, node: 665, tag: a, level: 19" node_number="665">PubMed</a></div><div title="valid: False, node: 666, tag: div, level: 18" node_number="666"><a title="valid: False, node: 667, tag: a, level: 19" node_number="667">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 668, tag: div, level: 14" node_number="668"><div title="valid: False, node: 669, tag: div, level: 15" node_number="669">14</div><div title="valid: False, node: 670, tag: div, level: 15" node_number="670"><div title="valid: False, node: 671, tag: div, level: 16" node_number="671"><div title="valid: False, node: 672, tag: div, level: 17" node_number="672">A. K. Ghosh, H. L. Osswald, G. Prato, Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med. Chem. <b title="valid: False, node: 673, tag: b, level: 18" node_number="673">59</b>, 5172&#8211;5208 (2016).</div><div title="valid: False, node: 674, tag: div, level: 17" node_number="674"><div title="valid: False, node: 675, tag: div, level: 18" node_number="675"><a title="valid: False, node: 676, tag: a, level: 19" node_number="676">Crossref</a></div><div title="valid: False, node: 677, tag: div, level: 18" node_number="677"><a title="valid: False, node: 678, tag: a, level: 19" node_number="678">PubMed</a></div><div title="valid: False, node: 679, tag: div, level: 18" node_number="679"><a title="valid: False, node: 680, tag: a, level: 19" node_number="680">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 681, tag: div, level: 14" node_number="681"><div title="valid: False, node: 682, tag: div, level: 15" node_number="682">15</div><div title="valid: False, node: 683, tag: div, level: 15" node_number="683"><div title="valid: False, node: 684, tag: div, level: 16" node_number="684"><div title="valid: False, node: 685, tag: div, level: 17" node_number="685">R. Cannalire, M. L. Barreca, G. Manfroni, V. Cecchetti, A journey around the medicinal chemistry of Hepatitis C virus inhibitors targeting NS4B: From target to preclinical drug candidates. J. Med. Chem. <b title="valid: False, node: 686, tag: b, level: 18" node_number="686">59</b>, 16&#8211;41 (2016).</div><div title="valid: False, node: 687, tag: div, level: 17" node_number="687"><div title="valid: False, node: 688, tag: div, level: 18" node_number="688"><a title="valid: False, node: 689, tag: a, level: 19" node_number="689">Crossref</a></div><div title="valid: False, node: 690, tag: div, level: 18" node_number="690"><a title="valid: False, node: 691, tag: a, level: 19" node_number="691">PubMed</a></div><div title="valid: False, node: 692, tag: div, level: 18" node_number="692"><a title="valid: False, node: 693, tag: a, level: 19" node_number="693">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 694, tag: div, level: 14" node_number="694"><div title="valid: False, node: 695, tag: div, level: 15" node_number="695">16</div><div title="valid: False, node: 696, tag: div, level: 15" node_number="696"><div title="valid: False, node: 697, tag: div, level: 16" node_number="697"><div title="valid: False, node: 698, tag: div, level: 17" node_number="698">J. Qiao, Y.-S. Li, R. Zeng, F.-L. Liu, R.-H. Luo, C. Huang, Y.-F. Wang, J. Zhang, B. Quan, C. Shen, X. Mao, X. Liu, W. Sun, W. Yang, X. Ni, K. Wang, L. Xu, Z.-L. Duan, Q.-C. Zou, H.-L. Zhang, W. Qu, Y.-H.-P. Long, M.-H. Li, R.-C. Yang, X. Liu, J. You, Y. Zhou, R. Yao, W.-P. Li, J.-M. Liu, P. Chen, Y. Liu, G.-F. Lin, X. Yang, J. Zou, L. Li, Y. Hu, G.-W. Lu, W.-M. Li, Y.-Q. Wei, Y.-T. Zheng, J. Lei, S. Yang, SARS-CoV-2 M<sup title="valid: False, node: 699, tag: sup, level: 18" node_number="699">pro</sup> inhibitors with antiviral activity in a transgenic mouse model. Science <b title="valid: False, node: 700, tag: b, level: 18" node_number="700">371</b>, 1374&#8211;1378 (2021).</div><div title="valid: False, node: 701, tag: div, level: 17" node_number="701"><div title="valid: False, node: 702, tag: div, level: 18" node_number="702"><a title="valid: False, node: 703, tag: a, level: 19" node_number="703">Crossref</a></div><div title="valid: False, node: 704, tag: div, level: 18" node_number="704"><a title="valid: False, node: 705, tag: a, level: 19" node_number="705">PubMed</a></div><div title="valid: False, node: 706, tag: div, level: 18" node_number="706"><a title="valid: False, node: 707, tag: a, level: 19" node_number="707">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 708, tag: div, level: 14" node_number="708"><div title="valid: False, node: 709, tag: div, level: 15" node_number="709">17</div><div title="valid: False, node: 710, tag: div, level: 15" node_number="710"><div title="valid: False, node: 711, tag: div, level: 16" node_number="711"><div title="valid: False, node: 712, tag: div, level: 17" node_number="712">R. L. Hoffman, R. S. Kania, M. A. Brothers, J. F. Davies, R. A. Ferre, K. S. Gajiwala, M. He, R. J. Hogan, K. Kozminski, L. Y. Li, J. W. Lockner, J. Lou, M. T. Marra, L. J. Mitchell Jr., B. W. Murray, J. A. Nieman, S. Noell, S. P. Planken, T. Rowe, K. Ryan, G. J. Smith 3rd, J. E. Solowiej, C. M. Steppan, B. Taggart, Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. <b title="valid: False, node: 713, tag: b, level: 18" node_number="713">63</b>, 12725&#8211;12747 (2020).</div><div title="valid: False, node: 714, tag: div, level: 17" node_number="714"><div title="valid: False, node: 715, tag: div, level: 18" node_number="715"><a title="valid: False, node: 716, tag: a, level: 19" node_number="716">Crossref</a></div><div title="valid: False, node: 717, tag: div, level: 18" node_number="717"><a title="valid: False, node: 718, tag: a, level: 19" node_number="718">PubMed</a></div><div title="valid: False, node: 719, tag: div, level: 18" node_number="719"><a title="valid: False, node: 720, tag: a, level: 19" node_number="720">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 721, tag: div, level: 14" node_number="721"><div title="valid: False, node: 722, tag: div, level: 15" node_number="722">18</div><div title="valid: False, node: 723, tag: div, level: 15" node_number="723"><div title="valid: False, node: 724, tag: div, level: 16" node_number="724"><div title="valid: False, node: 725, tag: div, level: 17" node_number="725">L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#945;-ketoamide inhibitors. Science <b title="valid: False, node: 726, tag: b, level: 18" node_number="726">368</b>, 409&#8211;412 (2020).</div><div title="valid: False, node: 727, tag: div, level: 17" node_number="727"><div title="valid: False, node: 728, tag: div, level: 18" node_number="728"><a title="valid: False, node: 729, tag: a, level: 19" node_number="729">Crossref</a></div><div title="valid: False, node: 730, tag: div, level: 18" node_number="730"><a title="valid: False, node: 731, tag: a, level: 19" node_number="731">PubMed</a></div><div title="valid: False, node: 732, tag: div, level: 18" node_number="732"><a title="valid: False, node: 733, tag: a, level: 19" node_number="733">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 734, tag: div, level: 14" node_number="734"><div title="valid: False, node: 735, tag: div, level: 15" node_number="735">19</div><div title="valid: False, node: 736, tag: div, level: 15" node_number="736"><div title="valid: False, node: 737, tag: div, level: 16" node_number="737"><div title="valid: False, node: 738, tag: div, level: 17" node_number="738">M. de Vries, A. S. Mohamed, R. A. Prescott, A. M. Valero-Jimenez, L. Desvignes, R. O&#8217;Connor, C. Steppan, J. C. Devlin, E. Ivanova, A. Herrera, A. Schinlever, P. Loose, K. Ruggles, S. B. Koralov, A. S. Anderson, J. Binder, M. Dittmann, A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL<sup title="valid: False, node: 739, tag: sup, level: 18" node_number="739">pro</sup> inhibitor PF-00835231 as a potential new treatment for COVID-19. J. Virol. <b title="valid: False, node: 740, tag: b, level: 18" node_number="740">95</b>, e01819&#8211;e01820 (2021).</div><div title="valid: False, node: 741, tag: div, level: 17" node_number="741"><div title="valid: False, node: 742, tag: div, level: 18" node_number="742"><a title="valid: False, node: 743, tag: a, level: 19" node_number="743">Crossref</a></div><div title="valid: False, node: 744, tag: div, level: 18" node_number="744"><a title="valid: False, node: 745, tag: a, level: 19" node_number="745">PubMed</a></div><div title="valid: False, node: 746, tag: div, level: 18" node_number="746"><a title="valid: False, node: 747, tag: a, level: 19" node_number="747">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 748, tag: div, level: 14" node_number="748"><div title="valid: False, node: 749, tag: div, level: 15" node_number="749">20</div><div title="valid: False, node: 750, tag: div, level: 15" node_number="750"><div title="valid: False, node: 751, tag: div, level: 16" node_number="751"><div title="valid: False, node: 752, tag: div, level: 17" node_number="752">B. Boras, R. M. Jones, B. J. Anson, D. Arenson, L. Aschenbrenner, M. A. Bakowski, N. Beutler, J. Binder, E. Chen, H. Eng, J. Hammond, R. Hoffman, E. P. Kadar, R. Kania, E. Kimoto, M. G. Kirkpatrick, L. Lanyon, E. K. Lendy, J. R. Lillis, S. A. Luthra, C. Ma, S. Noell, R. S. Obach, M. N. O&#8217; Brien, R. O&#8217;Connor, K. Ogilvie, D. Owen, M. Pettersson, M. R. Reese, T. F. Rogers, M. I. Rossulek, J. G. Sathish, C. Steppan, M. Ticehurst, L. W. Updyke, Y. Zhu, J. Wang, A. K. Chatterjee, A. D. Mesecar, A. S. Anderson, C. Allerton, Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv 293498 [Preprint] (2020). <a title="valid: False, node: 753, tag: a, level: 18" node_number="753">https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2</a>.</div><div title="valid: False, node: 754, tag: div, level: 17" node_number="754"><div title="valid: False, node: 755, tag: div, level: 18" node_number="755"><a title="valid: False, node: 756, tag: a, level: 19" node_number="756">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 757, tag: div, level: 14" node_number="757"><div title="valid: False, node: 758, tag: div, level: 15" node_number="758">21</div><div title="valid: False, node: 759, tag: div, level: 15" node_number="759"><div title="valid: False, node: 760, tag: div, level: 16" node_number="760"><div title="valid: False, node: 761, tag: div, level: 17" node_number="761">L. Di, C. Whitney-Pickett, J. P. Umland, H. Zhang, X. Zhang, D. F. Gebhard, Y. Lai, J. J. Federico 3rd, R. E. Davidson, R. Smith, E. L. Reyner, C. Lee, B. Feng, C. Rotter, M. V. Varma, S. Kempshall, K. Fenner, A. F. El-Kattan, T. E. Liston, M. D. Troutman, Development of a new permeability assay using low-efflux MDCKII cells. J. Pharm. Sci. <b title="valid: False, node: 762, tag: b, level: 18" node_number="762">100</b>, 4974&#8211;4985 (2011).</div><div title="valid: False, node: 763, tag: div, level: 17" node_number="763"><div title="valid: False, node: 764, tag: div, level: 18" node_number="764"><a title="valid: False, node: 765, tag: a, level: 19" node_number="765">Crossref</a></div><div title="valid: False, node: 766, tag: div, level: 18" node_number="766"><a title="valid: False, node: 767, tag: a, level: 19" node_number="767">PubMed</a></div><div title="valid: False, node: 768, tag: div, level: 18" node_number="768"><a title="valid: False, node: 769, tag: a, level: 19" node_number="769">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 770, tag: div, level: 14" node_number="770"><div title="valid: False, node: 771, tag: div, level: 15" node_number="771">22</div><div title="valid: False, node: 772, tag: div, level: 15" node_number="772"><div title="valid: False, node: 773, tag: div, level: 16" node_number="773"><div title="valid: False, node: 774, tag: div, level: 17" node_number="774">D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward, K. D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. <b title="valid: False, node: 775, tag: b, level: 18" node_number="775">45</b>, 2615&#8211;2623 (2002).</div><div title="valid: False, node: 776, tag: div, level: 17" node_number="776"><div title="valid: False, node: 777, tag: div, level: 18" node_number="777"><a title="valid: False, node: 778, tag: a, level: 19" node_number="778">Crossref</a></div><div title="valid: False, node: 779, tag: div, level: 18" node_number="779"><a title="valid: False, node: 780, tag: a, level: 19" node_number="780">PubMed</a></div><div title="valid: False, node: 781, tag: div, level: 18" node_number="781"><a title="valid: False, node: 782, tag: a, level: 19" node_number="782">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 783, tag: div, level: 14" node_number="783"><div title="valid: False, node: 784, tag: div, level: 15" node_number="784">23</div><div title="valid: False, node: 785, tag: div, level: 15" node_number="785"><div title="valid: False, node: 786, tag: div, level: 16" node_number="786"><div title="valid: False, node: 787, tag: div, level: 17" node_number="787">J. B. Moon, R. S. Coleman, R. P. Hanzlik, Reversible covalent inhibition of papain by a peptide nitrile. Carbon-13 NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc. <b title="valid: False, node: 788, tag: b, level: 18" node_number="788">108</b>, 1350&#8211;1351 (2002).</div><div title="valid: False, node: 789, tag: div, level: 17" node_number="789"><div title="valid: False, node: 790, tag: div, level: 18" node_number="790"><a title="valid: False, node: 791, tag: a, level: 19" node_number="791">Crossref</a></div><div title="valid: False, node: 792, tag: div, level: 18" node_number="792"><a title="valid: False, node: 793, tag: a, level: 19" node_number="793">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 794, tag: div, level: 14" node_number="794"><div title="valid: False, node: 795, tag: div, level: 15" node_number="795">24</div><div title="valid: False, node: 796, tag: div, level: 15" node_number="796"><div title="valid: False, node: 797, tag: div, level: 16" node_number="797"><div title="valid: False, node: 798, tag: div, level: 17" node_number="798">C.-P. Chuck, C. Chen, Z. Ke, D. Chi-Cheong Wan, H.-F. Chow, K.-B. Wong, Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases. Eur. J. Med. Chem. <b title="valid: False, node: 799, tag: b, level: 18" node_number="799">59</b>, 1&#8211;6 (2013).</div><div title="valid: False, node: 800, tag: div, level: 17" node_number="800"><div title="valid: False, node: 801, tag: div, level: 18" node_number="801"><a title="valid: False, node: 802, tag: a, level: 19" node_number="802">Crossref</a></div><div title="valid: False, node: 803, tag: div, level: 18" node_number="803"><a title="valid: False, node: 804, tag: a, level: 19" node_number="804">PubMed</a></div><div title="valid: False, node: 805, tag: div, level: 18" node_number="805"><a title="valid: False, node: 806, tag: a, level: 19" node_number="806">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 807, tag: div, level: 14" node_number="807"><div title="valid: False, node: 808, tag: div, level: 15" node_number="808">25</div><div title="valid: False, node: 809, tag: div, level: 15" node_number="809"><div title="valid: False, node: 810, tag: div, level: 16" node_number="810"><div title="valid: False, node: 811, tag: div, level: 17" node_number="811">S. Konno, P. Thanigaimalai, T. Yamamoto, K. Nakada, R. Kakiuchi, K. Takayama, Y. Yamazaki, F. Yakushiji, K. Akaji, Y. Kiso, Y. Kawasaki, S. E. Chen, E. Freire, Y. Hayashi, Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety. Bioorg. Med. Chem. <b title="valid: False, node: 812, tag: b, level: 18" node_number="812">21</b>, 412&#8211;424 (2013).</div><div title="valid: False, node: 813, tag: div, level: 17" node_number="813"><div title="valid: False, node: 814, tag: div, level: 18" node_number="814"><a title="valid: False, node: 815, tag: a, level: 19" node_number="815">Crossref</a></div><div title="valid: False, node: 816, tag: div, level: 18" node_number="816"><a title="valid: False, node: 817, tag: a, level: 19" node_number="817">PubMed</a></div><div title="valid: False, node: 818, tag: div, level: 18" node_number="818"><a title="valid: False, node: 819, tag: a, level: 19" node_number="819">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 820, tag: div, level: 14" node_number="820"><div title="valid: False, node: 821, tag: div, level: 15" node_number="821">26</div><div title="valid: False, node: 822, tag: div, level: 15" node_number="822"><div title="valid: False, node: 823, tag: div, level: 16" node_number="823"><div title="valid: False, node: 824, tag: div, level: 17" node_number="824">P. S. Dragovich, R. Zhou, S. E. Webber, T. J. Prins, A. K. Kwok, K. Okano, S. A. Fuhrman, L. S. Zalman, F. C. Maldonado, E. L. Brown, J. W. Meador 3rd, A. K. Patick, C. E. Ford, M. A. Brothers, S. L. Binford, D. A. Matthews, R. A. Ferre, S. T. Worland, Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors. Bioorg. Med. Chem. Lett. <b title="valid: False, node: 825, tag: b, level: 18" node_number="825">10</b>, 45&#8211;48 (2000).</div><div title="valid: False, node: 826, tag: div, level: 17" node_number="826"><div title="valid: False, node: 827, tag: div, level: 18" node_number="827"><a title="valid: False, node: 828, tag: a, level: 19" node_number="828">Crossref</a></div><div title="valid: False, node: 829, tag: div, level: 18" node_number="829"><a title="valid: False, node: 830, tag: a, level: 19" node_number="830">PubMed</a></div><div title="valid: False, node: 831, tag: div, level: 18" node_number="831"><a title="valid: False, node: 832, tag: a, level: 19" node_number="832">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 833, tag: div, level: 14" node_number="833"><div title="valid: False, node: 834, tag: div, level: 15" node_number="834">27</div><div title="valid: False, node: 835, tag: div, level: 15" node_number="835"><div title="valid: False, node: 836, tag: div, level: 16" node_number="836"><div title="valid: False, node: 837, tag: div, level: 17" node_number="837">M. Kato, K. Chiba, A. Hisaka, M. Ishigami, M. Kayama, N. Mizuno, Y. Nagata, S. Takakuwa, Y. Tsukamoto, K. Ueda, H. Kusuhara, K. Ito, Y. Sugiyama, The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab. Pharmacokinet. <b title="valid: False, node: 838, tag: b, level: 18" node_number="838">18</b>, 365&#8211;372 (2003).</div><div title="valid: False, node: 839, tag: div, level: 17" node_number="839"><div title="valid: False, node: 840, tag: div, level: 18" node_number="840"><a title="valid: False, node: 841, tag: a, level: 19" node_number="841">Crossref</a></div><div title="valid: False, node: 842, tag: div, level: 18" node_number="842"><a title="valid: False, node: 843, tag: a, level: 19" node_number="843">PubMed</a></div><div title="valid: False, node: 844, tag: div, level: 18" node_number="844"><a title="valid: False, node: 845, tag: a, level: 19" node_number="845">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 846, tag: div, level: 14" node_number="846"><div title="valid: False, node: 847, tag: div, level: 15" node_number="847">28</div><div title="valid: False, node: 848, tag: div, level: 15" node_number="848"><div title="valid: False, node: 849, tag: div, level: 16" node_number="849"><div title="valid: False, node: 850, tag: div, level: 17" node_number="850">R. L. Walsky, R. S. Obach, Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. <b title="valid: False, node: 851, tag: b, level: 18" node_number="851">32</b>, 647&#8211;660 (2004).</div><div title="valid: False, node: 852, tag: div, level: 17" node_number="852"><div title="valid: False, node: 853, tag: div, level: 18" node_number="853"><a title="valid: False, node: 854, tag: a, level: 19" node_number="854">Crossref</a></div><div title="valid: False, node: 855, tag: div, level: 18" node_number="855"><a title="valid: False, node: 856, tag: a, level: 19" node_number="856">PubMed</a></div><div title="valid: False, node: 857, tag: div, level: 18" node_number="857"><a title="valid: False, node: 858, tag: a, level: 19" node_number="858">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 859, tag: div, level: 14" node_number="859"><div title="valid: False, node: 860, tag: div, level: 15" node_number="860">29</div><div title="valid: False, node: 861, tag: div, level: 15" node_number="861"><div title="valid: False, node: 862, tag: div, level: 16" node_number="862"><div title="valid: False, node: 863, tag: div, level: 17" node_number="863">S. I. Hattori, N. Higashi-Kuwata, H. Hayashi, S. R. Allu, J. Raghavaiah, H. Bulut, D. Das, B. J. Anson, E. K. Lendy, Y. Takamatsu, N. Takamune, N. Kishimoto, K. Murayama, K. Hasegawa, M. Li, D. A. Davis, E. N. Kodama, R. Yarchoan, A. Wlodawer, S. Misumi, A. D. Mesecar, A. K. Ghosh, H. Mitsuya, A small molecule&#160;compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. <b title="valid: False, node: 864, tag: b, level: 18" node_number="864">12</b>, 668 (2021).</div><div title="valid: False, node: 865, tag: div, level: 17" node_number="865"><div title="valid: False, node: 866, tag: div, level: 18" node_number="866"><a title="valid: False, node: 867, tag: a, level: 19" node_number="867">Crossref</a></div><div title="valid: False, node: 868, tag: div, level: 18" node_number="868"><a title="valid: False, node: 869, tag: a, level: 19" node_number="869">PubMed</a></div><div title="valid: False, node: 870, tag: div, level: 18" node_number="870"><a title="valid: False, node: 871, tag: a, level: 19" node_number="871">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 872, tag: div, level: 14" node_number="872"><div title="valid: False, node: 873, tag: div, level: 15" node_number="873">30</div><div title="valid: False, node: 874, tag: div, level: 15" node_number="874"><div title="valid: False, node: 875, tag: div, level: 16" node_number="875"><div title="valid: False, node: 876, tag: div, level: 17" node_number="876">J. Cui, F. Li, Z. L. Shi, Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. <b title="valid: False, node: 877, tag: b, level: 18" node_number="877">17</b>, 181&#8211;192 (2019).</div><div title="valid: False, node: 878, tag: div, level: 17" node_number="878"><div title="valid: False, node: 879, tag: div, level: 18" node_number="879"><a title="valid: False, node: 880, tag: a, level: 19" node_number="880">Crossref</a></div><div title="valid: False, node: 881, tag: div, level: 18" node_number="881"><a title="valid: False, node: 882, tag: a, level: 19" node_number="882">PubMed</a></div><div title="valid: False, node: 883, tag: div, level: 18" node_number="883"><a title="valid: False, node: 884, tag: a, level: 19" node_number="884">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 885, tag: div, level: 14" node_number="885"><div title="valid: False, node: 886, tag: div, level: 15" node_number="886">31</div><div title="valid: False, node: 887, tag: div, level: 15" node_number="887"><div title="valid: False, node: 888, tag: div, level: 16" node_number="888"><div title="valid: False, node: 889, tag: div, level: 17" node_number="889">A. Barilli, R. Visigalli, F. Ferrari, M. Di Lascia, B. Riccardi, P. Puccini, V. Dall&#8217;Asta, B. M. Rotoli, Organic cation transporters (OCTs) in EpiAirway<sup title="valid: False, node: 890, tag: sup, level: 18" node_number="890">TM</sup>, a cellular model of normal human bronchial epithelium. Biomedicines <b title="valid: False, node: 891, tag: b, level: 18" node_number="891">8</b>, 127 (2020).</div><div title="valid: False, node: 892, tag: div, level: 17" node_number="892"><div title="valid: False, node: 893, tag: div, level: 18" node_number="893"><a title="valid: False, node: 894, tag: a, level: 19" node_number="894">Crossref</a></div><div title="valid: False, node: 895, tag: div, level: 18" node_number="895"><a title="valid: False, node: 896, tag: a, level: 19" node_number="896">PubMed</a></div><div title="valid: False, node: 897, tag: div, level: 18" node_number="897"><a title="valid: False, node: 898, tag: a, level: 19" node_number="898">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 899, tag: div, level: 14" node_number="899"><div title="valid: False, node: 900, tag: div, level: 15" node_number="900">32</div><div title="valid: False, node: 901, tag: div, level: 15" node_number="901"><div title="valid: False, node: 902, tag: div, level: 16" node_number="902"><div title="valid: False, node: 903, tag: div, level: 17" node_number="903">M. B. Reddy, P. N. Morcos, S. Le Pogam, Y. Ou, K. Frank, T. Lave, P. Smith, Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob. Agents Chemother. <b title="valid: False, node: 904, tag: b, level: 18" node_number="904">56</b>, 3144&#8211;3156 (2012).</div><div title="valid: False, node: 905, tag: div, level: 17" node_number="905"><div title="valid: False, node: 906, tag: div, level: 18" node_number="906"><a title="valid: False, node: 907, tag: a, level: 19" node_number="907">Crossref</a></div><div title="valid: False, node: 908, tag: div, level: 18" node_number="908"><a title="valid: False, node: 909, tag: a, level: 19" node_number="909">PubMed</a></div><div title="valid: False, node: 910, tag: div, level: 18" node_number="910"><a title="valid: False, node: 911, tag: a, level: 19" node_number="911">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 912, tag: div, level: 14" node_number="912"><div title="valid: False, node: 913, tag: div, level: 15" node_number="913">33</div><div title="valid: False, node: 914, tag: div, level: 15" node_number="914"><div title="valid: False, node: 915, tag: div, level: 16" node_number="915"><div title="valid: False, node: 916, tag: div, level: 17" node_number="916">S. R. Leist, K. H. Dinnon 3rd, A. Sch&#228;fer, L. V. Tse, K. Okuda, Y. J. Hou, A. West, C. E. Edwards, W. Sanders, E. J. Fritch, K. L. Gully, T. Scobey, A. J. Brown, T. P. Sheahan, N. J. Moorman, R. C. Boucher, L. E. Gralinski, S. A. Montgomery, R. S. Baric, A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell <b title="valid: False, node: 917, tag: b, level: 18" node_number="917">183</b>, 1070&#8211;1085.e12 (2020).</div><div title="valid: False, node: 918, tag: div, level: 17" node_number="918"><div title="valid: False, node: 919, tag: div, level: 18" node_number="919"><a title="valid: False, node: 920, tag: a, level: 19" node_number="920">Crossref</a></div><div title="valid: False, node: 921, tag: div, level: 18" node_number="921"><a title="valid: False, node: 922, tag: a, level: 19" node_number="922">PubMed</a></div><div title="valid: False, node: 923, tag: div, level: 18" node_number="923"><a title="valid: False, node: 924, tag: a, level: 19" node_number="924">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 925, tag: div, level: 14" node_number="925"><div title="valid: False, node: 926, tag: div, level: 15" node_number="926">34</div><div title="valid: False, node: 927, tag: div, level: 15" node_number="927"><div title="valid: False, node: 928, tag: div, level: 16" node_number="928"><div title="valid: False, node: 929, tag: div, level: 17" node_number="929">M. J. Banker, T. H. Clark, J. A. Williams, Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. <b title="valid: False, node: 930, tag: b, level: 18" node_number="930">92</b>, 967&#8211;974 (2003).</div><div title="valid: False, node: 931, tag: div, level: 17" node_number="931"><div title="valid: False, node: 932, tag: div, level: 18" node_number="932"><a title="valid: False, node: 933, tag: a, level: 19" node_number="933">Crossref</a></div><div title="valid: False, node: 934, tag: div, level: 18" node_number="934"><a title="valid: False, node: 935, tag: a, level: 19" node_number="935">PubMed</a></div><div title="valid: False, node: 936, tag: div, level: 18" node_number="936"><a title="valid: False, node: 937, tag: a, level: 19" node_number="937">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 938, tag: div, level: 14" node_number="938"><div title="valid: False, node: 939, tag: div, level: 15" node_number="939">35</div><div title="valid: False, node: 940, tag: div, level: 15" node_number="940"><div title="valid: False, node: 941, tag: div, level: 16" node_number="941"><div title="valid: False, node: 942, tag: div, level: 17" node_number="942">K. McKeage, C. M. Perry, S. J. Keam, Darunavir: A review of its use in the management of HIV infection in adults. Drugs <b title="valid: False, node: 943, tag: b, level: 18" node_number="943">69</b>, 477&#8211;503 (2009).</div><div title="valid: False, node: 944, tag: div, level: 17" node_number="944"><div title="valid: False, node: 945, tag: div, level: 18" node_number="945"><a title="valid: False, node: 946, tag: a, level: 19" node_number="946">Crossref</a></div><div title="valid: False, node: 947, tag: div, level: 18" node_number="947"><a title="valid: False, node: 948, tag: a, level: 19" node_number="948">PubMed</a></div><div title="valid: False, node: 949, tag: div, level: 18" node_number="949"><a title="valid: False, node: 950, tag: a, level: 19" node_number="950">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 951, tag: div, level: 14" node_number="951"><div title="valid: False, node: 952, tag: div, level: 15" node_number="952">36</div><div title="valid: False, node: 953, tag: div, level: 15" node_number="953"><div title="valid: False, node: 954, tag: div, level: 16" node_number="954"><div title="valid: False, node: 955, tag: div, level: 17" node_number="955">R. S. Cvetkovic, K. L. Goa, Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs <b title="valid: False, node: 956, tag: b, level: 18" node_number="956">63</b>, 769&#8211;802 (2003).</div><div title="valid: False, node: 957, tag: div, level: 17" node_number="957"><div title="valid: False, node: 958, tag: div, level: 18" node_number="958"><a title="valid: False, node: 959, tag: a, level: 19" node_number="959">Crossref</a></div><div title="valid: False, node: 960, tag: div, level: 18" node_number="960"><a title="valid: False, node: 961, tag: a, level: 19" node_number="961">PubMed</a></div><div title="valid: False, node: 962, tag: div, level: 18" node_number="962"><a title="valid: False, node: 963, tag: a, level: 19" node_number="963">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 964, tag: div, level: 14" node_number="964"><div title="valid: False, node: 965, tag: div, level: 15" node_number="965">37</div><div title="valid: False, node: 966, tag: div, level: 15" node_number="966"><div title="valid: False, node: 967, tag: div, level: 16" node_number="967"><div title="valid: False, node: 968, tag: div, level: 17" node_number="968">A. M. Prior, Y. Kim, S. Weerasekara, M. Moroze, K. R. Alliston, R. A. Uy, W. C. Groutas, K. O. Chang, D. H. Hua, Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors. Bioorg. Med. Chem. Lett. <b title="valid: False, node: 969, tag: b, level: 18" node_number="969">23</b>, 6317&#8211;6320 (2013).</div><div title="valid: False, node: 970, tag: div, level: 17" node_number="970"><div title="valid: False, node: 971, tag: div, level: 18" node_number="971"><a title="valid: False, node: 972, tag: a, level: 19" node_number="972">Crossref</a></div><div title="valid: False, node: 973, tag: div, level: 18" node_number="973"><a title="valid: False, node: 974, tag: a, level: 19" node_number="974">PubMed</a></div><div title="valid: False, node: 975, tag: div, level: 18" node_number="975"><a title="valid: False, node: 976, tag: a, level: 19" node_number="976">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 977, tag: div, level: 14" node_number="977"><div title="valid: False, node: 978, tag: div, level: 15" node_number="978">38</div><div title="valid: False, node: 979, tag: div, level: 15" node_number="979"><div title="valid: False, node: 980, tag: div, level: 16" node_number="980"><div title="valid: False, node: 981, tag: div, level: 17" node_number="981">P. Thanigaimalai, S. Konno, T. Yamamoto, Y. Koiwai, A. Taguchi, K. Takayama, F. Yakushiji, K. Akaji, S. E. Chen, A. Naser-Tavakolian, A. Sch&#246;n, E. Freire, Y. Hayashi, Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies. Eur. J. Med. Chem. <b title="valid: False, node: 982, tag: b, level: 18" node_number="982">68</b>, 372&#8211;384 (2013).</div><div title="valid: False, node: 983, tag: div, level: 17" node_number="983"><div title="valid: False, node: 984, tag: div, level: 18" node_number="984"><a title="valid: False, node: 985, tag: a, level: 19" node_number="985">Crossref</a></div><div title="valid: False, node: 986, tag: div, level: 18" node_number="986"><a title="valid: False, node: 987, tag: a, level: 19" node_number="987">PubMed</a></div><div title="valid: False, node: 988, tag: div, level: 18" node_number="988"><a title="valid: False, node: 989, tag: a, level: 19" node_number="989">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 990, tag: div, level: 14" node_number="990"><div title="valid: False, node: 991, tag: div, level: 15" node_number="991">39</div><div title="valid: False, node: 992, tag: div, level: 15" node_number="992"><div title="valid: False, node: 993, tag: div, level: 16" node_number="993"><div title="valid: False, node: 994, tag: div, level: 17" node_number="994">Use of the IMCA-CAT beamline 17-ID (or 17-BM) at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute.</div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 995, tag: div, level: 14" node_number="995"><div title="valid: False, node: 996, tag: div, level: 15" node_number="996">40</div><div title="valid: False, node: 997, tag: div, level: 15" node_number="997"><div title="valid: False, node: 998, tag: div, level: 16" node_number="998"><div title="valid: False, node: 999, tag: div, level: 17" node_number="999">This research used resources at the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) beamline 17-ID, supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute.</div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1000, tag: div, level: 14" node_number="1000"><div title="valid: False, node: 1001, tag: div, level: 15" node_number="1001">41</div><div title="valid: False, node: 1002, tag: div, level: 15" node_number="1002"><div title="valid: False, node: 1003, tag: div, level: 16" node_number="1003"><div title="valid: False, node: 1004, tag: div, level: 17" node_number="1004">This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357.</div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1005, tag: div, level: 14" node_number="1005"><div title="valid: False, node: 1006, tag: div, level: 15" node_number="1006">42</div><div title="valid: False, node: 1007, tag: div, level: 15" node_number="1007"><div title="valid: False, node: 1008, tag: div, level: 16" node_number="1008"><div title="valid: False, node: 1009, tag: div, level: 17" node_number="1009">C. Vonrhein, C. Flensburg, P. Keller, A. Sharff, O. Smart, W. Paciorek, T. Womack, G. Bricogne, Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. <b title="valid: False, node: 1010, tag: b, level: 18" node_number="1010">67</b>, 293&#8211;302 (2011).</div><div title="valid: False, node: 1011, tag: div, level: 17" node_number="1011"><div title="valid: False, node: 1012, tag: div, level: 18" node_number="1012"><a title="valid: False, node: 1013, tag: a, level: 19" node_number="1013">Crossref</a></div><div title="valid: False, node: 1014, tag: div, level: 18" node_number="1014"><a title="valid: False, node: 1015, tag: a, level: 19" node_number="1015">PubMed</a></div><div title="valid: False, node: 1016, tag: div, level: 18" node_number="1016"><a title="valid: False, node: 1017, tag: a, level: 19" node_number="1017">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1018, tag: div, level: 14" node_number="1018"><div title="valid: False, node: 1019, tag: div, level: 15" node_number="1019">43</div><div title="valid: False, node: 1020, tag: div, level: 15" node_number="1020"><div title="valid: False, node: 1021, tag: div, level: 16" node_number="1021"><div title="valid: False, node: 1022, tag: div, level: 17" node_number="1022">I. J. Tickle, F. C. P. Keller, W. Paciorek, A. Sharff, C. Vonrhein, G. Bricogne, &#8220;STARANISO&#8221; (Global Phasing Ltd., 2018).</div><div title="valid: False, node: 1023, tag: div, level: 17" node_number="1023"><div title="valid: False, node: 1024, tag: div, level: 18" node_number="1024"><a title="valid: False, node: 1025, tag: a, level: 19" node_number="1025">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1026, tag: div, level: 14" node_number="1026"><div title="valid: False, node: 1027, tag: div, level: 15" node_number="1027">44</div><div title="valid: False, node: 1028, tag: div, level: 15" node_number="1028"><div title="valid: False, node: 1029, tag: div, level: 16" node_number="1029"><div title="valid: False, node: 1030, tag: div, level: 17" node_number="1030">G. Bricogne, E. Blanc, M. Brandl, C. Flensburg, P. Keller, W. Paciorek, P. Roversi, A. Sharff, O. S. Smart, C. Vonrhein, T. O. Womack, &#8220;BUSTER version 2.11.4&#8221; (Global Phasing Ltd., 2016).</div><div title="valid: False, node: 1031, tag: div, level: 17" node_number="1031"><div title="valid: False, node: 1032, tag: div, level: 18" node_number="1032"><a title="valid: False, node: 1033, tag: a, level: 19" node_number="1033">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1034, tag: div, level: 14" node_number="1034"><div title="valid: False, node: 1035, tag: div, level: 15" node_number="1035">45</div><div title="valid: False, node: 1036, tag: div, level: 15" node_number="1036"><div title="valid: False, node: 1037, tag: div, level: 16" node_number="1037"><div title="valid: False, node: 1038, tag: div, level: 17" node_number="1038">A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, <i title="valid: False, node: 1039, tag: i, level: 18" node_number="1039">Phaser</i> crystallographic software. J. Appl. Cryst. <b title="valid: False, node: 1040, tag: b, level: 18" node_number="1040">40</b>, 658&#8211;674 (2007).</div><div title="valid: False, node: 1041, tag: div, level: 17" node_number="1041"><div title="valid: False, node: 1042, tag: div, level: 18" node_number="1042"><a title="valid: False, node: 1043, tag: a, level: 19" node_number="1043">Crossref</a></div><div title="valid: False, node: 1044, tag: div, level: 18" node_number="1044"><a title="valid: False, node: 1045, tag: a, level: 19" node_number="1045">PubMed</a></div><div title="valid: False, node: 1046, tag: div, level: 18" node_number="1046"><a title="valid: False, node: 1047, tag: a, level: 19" node_number="1047">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1048, tag: div, level: 14" node_number="1048"><div title="valid: False, node: 1049, tag: div, level: 15" node_number="1049">46</div><div title="valid: False, node: 1050, tag: div, level: 15" node_number="1050"><div title="valid: False, node: 1051, tag: div, level: 16" node_number="1051"><div title="valid: False, node: 1052, tag: div, level: 17" node_number="1052">A. Vagin, A. Teplyakov, Molecular replacement with MOLREP. Acta Crystallogr. <b title="valid: False, node: 1053, tag: b, level: 18" node_number="1053">66</b>, 22&#8211;25 (2010).</div><div title="valid: False, node: 1054, tag: div, level: 17" node_number="1054"><div title="valid: False, node: 1055, tag: div, level: 18" node_number="1055"><a title="valid: False, node: 1056, tag: a, level: 19" node_number="1056">Crossref</a></div><div title="valid: False, node: 1057, tag: div, level: 18" node_number="1057"><a title="valid: False, node: 1058, tag: a, level: 19" node_number="1058">PubMed</a></div><div title="valid: False, node: 1059, tag: div, level: 18" node_number="1059"><a title="valid: False, node: 1060, tag: a, level: 19" node_number="1060">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1061, tag: div, level: 14" node_number="1061"><div title="valid: False, node: 1062, tag: div, level: 15" node_number="1062">47</div><div title="valid: False, node: 1063, tag: div, level: 15" node_number="1063"><div title="valid: False, node: 1064, tag: div, level: 16" node_number="1064"><div title="valid: False, node: 1065, tag: div, level: 17" node_number="1065">M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin, K. S. Wilson, Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. <b title="valid: False, node: 1066, tag: b, level: 18" node_number="1066">67</b>, 235&#8211;242 (2011).</div><div title="valid: False, node: 1067, tag: div, level: 17" node_number="1067"><div title="valid: False, node: 1068, tag: div, level: 18" node_number="1068"><a title="valid: False, node: 1069, tag: a, level: 19" node_number="1069">Crossref</a></div><div title="valid: False, node: 1070, tag: div, level: 18" node_number="1070"><a title="valid: False, node: 1071, tag: a, level: 19" node_number="1071">PubMed</a></div><div title="valid: False, node: 1072, tag: div, level: 18" node_number="1072"><a title="valid: False, node: 1073, tag: a, level: 19" node_number="1073">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1074, tag: div, level: 14" node_number="1074"><div title="valid: False, node: 1075, tag: div, level: 15" node_number="1075">48</div><div title="valid: False, node: 1076, tag: div, level: 15" node_number="1076"><div title="valid: False, node: 1077, tag: div, level: 16" node_number="1077"><div title="valid: False, node: 1078, tag: div, level: 17" node_number="1078">OpenEye Scientific, &#8220;AFITT 2.4.1.2: OpenEye Scientific Software&#8221; (OpenEye Scientific, 2021); <a title="valid: False, node: 1079, tag: a, level: 18" node_number="1079">https://www.eyesopen.com/afitt</a>.</div><div title="valid: False, node: 1080, tag: div, level: 17" node_number="1080"><div title="valid: False, node: 1081, tag: div, level: 18" node_number="1081"><a title="valid: False, node: 1082, tag: a, level: 19" node_number="1082">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1083, tag: div, level: 14" node_number="1083"><div title="valid: False, node: 1084, tag: div, level: 15" node_number="1084">49</div><div title="valid: False, node: 1085, tag: div, level: 15" node_number="1085"><div title="valid: False, node: 1086, tag: div, level: 16" node_number="1086"><div title="valid: False, node: 1087, tag: div, level: 17" node_number="1087">S. Wlodek, A. G. Skillman, A. Nicholls, Automated ligand placement and refinement with a combined force field and shape potential. Acta Crystallogr. D Biol. Crystallogr. <b title="valid: False, node: 1088, tag: b, level: 18" node_number="1088">62</b>, 741&#8211;749 (2006).</div><div title="valid: False, node: 1089, tag: div, level: 17" node_number="1089"><div title="valid: False, node: 1090, tag: div, level: 18" node_number="1090"><a title="valid: False, node: 1091, tag: a, level: 19" node_number="1091">Crossref</a></div><div title="valid: False, node: 1092, tag: div, level: 18" node_number="1092"><a title="valid: False, node: 1093, tag: a, level: 19" node_number="1093">PubMed</a></div><div title="valid: False, node: 1094, tag: div, level: 18" node_number="1094"><a title="valid: False, node: 1095, tag: a, level: 19" node_number="1095">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1096, tag: div, level: 14" node_number="1096"><div title="valid: False, node: 1097, tag: div, level: 15" node_number="1097">50</div><div title="valid: False, node: 1098, tag: div, level: 15" node_number="1098"><div title="valid: False, node: 1099, tag: div, level: 16" node_number="1099"><div title="valid: False, node: 1100, tag: div, level: 17" node_number="1100">P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. <b title="valid: False, node: 1101, tag: b, level: 18" node_number="1101">66</b>, 486&#8211;501 (2010).</div><div title="valid: False, node: 1102, tag: div, level: 17" node_number="1102"><div title="valid: False, node: 1103, tag: div, level: 18" node_number="1103"><a title="valid: False, node: 1104, tag: a, level: 19" node_number="1104">Crossref</a></div><div title="valid: False, node: 1105, tag: div, level: 18" node_number="1105"><a title="valid: False, node: 1106, tag: a, level: 19" node_number="1106">PubMed</a></div><div title="valid: False, node: 1107, tag: div, level: 18" node_number="1107"><a title="valid: False, node: 1108, tag: a, level: 19" node_number="1108">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1109, tag: div, level: 14" node_number="1109"><div title="valid: False, node: 1110, tag: div, level: 15" node_number="1110">51</div><div title="valid: False, node: 1111, tag: div, level: 15" node_number="1111"><div title="valid: False, node: 1112, tag: div, level: 16" node_number="1112"><div title="valid: False, node: 1113, tag: div, level: 17" node_number="1113">M. S. Weiss, R. Hilgenfeld, On the use of the merging R factor as a quality indicator for X-ray data. J. Appl. Cryst. <b title="valid: False, node: 1114, tag: b, level: 18" node_number="1114">30</b>, 203&#8211;205 (1997).</div><div title="valid: False, node: 1115, tag: div, level: 17" node_number="1115"><div title="valid: False, node: 1116, tag: div, level: 18" node_number="1116"><a title="valid: False, node: 1117, tag: a, level: 19" node_number="1117">Crossref</a></div><div title="valid: False, node: 1118, tag: div, level: 18" node_number="1118"><a title="valid: False, node: 1119, tag: a, level: 19" node_number="1119">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1120, tag: div, level: 14" node_number="1120"><div title="valid: False, node: 1121, tag: div, level: 15" node_number="1121">52</div><div title="valid: False, node: 1122, tag: div, level: 15" node_number="1122"><div title="valid: False, node: 1123, tag: div, level: 16" node_number="1123"><div title="valid: False, node: 1124, tag: div, level: 17" node_number="1124">P. A. Karplus, K. Diederichs, Linking crystallographic model and data quality. Science <b title="valid: False, node: 1125, tag: b, level: 18" node_number="1125">336</b>, 1030&#8211;1033 (2012).</div><div title="valid: False, node: 1126, tag: div, level: 17" node_number="1126"><div title="valid: False, node: 1127, tag: div, level: 18" node_number="1127"><a title="valid: False, node: 1128, tag: a, level: 19" node_number="1128">Crossref</a></div><div title="valid: False, node: 1129, tag: div, level: 18" node_number="1129"><a title="valid: False, node: 1130, tag: a, level: 19" node_number="1130">PubMed</a></div><div title="valid: False, node: 1131, tag: div, level: 18" node_number="1131"><a title="valid: False, node: 1132, tag: a, level: 19" node_number="1132">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1133, tag: div, level: 14" node_number="1133"><div title="valid: False, node: 1134, tag: div, level: 15" node_number="1134">53</div><div title="valid: False, node: 1135, tag: div, level: 15" node_number="1135"><div title="valid: False, node: 1136, tag: div, level: 16" node_number="1136"><div title="valid: False, node: 1137, tag: div, level: 17" node_number="1137">A. T. Br&#252;nger, Free R value: Cross-validation in crystallography. Methods Enzymol. <b title="valid: False, node: 1138, tag: b, level: 18" node_number="1138">277</b>, 366&#8211;396 (1997).</div><div title="valid: False, node: 1139, tag: div, level: 17" node_number="1139"><div title="valid: False, node: 1140, tag: div, level: 18" node_number="1140"><a title="valid: False, node: 1141, tag: a, level: 19" node_number="1141">Crossref</a></div><div title="valid: False, node: 1142, tag: div, level: 18" node_number="1142"><a title="valid: False, node: 1143, tag: a, level: 19" node_number="1143">PubMed</a></div><div title="valid: False, node: 1144, tag: div, level: 18" node_number="1144"><a title="valid: False, node: 1145, tag: a, level: 19" node_number="1145">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1146, tag: div, level: 14" node_number="1146"><div title="valid: False, node: 1147, tag: div, level: 15" node_number="1147">54</div><div title="valid: False, node: 1148, tag: div, level: 15" node_number="1148"><div title="valid: False, node: 1149, tag: div, level: 16" node_number="1149"><div title="valid: False, node: 1150, tag: div, level: 17" node_number="1150">V. Grum-Tokars, K. Ratia, A. Begaye, S. C. Baker, A. D. Mesecar, Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery. Virus Res. <b title="valid: False, node: 1151, tag: b, level: 18" node_number="1151">133</b>, 63&#8211;73 (2008).</div><div title="valid: False, node: 1152, tag: div, level: 17" node_number="1152"><div title="valid: False, node: 1153, tag: div, level: 18" node_number="1153"><a title="valid: False, node: 1154, tag: a, level: 19" node_number="1154">Crossref</a></div><div title="valid: False, node: 1155, tag: div, level: 18" node_number="1155"><a title="valid: False, node: 1156, tag: a, level: 19" node_number="1156">PubMed</a></div><div title="valid: False, node: 1157, tag: div, level: 18" node_number="1157"><a title="valid: False, node: 1158, tag: a, level: 19" node_number="1158">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1159, tag: div, level: 14" node_number="1159"><div title="valid: False, node: 1160, tag: div, level: 15" node_number="1160">55</div><div title="valid: False, node: 1161, tag: div, level: 15" node_number="1161"><div title="valid: False, node: 1162, tag: div, level: 16" node_number="1162"><div title="valid: False, node: 1163, tag: div, level: 17" node_number="1163">Y. Kim, S. Lovell, K. C. Tiew, S. R. Mandadapu, K. R. Alliston, K. P. Battaile, W. C. Groutas, K. O. Chang, Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. <b title="valid: False, node: 1164, tag: b, level: 18" node_number="1164">86</b>, 11754&#8211;11762 (2012).</div><div title="valid: False, node: 1165, tag: div, level: 17" node_number="1165"><div title="valid: False, node: 1166, tag: div, level: 18" node_number="1166"><a title="valid: False, node: 1167, tag: a, level: 19" node_number="1167">Crossref</a></div><div title="valid: False, node: 1168, tag: div, level: 18" node_number="1168"><a title="valid: False, node: 1169, tag: a, level: 19" node_number="1169">PubMed</a></div><div title="valid: False, node: 1170, tag: div, level: 18" node_number="1170"><a title="valid: False, node: 1171, tag: a, level: 19" node_number="1171">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1172, tag: div, level: 14" node_number="1172"><div title="valid: False, node: 1173, tag: div, level: 15" node_number="1173">56</div><div title="valid: False, node: 1174, tag: div, level: 15" node_number="1174"><div title="valid: False, node: 1175, tag: div, level: 16" node_number="1175"><div title="valid: False, node: 1176, tag: div, level: 17" node_number="1176">L. J. Reed, H. Muench, A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. <b title="valid: False, node: 1177, tag: b, level: 18" node_number="1177">27</b>, 493&#8211;497 (1938).</div><div title="valid: False, node: 1178, tag: div, level: 17" node_number="1178"><div title="valid: False, node: 1179, tag: div, level: 18" node_number="1179"><a title="valid: False, node: 1180, tag: a, level: 19" node_number="1180">Crossref</a></div><div title="valid: False, node: 1181, tag: div, level: 18" node_number="1181"><a title="valid: False, node: 1182, tag: a, level: 19" node_number="1182">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1183, tag: div, level: 14" node_number="1183"><div title="valid: False, node: 1184, tag: div, level: 15" node_number="1184">57</div><div title="valid: False, node: 1185, tag: div, level: 15" node_number="1185"><div title="valid: False, node: 1186, tag: div, level: 16" node_number="1186"><div title="valid: False, node: 1187, tag: div, level: 17" node_number="1187">R. S. Obach, J. G. Baxter, T. E. Liston, B. M. Silber, B. C. Jones, F. MacIntyre, D. J. Rance, P. Wastall, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. <b title="valid: False, node: 1188, tag: b, level: 18" node_number="1188">283</b>, 46&#8211;58 (1997) doi.</div><div title="valid: False, node: 1189, tag: div, level: 17" node_number="1189"><div title="valid: False, node: 1190, tag: div, level: 18" node_number="1190"><a title="valid: False, node: 1191, tag: a, level: 19" node_number="1191">PubMed</a></div><div title="valid: False, node: 1192, tag: div, level: 18" node_number="1192"><a title="valid: False, node: 1193, tag: a, level: 19" node_number="1193">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1194, tag: div, level: 14" node_number="1194"><div title="valid: False, node: 1195, tag: div, level: 15" node_number="1195">58</div><div title="valid: False, node: 1196, tag: div, level: 15" node_number="1196"><div title="valid: False, node: 1197, tag: div, level: 16" node_number="1197"><div title="valid: False, node: 1198, tag: div, level: 17" node_number="1198">B. Davies, T. Morris, Physiological parameters in laboratory animals and humans. Pharm. Res. <b title="valid: False, node: 1199, tag: b, level: 18" node_number="1199">10</b>, 1093&#8211;1095 (1993).</div><div title="valid: False, node: 1200, tag: div, level: 17" node_number="1200"><div title="valid: False, node: 1201, tag: div, level: 18" node_number="1201"><a title="valid: False, node: 1202, tag: a, level: 19" node_number="1202">Crossref</a></div><div title="valid: False, node: 1203, tag: div, level: 18" node_number="1203"><a title="valid: False, node: 1204, tag: a, level: 19" node_number="1204">PubMed</a></div><div title="valid: False, node: 1205, tag: div, level: 18" node_number="1205"><a title="valid: False, node: 1206, tag: a, level: 19" node_number="1206">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1207, tag: div, level: 14" node_number="1207"><div title="valid: False, node: 1208, tag: div, level: 15" node_number="1208">59</div><div title="valid: False, node: 1209, tag: div, level: 15" node_number="1209"><div title="valid: False, node: 1210, tag: div, level: 16" node_number="1210"><div title="valid: False, node: 1211, tag: div, level: 17" node_number="1211">S. Hamada, S. Sutou, T. Morita, A. Wakata, S. Asanami, S. Hosoya, S. Ozawa, K. Kondo, M. Nakajima, H. Shimada, K. Osawa, Y. Kondo, N. Asano, S. Sato, H. Tamura, N. Yajima, R. Marshall, C. Moore, D. H. Blakey, L. M. Schechtman, J. L. Weaver, D. K. Torous, R. Proudlock, S. Ito, C. Namiki, M. Hayashi, Evaluation of the rodent micronucleus assay by a 28-day treatment protocol: Summary of the 13th Collaborative Study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Environmental Mutagen Society of Japan (JEMS)-Mammalian Mutagenicity Study Group (MMS). Environ. Mol. Mutagen. <b title="valid: False, node: 1212, tag: b, level: 18" node_number="1212">37</b>, 93&#8211;110 (2001).</div><div title="valid: False, node: 1213, tag: div, level: 17" node_number="1213"><div title="valid: False, node: 1214, tag: div, level: 18" node_number="1214"><a title="valid: False, node: 1215, tag: a, level: 19" node_number="1215">Crossref</a></div><div title="valid: False, node: 1216, tag: div, level: 18" node_number="1216"><a title="valid: False, node: 1217, tag: a, level: 19" node_number="1217">PubMed</a></div><div title="valid: False, node: 1218, tag: div, level: 18" node_number="1218"><a title="valid: False, node: 1219, tag: a, level: 19" node_number="1219">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1220, tag: div, level: 14" node_number="1220"><div title="valid: False, node: 1221, tag: div, level: 15" node_number="1221">60</div><div title="valid: False, node: 1222, tag: div, level: 15" node_number="1222"><div title="valid: False, node: 1223, tag: div, level: 16" node_number="1223"><div title="valid: False, node: 1224, tag: div, level: 17" node_number="1224">M. Hayashi, J. T. MacGregor, D. G. Gatehouse, I.-D. Adler, D. H. Blakey, S. D. Dertinger, G. Krishna, T. Morita, A. Russo, S. Sutou, In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring. Environ. Mol. Mutagen. <b title="valid: False, node: 1225, tag: b, level: 18" node_number="1225">35</b>, 234&#8211;252 (2000).</div><div title="valid: False, node: 1226, tag: div, level: 17" node_number="1226"><div title="valid: False, node: 1227, tag: div, level: 18" node_number="1227"><a title="valid: False, node: 1228, tag: a, level: 19" node_number="1228">Crossref</a></div><div title="valid: False, node: 1229, tag: div, level: 18" node_number="1229"><a title="valid: False, node: 1230, tag: a, level: 19" node_number="1230">PubMed</a></div><div title="valid: False, node: 1231, tag: div, level: 18" node_number="1231"><a title="valid: False, node: 1232, tag: a, level: 19" node_number="1232">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1233, tag: div, level: 14" node_number="1233"><div title="valid: False, node: 1234, tag: div, level: 15" node_number="1234">61</div><div title="valid: False, node: 1235, tag: div, level: 15" node_number="1235"><div title="valid: False, node: 1236, tag: div, level: 16" node_number="1236"><div title="valid: False, node: 1237, tag: div, level: 17" node_number="1237">Organisation for Economic Co-operation and Development, &#8220;Test no. 474: Mammalian erythrocyte micronucleus test (OECD, 2016); <a title="valid: False, node: 1238, tag: a, level: 18" node_number="1238">https://www.oecd.org/env/test-no-474-mammalian-erythrocyte-micronucleus-test-9789264264762-en.htm</a>.</div><div title="valid: False, node: 1239, tag: div, level: 17" node_number="1239"><div title="valid: False, node: 1240, tag: div, level: 18" node_number="1240"><a title="valid: False, node: 1241, tag: a, level: 19" node_number="1241">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1242, tag: div, level: 14" node_number="1242"><div title="valid: False, node: 1243, tag: div, level: 15" node_number="1243">62</div><div title="valid: False, node: 1244, tag: div, level: 15" node_number="1244"><div title="valid: False, node: 1245, tag: div, level: 16" node_number="1245"><div title="valid: False, node: 1246, tag: div, level: 17" node_number="1246">International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, &#8220;Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use&#8221; (ICH, 2011); <a title="valid: False, node: 1247, tag: a, level: 18" node_number="1247">https://database.ich.org/sites/default/files/S2%28R1%29%20Guideline.pdf</a>.</div><div title="valid: False, node: 1248, tag: div, level: 17" node_number="1248"><div title="valid: False, node: 1249, tag: div, level: 18" node_number="1249"><a title="valid: False, node: 1250, tag: a, level: 19" node_number="1250">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1251, tag: div, level: 14" node_number="1251"><div title="valid: False, node: 1252, tag: div, level: 15" node_number="1252">63</div><div title="valid: False, node: 1253, tag: div, level: 15" node_number="1253"><div title="valid: False, node: 1254, tag: div, level: 16" node_number="1254"><div title="valid: False, node: 1255, tag: div, level: 17" node_number="1255">S. D. Dertinger, D. K. Torous, K. R. Tometsko, Simple and reliable enumeration of micronucleated reticulocytes with a single-laser flow cytometer. Mutat. Res. <b title="valid: False, node: 1256, tag: b, level: 18" node_number="1256">371</b>, 283&#8211;292 (1996).</div><div title="valid: False, node: 1257, tag: div, level: 17" node_number="1257"><div title="valid: False, node: 1258, tag: div, level: 18" node_number="1258"><a title="valid: False, node: 1259, tag: a, level: 19" node_number="1259">Crossref</a></div><div title="valid: False, node: 1260, tag: div, level: 18" node_number="1260"><a title="valid: False, node: 1261, tag: a, level: 19" node_number="1261">PubMed</a></div><div title="valid: False, node: 1262, tag: div, level: 18" node_number="1262"><a title="valid: False, node: 1263, tag: a, level: 19" node_number="1263">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1264, tag: div, level: 14" node_number="1264"><div title="valid: False, node: 1265, tag: div, level: 15" node_number="1265">64</div><div title="valid: False, node: 1266, tag: div, level: 15" node_number="1266"><div title="valid: False, node: 1267, tag: div, level: 16" node_number="1267"><div title="valid: False, node: 1268, tag: div, level: 17" node_number="1268">M. H. L. Green, W. J. Muriel, Mutagen testing using TRP+ reversion in Escherichia coli. Mutat. Res. <b title="valid: False, node: 1269, tag: b, level: 18" node_number="1269">38</b>, 3&#8211;32 (1976).</div><div title="valid: False, node: 1270, tag: div, level: 17" node_number="1270"><div title="valid: False, node: 1271, tag: div, level: 18" node_number="1271"><a title="valid: False, node: 1272, tag: a, level: 19" node_number="1272">Crossref</a></div><div title="valid: False, node: 1273, tag: div, level: 18" node_number="1273"><a title="valid: False, node: 1274, tag: a, level: 19" node_number="1274">PubMed</a></div><div title="valid: False, node: 1275, tag: div, level: 18" node_number="1275"><a title="valid: False, node: 1276, tag: a, level: 19" node_number="1276">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1277, tag: div, level: 14" node_number="1277"><div title="valid: False, node: 1278, tag: div, level: 15" node_number="1278">65</div><div title="valid: False, node: 1279, tag: div, level: 15" node_number="1279"><div title="valid: False, node: 1280, tag: div, level: 16" node_number="1280"><div title="valid: False, node: 1281, tag: div, level: 17" node_number="1281">D. M. Maron, B. N. Ames, Revised methods for the Salmonella mutagenicity test. Mutat. Res. <b title="valid: False, node: 1282, tag: b, level: 18" node_number="1282">113</b>, 173&#8211;215 (1983).</div><div title="valid: False, node: 1283, tag: div, level: 17" node_number="1283"><div title="valid: False, node: 1284, tag: div, level: 18" node_number="1284"><a title="valid: False, node: 1285, tag: a, level: 19" node_number="1285">Crossref</a></div><div title="valid: False, node: 1286, tag: div, level: 18" node_number="1286"><a title="valid: False, node: 1287, tag: a, level: 19" node_number="1287">PubMed</a></div><div title="valid: False, node: 1288, tag: div, level: 18" node_number="1288"><a title="valid: False, node: 1289, tag: a, level: 19" node_number="1289">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1290, tag: div, level: 14" node_number="1290"><div title="valid: False, node: 1291, tag: div, level: 15" node_number="1291">66</div><div title="valid: False, node: 1292, tag: div, level: 15" node_number="1292"><div title="valid: False, node: 1293, tag: div, level: 16" node_number="1293"><div title="valid: False, node: 1294, tag: div, level: 17" node_number="1294">Organisation for Economic Co-operation and Development, &#8220;Test no. 471: Bacterial reverse mutation test&#8221; (OECD, 2020); <a title="valid: False, node: 1295, tag: a, level: 18" node_number="1295">https://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en</a>.</div><div title="valid: False, node: 1296, tag: div, level: 17" node_number="1296"><div title="valid: False, node: 1297, tag: div, level: 18" node_number="1297"><a title="valid: False, node: 1298, tag: a, level: 19" node_number="1298">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1299, tag: div, level: 14" node_number="1299"><div title="valid: False, node: 1300, tag: div, level: 15" node_number="1300">67</div><div title="valid: False, node: 1301, tag: div, level: 15" node_number="1301"><div title="valid: False, node: 1302, tag: div, level: 16" node_number="1302"><div title="valid: False, node: 1303, tag: div, level: 17" node_number="1303">M. Kirsch-Volders, T. Sofuni, M. Aardema, S. Albertini, D. Eastmond, M. Fenech, M. Ishidate Jr., E. Lorge, H. Norppa, J. Surrall&#233;s, W. von der Hude, A. Wakata, Report from the In Vitro Micronucleus Assay Working Group. Environ. Mol. Mutagen. <b title="valid: False, node: 1304, tag: b, level: 18" node_number="1304">35</b>, 167&#8211;172 (2000).</div><div title="valid: False, node: 1305, tag: div, level: 17" node_number="1305"><div title="valid: False, node: 1306, tag: div, level: 18" node_number="1306"><a title="valid: False, node: 1307, tag: a, level: 19" node_number="1307">Crossref</a></div><div title="valid: False, node: 1308, tag: div, level: 18" node_number="1308"><a title="valid: False, node: 1309, tag: a, level: 19" node_number="1309">PubMed</a></div><div title="valid: False, node: 1310, tag: div, level: 18" node_number="1310"><a title="valid: False, node: 1311, tag: a, level: 19" node_number="1311">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1312, tag: div, level: 14" node_number="1312"><div title="valid: False, node: 1313, tag: div, level: 15" node_number="1313">68</div><div title="valid: False, node: 1314, tag: div, level: 15" node_number="1314"><div title="valid: False, node: 1315, tag: div, level: 16" node_number="1315"><div title="valid: False, node: 1316, tag: div, level: 17" node_number="1316">J. M. Parry, A. Sors, The detection and assessment of the aneugenic potential of environmental chemicals: The European Community Aneuploidy Project. Mutat. Res. <b title="valid: False, node: 1317, tag: b, level: 18" node_number="1317">287</b>, 3&#8211;15 (1993).</div><div title="valid: False, node: 1318, tag: div, level: 17" node_number="1318"><div title="valid: False, node: 1319, tag: div, level: 18" node_number="1319"><a title="valid: False, node: 1320, tag: a, level: 19" node_number="1320">Crossref</a></div><div title="valid: False, node: 1321, tag: div, level: 18" node_number="1321"><a title="valid: False, node: 1322, tag: a, level: 19" node_number="1322">PubMed</a></div><div title="valid: False, node: 1323, tag: div, level: 18" node_number="1323"><a title="valid: False, node: 1324, tag: a, level: 19" node_number="1324">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1325, tag: div, level: 14" node_number="1325"><div title="valid: False, node: 1326, tag: div, level: 15" node_number="1326">69</div><div title="valid: False, node: 1327, tag: div, level: 15" node_number="1327"><div title="valid: False, node: 1328, tag: div, level: 16" node_number="1328"><div title="valid: False, node: 1329, tag: div, level: 17" node_number="1329">Organisation for Economic Co-operation and Development, &#8220;Test no. 487: In vitro mammalian cell micronucleus test&#8221; (OECD, 2016); <a title="valid: False, node: 1330, tag: a, level: 18" node_number="1330">https://www.oecd.org/chemicalsafety/test-no-487-in-vitro-mammalian-cell-micronucleus-test-9789264264861-en.htm</a>.</div><div title="valid: False, node: 1331, tag: div, level: 17" node_number="1331"><div title="valid: False, node: 1332, tag: div, level: 18" node_number="1332"><a title="valid: False, node: 1333, tag: a, level: 19" node_number="1333">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1334, tag: div, level: 14" node_number="1334"><div title="valid: False, node: 1335, tag: div, level: 15" node_number="1335">70</div><div title="valid: False, node: 1336, tag: div, level: 15" node_number="1336"><div title="valid: False, node: 1337, tag: div, level: 16" node_number="1337"><div title="valid: False, node: 1338, tag: div, level: 17" node_number="1338">Y. Cheng, W. H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. <b title="valid: False, node: 1339, tag: b, level: 18" node_number="1339">22</b>, 3099&#8211;3108 (1973).</div><div title="valid: False, node: 1340, tag: div, level: 17" node_number="1340"><div title="valid: False, node: 1341, tag: div, level: 18" node_number="1341"><a title="valid: False, node: 1342, tag: a, level: 19" node_number="1342">Crossref</a></div><div title="valid: False, node: 1343, tag: div, level: 18" node_number="1343"><a title="valid: False, node: 1344, tag: a, level: 19" node_number="1344">PubMed</a></div><div title="valid: False, node: 1345, tag: div, level: 18" node_number="1345"><a title="valid: False, node: 1346, tag: a, level: 19" node_number="1346">Google Scholar</a></div></div></div></div></div></section></div></section><div class="valid" valid="valid" title="valid: True, node: 1347, tag: div, level: 11" node_number="1347"><div class="valid" valid="valid" title="valid: True, node: 1348, tag: div, level: 12" node_number="1348"><header class="valid" valid="valid" title="valid: True, node: 1349, tag: header, level: 13" node_number="1349"><h2 class="valid" valid="valid" title="valid: True, node: 1350, tag: h2, level: 14" node_number="1350">Information Authors</h2></header><section class="valid" valid="valid" title="valid: True, node: 1351, tag: section, level: 13" node_number="1351"><h3 class="valid" valid="valid" title="valid: True, node: 1352, tag: h3, level: 14" node_number="1352">Information</h3><section class="valid" valid="valid" title="valid: True, node: 1353, tag: section, level: 14" node_number="1353"><h4 title="valid: False, node: 1354, tag: h4, level: 15" node_number="1354">Published In</h4><div title="valid: False, node: 1355, tag: div, level: 15" node_number="1355"> <div title="valid: False, node: 1356, tag: div, level: 16" node_number="1356"><div title="valid: False, node: 1357, tag: div, level: 17" node_number="1357">Science</div><div title="valid: False, node: 1358, tag: div, level: 17" node_number="1358">Volume 374 | Issue 657524 December 2021</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1359, tag: section, level: 14" node_number="1359"><h4 title="valid: False, node: 1360, tag: h4, level: 15" node_number="1360">Copyright</h4><div title="valid: False, node: 1361, tag: div, level: 15" node_number="1361">Copyright &#169; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</div><div title="valid: False, node: 1362, tag: div, level: 15" node_number="1362">https://creativecommons.org/licenses/by/4.0/</div><div title="valid: False, node: 1363, tag: div, level: 15" node_number="1363">This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></section><section class="valid" valid="valid" title="valid: True, node: 1364, tag: section, level: 14" node_number="1364"><h4 title="valid: False, node: 1365, tag: h4, level: 15" node_number="1365">Article versions</h4><div title="valid: False, node: 1366, tag: div, level: 15" node_number="1366">You are viewing the most recent version of this article.</div><div title="valid: False, node: 1367, tag: div, level: 15" node_number="1367"><a title="valid: False, node: 1368, tag: a, level: 16" node_number="1368">2 November 2021: Previous PDF (Version 1)</a></div></section><section class="valid" valid="valid" title="valid: True, node: 1369, tag: section, level: 14" node_number="1369"><h4 title="valid: False, node: 1370, tag: h4, level: 15" node_number="1370">Submission history</h4><div title="valid: False, node: 1371, tag: div, level: 15" node_number="1371"><b title="valid: False, node: 1372, tag: b, level: 16" node_number="1372">Received</b>: 15 July 2021</div><div title="valid: False, node: 1373, tag: div, level: 15" node_number="1373"><b title="valid: False, node: 1374, tag: b, level: 16" node_number="1374">Accepted</b>: 28 October 2021</div><div title="valid: False, node: 1375, tag: div, level: 15" node_number="1375"><b title="valid: False, node: 1376, tag: b, level: 16" node_number="1376">Published in print</b>: 24 December 2021</div></section><section class="valid" valid="valid" title="valid: True, node: 1377, tag: section, level: 14" node_number="1377"><h4 title="valid: False, node: 1378, tag: h4, level: 15" node_number="1378">Permissions</h4><div title="valid: False, node: 1379, tag: div, level: 15" node_number="1379">Request permissions for this article.</div><div title="valid: False, node: 1380, tag: div, level: 15" node_number="1380"><a title="valid: False, node: 1381, tag: a, level: 16" node_number="1381">Request Permissions</a></div></section><section class="valid" valid="valid" title="valid: True, node: 1382, tag: section, level: 14" node_number="1382"><h4 title="valid: False, node: 1383, tag: h4, level: 15" node_number="1383">Acknowledgments</h4><div title="valid: False, node: 1384, tag: div, level: 15" node_number="1384">The authors thank the participants of the first-in-human (FIH) study. We would also like to acknowledge the many Pfizer colleagues who have contributed to the COVID-19 oral protease program across a number of disciplines. In particular, we acknowledge S. Sakata, J. Arcari, and J. Zhang for external research resourcing; K. Farley for NMR studies; L. Lanyon for protease panel data; Y. Lian, E. LaChapelle, S. Wright, S. O&#8217;Neil, E. Yang, J. Humphrey, and B. Boscoe for compound synthesis; S. Jenkinson for safety pharmacology data; K. Ryan for structural biology support; E. Collins and C. Allais for FIH-enabling active pharmaceutical ingredient supply; F. Clark for bioanalysis; H. Shi for clinical assay support; G. Nucci and A. Bergman for first-in-human study design and clinical pharmacology; F. Hackman for clinical statistics; S. Toussi for medical monitoring; K. Bartsch for clinical study leadership; S. Pawlak for clinical trial leadership; C. Fredette for clinical trial project management; D. Ding for regulatory documentation support; and M. Dolsten for scientific discussion and advice. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. Extraordinary facility operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on the response to COVID-19, with funding provided by the Coronavirus CARES Act.</div><div title="valid: False, node: 1385, tag: div, level: 15" node_number="1385"><b title="valid: False, node: 1386, tag: b, level: 16" node_number="1386">Funding:</b> This study was sponsored by Pfizer, Inc.</div><div title="valid: False, node: 1387, tag: div, level: 15" node_number="1387"><b title="valid: False, node: 1388, tag: b, level: 16" node_number="1388">Author contributions:</b> Conceptualization: C.M.N.A., A.S.A., D.R.O., M.P.; Formal analysis: L.D., B.B., S.E.G., Q.Y., D.K.R., J.J.N., A.D., R.S.O., R.S.P.S.; Investigation: M.A., S.B., J.C.L., J.L., K.O., L.W., R.F., K.S.G., W.L., R.S.O., D.K.R., S.A.G., L.A., S.N., H.E.; Methodology: J.B.T., Q.Y., M.F.S., P.R.V., M.R.R., M.P., D.R.O., N.C.P., A.C., E.P.K., K.J.C., R.S.P.S.; Project administration: D.R.O., M.R.R., J.B.T., A.S.K., C.M.S., L.U., J.G.S., B.L.H., Y.Z., S.W.M., R.D.C., N.C.P.; Resources: A.D., J.J.N., K.J.C.; Supervision: M.R.R., C.E.S., A.E.S., B.L.H., P.R.V., R.D.C.; Visualization: S.W.M., D.K.R., S.N., B.B., L.A., H.E.; Writing &#8211; original draft: D.R.O., A.S.K., M.F.S., C.M.S., R.D.C., M.R.R., J.G.S., C.M.S., Y.Z.; Writing &#8211; review and editing: D.R.O., A.S.K., M.F.S., A.S.A., C.M.N.A.</div><div title="valid: False, node: 1389, tag: div, level: 15" node_number="1389"><b title="valid: False, node: 1390, tag: b, level: 16" node_number="1390">Competing interests:</b> D.R.O., C.M.N.A., A.S.A., L.A., M.A., S.B., B.B., R.D.C., A.C., K.J.C., A.D., L.D., H.E., R.F., K.S.G., S.E.G., E.P.K., A.S.K., J.C.L., J.L., W.L., S.N., R.S.O., K.O., N.C.P., D.K.R., M.R.R., M.F.S., J.G.S., R.P.S., C.M.S., A.S., J.B.T., L.U., P.R.V., L.W., Q.Y., and Y.Z. are employees of Pfizer and some of the authors are shareholders in Pfizer Inc. S.W.M., J.J.N., and M.P. were employees of Pfizer Inc. during part of this study.</div><div title="valid: False, node: 1391, tag: div, level: 15" node_number="1391"><b title="valid: False, node: 1392, tag: b, level: 16" node_number="1392">Data and materials availability:</b> All nonclinical data are available in the main text or the supplementary materials. X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under accession codes 7RFR, 7RFU, 7RFS, and 7RFW. Individualized <a title="valid: False, node: 1393, tag: a, level: 16" node_number="1393">Fig. 5</a> data and the statistical analysis plan are available on <a title="valid: False, node: 1394, tag: a, level: 16" node_number="1394">www.Figshare.com</a> with the following DOI: 10.25454/pfizer.figshare.16699669. Pfizer compound use requests are processed through the Pure Compound Grants program (see <a title="valid: False, node: 1395, tag: a, level: 16" node_number="1395">https://www.cybergrants.com/pfizer/Research</a>). Pfizer Inc. has applied for patent applications covering PF-07321332 as well as related compounds. A phase 1 clinical trial has been registered at <a title="valid: False, node: 1396, tag: a, level: 16" node_number="1396">www.ClinicalTrials.gov</a> under identifier NCT04756531. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 1397, tag: a, level: 16" node_number="1397">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section></section><section class="valid" valid="valid" title="valid: True, node: 1398, tag: section, level: 13" node_number="1398"><h3 class="valid" valid="valid" title="valid: True, node: 1399, tag: h3, level: 14" node_number="1399">Authors</h3><section class="valid" valid="valid" title="valid: True, node: 1400, tag: section, level: 14" node_number="1400"><h4 title="valid: False, node: 1401, tag: h4, level: 15" node_number="1401">Affiliations</h4><div title="valid: False, node: 1402, tag: div, level: 15" node_number="1402"><div title="valid: False, node: 1403, tag: div, level: 16" node_number="1403">Dafydd R. Owen<sup title="valid: False, node: 1404, tag: sup, level: 17" node_number="1404">*</sup> <a title="valid: False, node: 1405, tag: a, level: 17" node_number="1405">https://orcid.org/0000-0003-3106-7809</a> <a title="valid: False, node: 1406, tag: a, level: 17" node_number="1406">[email&#160;protected]</a></div><div title="valid: False, node: 1407, tag: div, level: 16" node_number="1407"><div title="valid: False, node: 1408, tag: div, level: 17" node_number="1408"><div title="valid: False, node: 1409, tag: div, level: 18" node_number="1409">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1410, tag: div, level: 17" node_number="1410">View all articles by this author</div></div></div><div title="valid: False, node: 1411, tag: div, level: 15" node_number="1411"><div title="valid: False, node: 1412, tag: div, level: 16" node_number="1412">Charlotte M. N. Allerton https://orcid.org/0000-0001-8665-159X</div><div title="valid: False, node: 1413, tag: div, level: 16" node_number="1413"><div title="valid: False, node: 1414, tag: div, level: 17" node_number="1414"><div title="valid: False, node: 1415, tag: div, level: 18" node_number="1415">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1416, tag: div, level: 17" node_number="1416">View all articles by this author</div></div></div><div title="valid: False, node: 1417, tag: div, level: 15" node_number="1417"><div title="valid: False, node: 1418, tag: div, level: 16" node_number="1418">Annaliesa S. Anderson</div><div title="valid: False, node: 1419, tag: div, level: 16" node_number="1419"><div title="valid: False, node: 1420, tag: div, level: 17" node_number="1420"><div title="valid: False, node: 1421, tag: div, level: 18" node_number="1421">Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div title="valid: False, node: 1422, tag: div, level: 17" node_number="1422">View all articles by this author</div></div></div><div title="valid: False, node: 1423, tag: div, level: 15" node_number="1423"><div title="valid: False, node: 1424, tag: div, level: 16" node_number="1424">Lisa Aschenbrenner</div><div title="valid: False, node: 1425, tag: div, level: 16" node_number="1425"><div title="valid: False, node: 1426, tag: div, level: 17" node_number="1426"><div title="valid: False, node: 1427, tag: div, level: 18" node_number="1427">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1428, tag: div, level: 17" node_number="1428">View all articles by this author</div></div></div><div title="valid: False, node: 1429, tag: div, level: 15" node_number="1429"><div title="valid: False, node: 1430, tag: div, level: 16" node_number="1430">Melissa Avery</div><div title="valid: False, node: 1431, tag: div, level: 16" node_number="1431"><div title="valid: False, node: 1432, tag: div, level: 17" node_number="1432"><div title="valid: False, node: 1433, tag: div, level: 18" node_number="1433">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1434, tag: div, level: 17" node_number="1434">View all articles by this author</div></div></div><div title="valid: False, node: 1435, tag: div, level: 15" node_number="1435"><div title="valid: False, node: 1436, tag: div, level: 16" node_number="1436">Simon Berritt https://orcid.org/0000-0001-5572-6771</div><div title="valid: False, node: 1437, tag: div, level: 16" node_number="1437"><div title="valid: False, node: 1438, tag: div, level: 17" node_number="1438"><div title="valid: False, node: 1439, tag: div, level: 18" node_number="1439">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1440, tag: div, level: 17" node_number="1440">View all articles by this author</div></div></div><div title="valid: False, node: 1441, tag: div, level: 15" node_number="1441"><div title="valid: False, node: 1442, tag: div, level: 16" node_number="1442">Britton Boras https://orcid.org/0000-0003-3624-9177</div><div title="valid: False, node: 1443, tag: div, level: 16" node_number="1443"><div title="valid: False, node: 1444, tag: div, level: 17" node_number="1444"><div title="valid: False, node: 1445, tag: div, level: 18" node_number="1445">Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div title="valid: False, node: 1446, tag: div, level: 17" node_number="1446">View all articles by this author</div></div></div><div title="valid: False, node: 1447, tag: div, level: 15" node_number="1447"><div title="valid: False, node: 1448, tag: div, level: 16" node_number="1448">Rhonda D. Cardin</div><div title="valid: False, node: 1449, tag: div, level: 16" node_number="1449"><div title="valid: False, node: 1450, tag: div, level: 17" node_number="1450"><div title="valid: False, node: 1451, tag: div, level: 18" node_number="1451">Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div title="valid: False, node: 1452, tag: div, level: 17" node_number="1452">View all articles by this author</div></div></div><div title="valid: False, node: 1453, tag: div, level: 15" node_number="1453"><div title="valid: False, node: 1454, tag: div, level: 16" node_number="1454">Anthony Carlo</div><div title="valid: False, node: 1455, tag: div, level: 16" node_number="1455"><div title="valid: False, node: 1456, tag: div, level: 17" node_number="1456"><div title="valid: False, node: 1457, tag: div, level: 18" node_number="1457">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1458, tag: div, level: 17" node_number="1458">View all articles by this author</div></div></div><div title="valid: False, node: 1459, tag: div, level: 15" node_number="1459"><div title="valid: False, node: 1460, tag: div, level: 16" node_number="1460">Karen J. Coffman https://orcid.org/0000-0001-6164-7500</div><div title="valid: False, node: 1461, tag: div, level: 16" node_number="1461"><div title="valid: False, node: 1462, tag: div, level: 17" node_number="1462"><div title="valid: False, node: 1463, tag: div, level: 18" node_number="1463">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1464, tag: div, level: 17" node_number="1464">View all articles by this author</div></div></div><div title="valid: False, node: 1465, tag: div, level: 15" node_number="1465"><div title="valid: False, node: 1466, tag: div, level: 16" node_number="1466">Alyssa Dantonio</div><div title="valid: False, node: 1467, tag: div, level: 16" node_number="1467"><div title="valid: False, node: 1468, tag: div, level: 17" node_number="1468"><div title="valid: False, node: 1469, tag: div, level: 18" node_number="1469">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1470, tag: div, level: 17" node_number="1470">View all articles by this author</div></div></div><div title="valid: False, node: 1471, tag: div, level: 15" node_number="1471"><div title="valid: False, node: 1472, tag: div, level: 16" node_number="1472">Li Di https://orcid.org/0000-0001-6117-9022</div><div title="valid: False, node: 1473, tag: div, level: 16" node_number="1473"><div title="valid: False, node: 1474, tag: div, level: 17" node_number="1474"><div title="valid: False, node: 1475, tag: div, level: 18" node_number="1475">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1476, tag: div, level: 17" node_number="1476">View all articles by this author</div></div></div><div title="valid: False, node: 1477, tag: div, level: 15" node_number="1477"><div title="valid: False, node: 1478, tag: div, level: 16" node_number="1478">Heather Eng https://orcid.org/0000-0002-2914-3967</div><div title="valid: False, node: 1479, tag: div, level: 16" node_number="1479"><div title="valid: False, node: 1480, tag: div, level: 17" node_number="1480"><div title="valid: False, node: 1481, tag: div, level: 18" node_number="1481">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1482, tag: div, level: 17" node_number="1482">View all articles by this author</div></div></div><div title="valid: False, node: 1483, tag: div, level: 15" node_number="1483"><div title="valid: False, node: 1484, tag: div, level: 16" node_number="1484">RoseAnn Ferre https://orcid.org/0000-0001-7462-1879</div><div title="valid: False, node: 1485, tag: div, level: 16" node_number="1485"><div title="valid: False, node: 1486, tag: div, level: 17" node_number="1486"><div title="valid: False, node: 1487, tag: div, level: 18" node_number="1487">Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div title="valid: False, node: 1488, tag: div, level: 17" node_number="1488">View all articles by this author</div></div></div><div title="valid: False, node: 1489, tag: div, level: 15" node_number="1489"><div title="valid: False, node: 1490, tag: div, level: 16" node_number="1490">Ketan S. Gajiwala</div><div title="valid: False, node: 1491, tag: div, level: 16" node_number="1491"><div title="valid: False, node: 1492, tag: div, level: 17" node_number="1492"><div title="valid: False, node: 1493, tag: div, level: 18" node_number="1493">Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div title="valid: False, node: 1494, tag: div, level: 17" node_number="1494">View all articles by this author</div></div></div><div title="valid: False, node: 1495, tag: div, level: 15" node_number="1495"><div title="valid: False, node: 1496, tag: div, level: 16" node_number="1496">Scott A. Gibson</div><div title="valid: False, node: 1497, tag: div, level: 16" node_number="1497"><div title="valid: False, node: 1498, tag: div, level: 17" node_number="1498"><div title="valid: False, node: 1499, tag: div, level: 18" node_number="1499">Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA.</div></div><div title="valid: False, node: 1500, tag: div, level: 17" node_number="1500">View all articles by this author</div></div></div><div title="valid: False, node: 1501, tag: div, level: 15" node_number="1501"><div title="valid: False, node: 1502, tag: div, level: 16" node_number="1502">Samantha E. Greasley https://orcid.org/0000-0002-7978-6477</div><div title="valid: False, node: 1503, tag: div, level: 16" node_number="1503"><div title="valid: False, node: 1504, tag: div, level: 17" node_number="1504"><div title="valid: False, node: 1505, tag: div, level: 18" node_number="1505">Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div title="valid: False, node: 1506, tag: div, level: 17" node_number="1506">View all articles by this author</div></div></div><div title="valid: False, node: 1507, tag: div, level: 15" node_number="1507"><div title="valid: False, node: 1508, tag: div, level: 16" node_number="1508">Brett L. Hurst https://orcid.org/0000-0003-1025-5878</div><div title="valid: False, node: 1509, tag: div, level: 16" node_number="1509"><div title="valid: False, node: 1510, tag: div, level: 17" node_number="1510"><div title="valid: False, node: 1511, tag: div, level: 18" node_number="1511">Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA.</div></div><div title="valid: False, node: 1512, tag: div, level: 17" node_number="1512">View all articles by this author</div></div></div><div title="valid: False, node: 1513, tag: div, level: 15" node_number="1513"><div title="valid: False, node: 1514, tag: div, level: 16" node_number="1514">Eugene P. Kadar https://orcid.org/0000-0003-3724-6517</div><div title="valid: False, node: 1515, tag: div, level: 16" node_number="1515"><div title="valid: False, node: 1516, tag: div, level: 17" node_number="1516"><div title="valid: False, node: 1517, tag: div, level: 18" node_number="1517">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1518, tag: div, level: 17" node_number="1518">View all articles by this author</div></div></div><div title="valid: False, node: 1519, tag: div, level: 15" node_number="1519"><div title="valid: False, node: 1520, tag: div, level: 16" node_number="1520">Amit S. Kalgutkar https://orcid.org/0000-0001-9701-756X</div><div title="valid: False, node: 1521, tag: div, level: 16" node_number="1521"><div title="valid: False, node: 1522, tag: div, level: 17" node_number="1522"><div title="valid: False, node: 1523, tag: div, level: 18" node_number="1523">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1524, tag: div, level: 17" node_number="1524">View all articles by this author</div></div></div><div title="valid: False, node: 1525, tag: div, level: 15" node_number="1525"><div title="valid: False, node: 1526, tag: div, level: 16" node_number="1526">Jack C. Lee</div><div title="valid: False, node: 1527, tag: div, level: 16" node_number="1527"><div title="valid: False, node: 1528, tag: div, level: 17" node_number="1528"><div title="valid: False, node: 1529, tag: div, level: 18" node_number="1529">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1530, tag: div, level: 17" node_number="1530">View all articles by this author</div></div></div><div title="valid: False, node: 1531, tag: div, level: 15" node_number="1531"><div title="valid: False, node: 1532, tag: div, level: 16" node_number="1532">Jisun Lee https://orcid.org/0000-0003-1750-0063</div><div title="valid: False, node: 1533, tag: div, level: 16" node_number="1533"><div title="valid: False, node: 1534, tag: div, level: 17" node_number="1534"><div title="valid: False, node: 1535, tag: div, level: 18" node_number="1535">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1536, tag: div, level: 17" node_number="1536">View all articles by this author</div></div></div><div title="valid: False, node: 1537, tag: div, level: 15" node_number="1537"><div title="valid: False, node: 1538, tag: div, level: 16" node_number="1538">Wei Liu</div><div title="valid: False, node: 1539, tag: div, level: 16" node_number="1539"><div title="valid: False, node: 1540, tag: div, level: 17" node_number="1540"><div title="valid: False, node: 1541, tag: div, level: 18" node_number="1541">Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div title="valid: False, node: 1542, tag: div, level: 17" node_number="1542">View all articles by this author</div></div></div><div title="valid: False, node: 1543, tag: div, level: 15" node_number="1543"><div title="valid: False, node: 1544, tag: div, level: 16" node_number="1544">Stephen W. Mason</div><div title="valid: False, node: 1545, tag: div, level: 16" node_number="1545"><div title="valid: False, node: 1546, tag: div, level: 17" node_number="1546"><div title="valid: False, node: 1547, tag: div, level: 18" node_number="1547">Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div title="valid: False, node: 1548, tag: div, level: 17" node_number="1548"><div title="valid: False, node: 1549, tag: div, level: 18" node_number="1549">Present address: Janssen Biopharma; South San Francisco, CA 94080, USA.</div></div><div title="valid: False, node: 1550, tag: div, level: 17" node_number="1550">View all articles by this author</div></div></div><div title="valid: False, node: 1551, tag: div, level: 15" node_number="1551"><div title="valid: False, node: 1552, tag: div, level: 16" node_number="1552">Stephen Noell https://orcid.org/0000-0003-3054-2575</div><div title="valid: False, node: 1553, tag: div, level: 16" node_number="1553"><div title="valid: False, node: 1554, tag: div, level: 17" node_number="1554"><div title="valid: False, node: 1555, tag: div, level: 18" node_number="1555">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1556, tag: div, level: 17" node_number="1556">View all articles by this author</div></div></div><div title="valid: False, node: 1557, tag: div, level: 15" node_number="1557"><div title="valid: False, node: 1558, tag: div, level: 16" node_number="1558">Jonathan J. Novak https://orcid.org/0000-0002-3635-7955</div><div title="valid: False, node: 1559, tag: div, level: 16" node_number="1559"><div title="valid: False, node: 1560, tag: div, level: 17" node_number="1560"><div title="valid: False, node: 1561, tag: div, level: 18" node_number="1561">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1562, tag: div, level: 17" node_number="1562"><div title="valid: False, node: 1563, tag: div, level: 18" node_number="1563">Present address: Praxis Precision Medicines; Cambridge, MA 02142, USA.</div></div><div title="valid: False, node: 1564, tag: div, level: 17" node_number="1564">View all articles by this author</div></div></div><div title="valid: False, node: 1565, tag: div, level: 15" node_number="1565"><div title="valid: False, node: 1566, tag: div, level: 16" node_number="1566">R. Scott Obach https://orcid.org/0000-0002-6604-401X</div><div title="valid: False, node: 1567, tag: div, level: 16" node_number="1567"><div title="valid: False, node: 1568, tag: div, level: 17" node_number="1568"><div title="valid: False, node: 1569, tag: div, level: 18" node_number="1569">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1570, tag: div, level: 17" node_number="1570">View all articles by this author</div></div></div><div title="valid: False, node: 1571, tag: div, level: 15" node_number="1571"><div title="valid: False, node: 1572, tag: div, level: 16" node_number="1572">Kevin Ogilvie</div><div title="valid: False, node: 1573, tag: div, level: 16" node_number="1573"><div title="valid: False, node: 1574, tag: div, level: 17" node_number="1574"><div title="valid: False, node: 1575, tag: div, level: 18" node_number="1575">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1576, tag: div, level: 17" node_number="1576">View all articles by this author</div></div></div><div title="valid: False, node: 1577, tag: div, level: 15" node_number="1577"><div title="valid: False, node: 1578, tag: div, level: 16" node_number="1578">Nandini C. Patel https://orcid.org/0000-0002-2735-7662</div><div title="valid: False, node: 1579, tag: div, level: 16" node_number="1579"><div title="valid: False, node: 1580, tag: div, level: 17" node_number="1580"><div title="valid: False, node: 1581, tag: div, level: 18" node_number="1581">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1582, tag: div, level: 17" node_number="1582">View all articles by this author</div></div></div><div title="valid: False, node: 1583, tag: div, level: 15" node_number="1583"><div title="valid: False, node: 1584, tag: div, level: 16" node_number="1584">Martin Pettersson https://orcid.org/0000-0001-8748-9539</div><div title="valid: False, node: 1585, tag: div, level: 16" node_number="1585"><div title="valid: False, node: 1586, tag: div, level: 17" node_number="1586"><div title="valid: False, node: 1587, tag: div, level: 18" node_number="1587">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1588, tag: div, level: 17" node_number="1588"><div title="valid: False, node: 1589, tag: div, level: 18" node_number="1589">Present address: GRT Therapeutics; Cambridge, MA 02142, USA.</div></div><div title="valid: False, node: 1590, tag: div, level: 17" node_number="1590">View all articles by this author</div></div></div><div title="valid: False, node: 1591, tag: div, level: 15" node_number="1591"><div title="valid: False, node: 1592, tag: div, level: 16" node_number="1592">Devendra K. Rai</div><div title="valid: False, node: 1593, tag: div, level: 16" node_number="1593"><div title="valid: False, node: 1594, tag: div, level: 17" node_number="1594"><div title="valid: False, node: 1595, tag: div, level: 18" node_number="1595">Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div title="valid: False, node: 1596, tag: div, level: 17" node_number="1596">View all articles by this author</div></div></div><div title="valid: False, node: 1597, tag: div, level: 15" node_number="1597"><div title="valid: False, node: 1598, tag: div, level: 16" node_number="1598">Matthew R. Reese https://orcid.org/0000-0002-1066-2652</div><div title="valid: False, node: 1599, tag: div, level: 16" node_number="1599"><div title="valid: False, node: 1600, tag: div, level: 17" node_number="1600"><div title="valid: False, node: 1601, tag: div, level: 18" node_number="1601">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1602, tag: div, level: 17" node_number="1602">View all articles by this author</div></div></div><div title="valid: False, node: 1603, tag: div, level: 15" node_number="1603"><div title="valid: False, node: 1604, tag: div, level: 16" node_number="1604">Matthew F. Sammons https://orcid.org/0000-0001-6472-0646</div><div title="valid: False, node: 1605, tag: div, level: 16" node_number="1605"><div title="valid: False, node: 1606, tag: div, level: 17" node_number="1606"><div title="valid: False, node: 1607, tag: div, level: 18" node_number="1607">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1608, tag: div, level: 17" node_number="1608">View all articles by this author</div></div></div><div title="valid: False, node: 1609, tag: div, level: 15" node_number="1609"><div title="valid: False, node: 1610, tag: div, level: 16" node_number="1610">Jean G. Sathish</div><div title="valid: False, node: 1611, tag: div, level: 16" node_number="1611"><div title="valid: False, node: 1612, tag: div, level: 17" node_number="1612"><div title="valid: False, node: 1613, tag: div, level: 18" node_number="1613">Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div title="valid: False, node: 1614, tag: div, level: 17" node_number="1614">View all articles by this author</div></div></div><div title="valid: False, node: 1615, tag: div, level: 15" node_number="1615"><div title="valid: False, node: 1616, tag: div, level: 16" node_number="1616">Ravi Shankar P. Singh https://orcid.org/0000-0001-6298-8219</div><div title="valid: False, node: 1617, tag: div, level: 16" node_number="1617"><div title="valid: False, node: 1618, tag: div, level: 17" node_number="1618"><div title="valid: False, node: 1619, tag: div, level: 18" node_number="1619">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1620, tag: div, level: 17" node_number="1620">View all articles by this author</div></div></div><div title="valid: False, node: 1621, tag: div, level: 15" node_number="1621"><div title="valid: False, node: 1622, tag: div, level: 16" node_number="1622">Claire M. Steppan https://orcid.org/0000-0002-2609-7707</div><div title="valid: False, node: 1623, tag: div, level: 16" node_number="1623"><div title="valid: False, node: 1624, tag: div, level: 17" node_number="1624"><div title="valid: False, node: 1625, tag: div, level: 18" node_number="1625">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1626, tag: div, level: 17" node_number="1626">View all articles by this author</div></div></div><div title="valid: False, node: 1627, tag: div, level: 15" node_number="1627"><div title="valid: False, node: 1628, tag: div, level: 16" node_number="1628">Al E. Stewart</div><div title="valid: False, node: 1629, tag: div, level: 16" node_number="1629"><div title="valid: False, node: 1630, tag: div, level: 17" node_number="1630"><div title="valid: False, node: 1631, tag: div, level: 18" node_number="1631">Pfizer Worldwide Research, Development Medical, La Jolla, CA 92121, USA.</div></div><div title="valid: False, node: 1632, tag: div, level: 17" node_number="1632">View all articles by this author</div></div></div><div title="valid: False, node: 1633, tag: div, level: 15" node_number="1633"><div title="valid: False, node: 1634, tag: div, level: 16" node_number="1634">Jamison B. Tuttle</div><div title="valid: False, node: 1635, tag: div, level: 16" node_number="1635"><div title="valid: False, node: 1636, tag: div, level: 17" node_number="1636"><div title="valid: False, node: 1637, tag: div, level: 18" node_number="1637">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1638, tag: div, level: 17" node_number="1638">View all articles by this author</div></div></div><div title="valid: False, node: 1639, tag: div, level: 15" node_number="1639"><div title="valid: False, node: 1640, tag: div, level: 16" node_number="1640">Lawrence Updyke</div><div title="valid: False, node: 1641, tag: div, level: 16" node_number="1641"><div title="valid: False, node: 1642, tag: div, level: 17" node_number="1642"><div title="valid: False, node: 1643, tag: div, level: 18" node_number="1643">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1644, tag: div, level: 17" node_number="1644">View all articles by this author</div></div></div><div title="valid: False, node: 1645, tag: div, level: 15" node_number="1645"><div title="valid: False, node: 1646, tag: div, level: 16" node_number="1646">Patrick R. Verhoest</div><div title="valid: False, node: 1647, tag: div, level: 16" node_number="1647"><div title="valid: False, node: 1648, tag: div, level: 17" node_number="1648"><div title="valid: False, node: 1649, tag: div, level: 18" node_number="1649">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1650, tag: div, level: 17" node_number="1650">View all articles by this author</div></div></div><div title="valid: False, node: 1651, tag: div, level: 15" node_number="1651"><div title="valid: False, node: 1652, tag: div, level: 16" node_number="1652">Liuqing Wei</div><div title="valid: False, node: 1653, tag: div, level: 16" node_number="1653"><div title="valid: False, node: 1654, tag: div, level: 17" node_number="1654"><div title="valid: False, node: 1655, tag: div, level: 18" node_number="1655">Pfizer Worldwide Research, Development Medical; Groton, CT 06340, USA.</div></div><div title="valid: False, node: 1656, tag: div, level: 17" node_number="1656">View all articles by this author</div></div></div><div title="valid: False, node: 1657, tag: div, level: 15" node_number="1657"><div title="valid: False, node: 1658, tag: div, level: 16" node_number="1658">Qingyi Yang</div><div title="valid: False, node: 1659, tag: div, level: 16" node_number="1659"><div title="valid: False, node: 1660, tag: div, level: 17" node_number="1660"><div title="valid: False, node: 1661, tag: div, level: 18" node_number="1661">Pfizer Worldwide Research, Development Medical, Cambridge, MA 02139, USA.</div></div><div title="valid: False, node: 1662, tag: div, level: 17" node_number="1662">View all articles by this author</div></div></div><div title="valid: False, node: 1663, tag: div, level: 15" node_number="1663"><div title="valid: False, node: 1664, tag: div, level: 16" node_number="1664">Yuao Zhu</div><div title="valid: False, node: 1665, tag: div, level: 16" node_number="1665"><div title="valid: False, node: 1666, tag: div, level: 17" node_number="1666"><div title="valid: False, node: 1667, tag: div, level: 18" node_number="1667">Pfizer Worldwide Research, Development Medical, Pearl River, NY 10965, USA.</div></div><div title="valid: False, node: 1668, tag: div, level: 17" node_number="1668">View all articles by this author</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1669, tag: section, level: 14" node_number="1669"><h4 title="valid: False, node: 1670, tag: h4, level: 15" node_number="1670">Notes</h4><div title="valid: False, node: 1671, tag: div, level: 15" node_number="1671">*Corresponding author. Email: [email&#160;protected]</div></section></section></div><div class="valid" valid="valid" title="valid: True, node: 1672, tag: div, level: 12" node_number="1672"><header class="valid" valid="valid" title="valid: True, node: 1673, tag: header, level: 13" node_number="1673"><h2 class="valid" valid="valid" title="valid: True, node: 1674, tag: h2, level: 14" node_number="1674">Metrics Citations</h2></header><section class="valid" valid="valid" title="valid: True, node: 1675, tag: section, level: 13" node_number="1675"><h3 class="valid" valid="valid" title="valid: True, node: 1676, tag: h3, level: 14" node_number="1676">Metrics</h3><section class="valid" valid="valid" title="valid: True, node: 1677, tag: section, level: 14" node_number="1677"> <h5 title="valid: False, node: 1678, tag: h5, level: 15" node_number="1678"> Article Usage </h5> </section><section class="valid" valid="valid" title="valid: True, node: 1679, tag: section, level: 14" node_number="1679"> <h5 title="valid: False, node: 1680, tag: h5, level: 15" node_number="1680"> Altmetrics </h5> </section></section><section class="valid" valid="valid" title="valid: True, node: 1681, tag: section, level: 13" node_number="1681"><h3 class="valid" valid="valid" title="valid: True, node: 1682, tag: h3, level: 14" node_number="1682">Citations</h3><section class="valid" valid="valid" title="valid: True, node: 1683, tag: section, level: 14" node_number="1683"> <div title="valid: False, node: 1684, tag: div, level: 15" node_number="1684"> <h5 title="valid: False, node: 1685, tag: h5, level: 16" node_number="1685">Export citation</h5> <p title="valid: False, node: 1686, tag: p, level: 16" node_number="1686">Select the format you want to export the citation of this publication.</p> </div> <div title="valid: False, node: 1687, tag: div, level: 15" node_number="1687"> <h5 title="valid: False, node: 1688, tag: h5, level: 16" node_number="1688"> Cited by </h5> <section title="valid: False, node: 1689, tag: section, level: 16" node_number="1689"><div title="valid: False, node: 1690, tag: div, level: 17" node_number="1690"><div title="valid: False, node: 1691, tag: div, level: 18" node_number="1691"><ol title="valid: False, node: 1692, tag: ol, level: 19" node_number="1692"><li title="valid: False, node: 1693, tag: li, level: 20" node_number="1693"><ul title="valid: False, node: 1694, tag: ul, level: 21" node_number="1694"><li title="valid: False, node: 1695, tag: li, level: 22" node_number="1695">Yong Ni, </li><li title="valid: False, node: 1696, tag: li, level: 22" node_number="1696">Jinbiao Liao, </li><li title="valid: False, node: 1697, tag: li, level: 22" node_number="1697">Zhenlong Qian, </li><li title="valid: False, node: 1698, tag: li, level: 22" node_number="1698">Chunxiu Wu, </li><li title="valid: False, node: 1699, tag: li, level: 22" node_number="1699">Xiangyu Zhang, </li><li title="valid: False, node: 1700, tag: li, level: 22" node_number="1700">Ji Zhang, </li><li title="valid: False, node: 1701, tag: li, level: 22" node_number="1701">Youhua Xie, </li><li title="valid: False, node: 1702, tag: li, level: 22" node_number="1702">Sheng Jiang, </li></ul>Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro, Bioorganic Medicinal Chemistry, 53, (116523), (2022).https://doi.org/10.1016/j.bmc.2021.116523<div title="valid: False, node: 1703, tag: div, level: 21" node_number="1703">Crossref</div></li><li title="valid: False, node: 1704, tag: li, level: 20" node_number="1704"><ul title="valid: False, node: 1705, tag: ul, level: 21" node_number="1705"><li title="valid: False, node: 1706, tag: li, level: 22" node_number="1706">Chunlong Ma, </li><li title="valid: False, node: 1707, tag: li, level: 22" node_number="1707">Zilei Xia, </li><li title="valid: False, node: 1708, tag: li, level: 22" node_number="1708">Michael Dominic Sacco, </li><li title="valid: False, node: 1709, tag: li, level: 22" node_number="1709">Yanmei Hu, </li><li title="valid: False, node: 1710, tag: li, level: 22" node_number="1710">Julia Alma Townsend, </li><li title="valid: False, node: 1711, tag: li, level: 22" node_number="1711">Xiangzhi Meng, </li><li title="valid: False, node: 1712, tag: li, level: 22" node_number="1712">Juliana Choza, </li><li title="valid: False, node: 1713, tag: li, level: 22" node_number="1713">Haozhou Tan, </li><li title="valid: False, node: 1714, tag: li, level: 22" node_number="1714">Janice Jang, </li><li title="valid: False, node: 1715, tag: li, level: 22" node_number="1715">Maura V. Gongora, </li><li title="valid: False, node: 1716, tag: li, level: 22" node_number="1716">Xiujun Zhang, </li><li title="valid: False, node: 1717, tag: li, level: 22" node_number="1717">Fushun Zhang, </li><li title="valid: False, node: 1718, tag: li, level: 22" node_number="1718">Yan Xiang, </li><li title="valid: False, node: 1719, tag: li, level: 22" node_number="1719">Michael Thomas Marty, </li><li title="valid: False, node: 1720, tag: li, level: 22" node_number="1720">Yu Chen, </li><li title="valid: False, node: 1721, tag: li, level: 22" node_number="1721">Jun Wang, </li></ul>Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity, Journal of the American Chemical Society, 143, 49, (20697-20709), (2021).https://doi.org/10.1021/jacs.1c08060<div title="valid: False, node: 1722, tag: div, level: 21" node_number="1722">Crossref</div></li><li title="valid: False, node: 1723, tag: li, level: 20" node_number="1723"><ul title="valid: False, node: 1724, tag: ul, level: 21" node_number="1724"><li title="valid: False, node: 1725, tag: li, level: 22" node_number="1725">Chunlong Ma, </li><li title="valid: False, node: 1726, tag: li, level: 22" node_number="1726">Haozhou Tan, </li><li title="valid: False, node: 1727, tag: li, level: 22" node_number="1727">Juliana Choza, </li><li title="valid: False, node: 1728, tag: li, level: 22" node_number="1728">Yuyin Wang, </li><li title="valid: False, node: 1729, tag: li, level: 22" node_number="1729">Jun Wang, </li></ul>Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays, Acta Pharmaceutica Sinica B, (2021).https://doi.org/10.1016/j.apsb.2021.10.026<div title="valid: False, node: 1730, tag: div, level: 21" node_number="1730">Crossref</div></li><li title="valid: False, node: 1731, tag: li, level: 20" node_number="1731"><ul title="valid: False, node: 1732, tag: ul, level: 21" node_number="1732"><li title="valid: False, node: 1733, tag: li, level: 22" node_number="1733">Yuanlin Song, </li><li title="valid: False, node: 1734, tag: li, level: 22" node_number="1734">Fujita Masaki, </li></ul>Preparation for the challenge of heavily mutated Omicron variant, Clinical and Translational Medicine, 11, 12, (2021).https://doi.org/10.1002/ctm2.679<div title="valid: False, node: 1735, tag: div, level: 21" node_number="1735">Crossref</div></li><li title="valid: False, node: 1736, tag: li, level: 20" node_number="1736"><ul title="valid: False, node: 1737, tag: ul, level: 21" node_number="1737"><li title="valid: False, node: 1738, tag: li, level: 22" node_number="1738">Judith M. White, </li><li title="valid: False, node: 1739, tag: li, level: 22" node_number="1739">Joshua T. Schiffer, </li><li title="valid: False, node: 1740, tag: li, level: 22" node_number="1740">Rachel A. Bender Ignacio, </li><li title="valid: False, node: 1741, tag: li, level: 22" node_number="1741">Shuang Xu, </li><li title="valid: False, node: 1742, tag: li, level: 22" node_number="1742">Denis Kainov, </li><li title="valid: False, node: 1743, tag: li, level: 22" node_number="1743">Aleksandr Ianevski, </li><li title="valid: False, node: 1744, tag: li, level: 22" node_number="1744">Tero Aittokallio, </li><li title="valid: False, node: 1745, tag: li, level: 22" node_number="1745">Matthew Frieman, </li><li title="valid: False, node: 1746, tag: li, level: 22" node_number="1746">Gene G. Olinger, </li><li title="valid: False, node: 1747, tag: li, level: 22" node_number="1747">Stephen J. Polyak, </li></ul>Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses, mBio, 12, 6, (2021).https://doi.org/10.1128/mbio.03347-21<div title="valid: False, node: 1748, tag: div, level: 21" node_number="1748">Crossref</div></li><li title="valid: False, node: 1749, tag: li, level: 20" node_number="1749"><ul title="valid: False, node: 1750, tag: ul, level: 21" node_number="1750"><li title="valid: False, node: 1751, tag: li, level: 22" node_number="1751">Maria Yu. Zakharova, </li><li title="valid: False, node: 1752, tag: li, level: 22" node_number="1752">Alexandra A. Kuznetsova, </li><li title="valid: False, node: 1753, tag: li, level: 22" node_number="1753">Victoria I. Uvarova, </li><li title="valid: False, node: 1754, tag: li, level: 22" node_number="1754">Anastasiia D. Fomina, </li><li title="valid: False, node: 1755, tag: li, level: 22" node_number="1755">Liubov I. Kozlovskaya, </li><li title="valid: False, node: 1756, tag: li, level: 22" node_number="1756">Elena N. Kaliberda, </li><li title="valid: False, node: 1757, tag: li, level: 22" node_number="1757">Inna N. Kurbatskaia, </li><li title="valid: False, node: 1758, tag: li, level: 22" node_number="1758">Ivan V. Smirnov, </li><li title="valid: False, node: 1759, tag: li, level: 22" node_number="1759">Anatoly A. Bulygin, </li><li title="valid: False, node: 1760, tag: li, level: 22" node_number="1760">Vera D. Knorre, </li><li title="valid: False, node: 1761, tag: li, level: 22" node_number="1761">Olga S. Fedorova, </li><li title="valid: False, node: 1762, tag: li, level: 22" node_number="1762">Alexandre Varnek, </li><li title="valid: False, node: 1763, tag: li, level: 22" node_number="1763">Dmitry I. Osolodkin, </li><li title="valid: False, node: 1764, tag: li, level: 22" node_number="1764">Aydar A. Ishmukhametov, </li><li title="valid: False, node: 1765, tag: li, level: 22" node_number="1765">Alexey M. Egorov, </li><li title="valid: False, node: 1766, tag: li, level: 22" node_number="1766">Alexander G. Gabibov, </li><li title="valid: False, node: 1767, tag: li, level: 22" node_number="1767">Nikita A. Kuznetsov, </li></ul>Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery, Frontiers in Pharmacology, 12, (2021).https://doi.org/10.3389/fphar.2021.773198<div title="valid: False, node: 1768, tag: div, level: 21" node_number="1768">Crossref</div></li></ol></div><div title="valid: False, node: 1769, tag: div, level: 18" node_number="1769"><div title="valid: False, node: 1770, tag: div, level: 19" node_number="1770">Loading...</div></div></div></section> </div> </section></section></div><div class="valid" valid="valid" title="valid: True, node: 1771, tag: div, level: 12" node_number="1771"><header class="valid" valid="valid" title="valid: True, node: 1772, tag: header, level: 13" node_number="1772"><h2 class="valid" valid="valid" title="valid: True, node: 1773, tag: h2, level: 14" node_number="1773">View Options</h2></header><div class="valid" valid="valid" title="valid: True, node: 1774, tag: div, level: 13" node_number="1774"><h3 class="valid" valid="valid" title="valid: True, node: 1775, tag: h3, level: 14" node_number="1775">View options</h3><section class="valid" valid="valid" title="valid: True, node: 1776, tag: section, level: 14" node_number="1776"><h4 title="valid: False, node: 1777, tag: h4, level: 15" node_number="1777">PDF format</h4><p title="valid: False, node: 1778, tag: p, level: 15" node_number="1778">Download this article as a PDF file</p>Download PDF</section></div><div class="valid" valid="valid" title="valid: True, node: 1779, tag: div, level: 13" node_number="1779"><h3 class="valid" valid="valid" title="valid: True, node: 1780, tag: h3, level: 14" node_number="1780">Get Access</h3><section class="valid" valid="valid" title="valid: True, node: 1781, tag: section, level: 14" node_number="1781"> <div title="valid: False, node: 1782, tag: div, level: 15" node_number="1782"><h5 title="valid: False, node: 1783, tag: h5, level: 16" node_number="1783">Log in to view the full text</h5> <p title="valid: False, node: 1784, tag: p, level: 16" node_number="1784">AAAS Log in</p> <p title="valid: False, node: 1785, tag: p, level: 16" node_number="1785">AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul title="valid: False, node: 1786, tag: ul, level: 16" node_number="1786"> <li title="valid: False, node: 1787, tag: li, level: 17" node_number="1787">Become a AAAS Member</li> <li title="valid: False, node: 1788, tag: li, level: 17" node_number="1788">Activate your Account</li> <li title="valid: False, node: 1789, tag: li, level: 17" node_number="1789">Purchase Access to Other Journals in the Science Family</li> <li title="valid: False, node: 1790, tag: li, level: 17" node_number="1790"><a title="valid: False, node: 1791, tag: a, level: 18" node_number="1791">Account Help</a></li> </ul> <div title="valid: False, node: 1792, tag: div, level: 16" node_number="1792"> <div title="valid: False, node: 1793, tag: div, level: 17" node_number="1793">Log in via OpenAthens. <div title="valid: False, node: 1794, tag: div, level: 18" node_number="1794"><a title="valid: False, node: 1795, tag: a, level: 19" node_number="1795">via OpenAthens</a></div> </div> <div title="valid: False, node: 1796, tag: div, level: 17" node_number="1796">Log in via Shibboleth. <div title="valid: False, node: 1797, tag: div, level: 18" node_number="1797"><a title="valid: False, node: 1798, tag: a, level: 19" node_number="1798">via Shibboleth</a></div> </div> </div> </div> <div title="valid: False, node: 1799, tag: div, level: 15" node_number="1799"><h5 title="valid: False, node: 1800, tag: h5, level: 16" node_number="1800">More options</h5><p title="valid: False, node: 1801, tag: p, level: 16" node_number="1801"><a title="valid: False, node: 1802, tag: a, level: 17" node_number="1802">Purchase digital access to this article</a></p><p title="valid: False, node: 1803, tag: p, level: 16" node_number="1803">Download and print this article for your personal scholarly, research, and educational use.</p><p title="valid: False, node: 1804, tag: p, level: 16" node_number="1804"><a title="valid: False, node: 1805, tag: a, level: 17" node_number="1805">Purchase this issue in print</a></p><p title="valid: False, node: 1806, tag: p, level: 16" node_number="1806">Buy a single issue of Science for just $15 USD.</p></div> </section></div></div><div class="valid" valid="valid" title="valid: True, node: 1807, tag: div, level: 12" node_number="1807"><header class="valid" valid="valid" title="valid: True, node: 1808, tag: header, level: 13" node_number="1808"><h2 class="valid" valid="valid" title="valid: True, node: 1809, tag: h2, level: 14" node_number="1809">Media</h2></header><section class="valid" valid="valid" title="valid: True, node: 1810, tag: section, level: 13" node_number="1810"><h3 class="valid" valid="valid" title="valid: True, node: 1811, tag: h3, level: 14" node_number="1811">Figures</h3></section><section class="valid" valid="valid" title="valid: True, node: 1812, tag: section, level: 13" node_number="1812"><h3 class="valid" valid="valid" title="valid: True, node: 1813, tag: h3, level: 14" node_number="1813">Multimedia</h3></section></div><div class="valid" valid="valid" title="valid: True, node: 1814, tag: div, level: 12" node_number="1814"><header class="valid" valid="valid" title="valid: True, node: 1815, tag: header, level: 13" node_number="1815"><h2 class="valid" valid="valid" title="valid: True, node: 1816, tag: h2, level: 14" node_number="1816">Tables</h2></header></div><div class="valid" valid="valid" title="valid: True, node: 1817, tag: div, level: 12" node_number="1817"><header class="valid" valid="valid" title="valid: True, node: 1818, tag: header, level: 13" node_number="1818"><h2 class="valid" valid="valid" title="valid: True, node: 1819, tag: h2, level: 14" node_number="1819">Share</h2></header><h3 class="valid" valid="valid" title="valid: True, node: 1820, tag: h3, level: 13" node_number="1820">Share</h3><div class="valid" valid="valid" title="valid: True, node: 1821, tag: div, level: 13" node_number="1821"><section class="valid" valid="valid" title="valid: True, node: 1822, tag: section, level: 14" node_number="1822"><h4 title="valid: False, node: 1823, tag: h4, level: 15" node_number="1823">Share article link</h4><div title="valid: False, node: 1824, tag: div, level: 15" node_number="1824"><a title="valid: False, node: 1825, tag: a, level: 16" node_number="1825">Copy Link</a><div title="valid: False, node: 1826, tag: div, level: 16" node_number="1826"><p title="valid: False, node: 1827, tag: p, level: 17" node_number="1827">Copied!</p><p title="valid: False, node: 1828, tag: p, level: 17" node_number="1828">Copying failed.</p></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1829, tag: section, level: 14" node_number="1829"><h4 title="valid: False, node: 1830, tag: h4, level: 15" node_number="1830">Share on social media</h4><div title="valid: False, node: 1831, tag: div, level: 15" node_number="1831"><a title="valid: False, node: 1832, tag: a, level: 16" node_number="1832">facebook</a><a title="valid: False, node: 1833, tag: a, level: 16" node_number="1833">twitter</a><a title="valid: False, node: 1834, tag: a, level: 16" node_number="1834">linkedin</a><a title="valid: False, node: 1835, tag: a, level: 16" node_number="1835">email</a></div></section></div></div></div></article><section class="valid" valid="valid" title="valid: True, node: 1836, tag: section, level: 10" node_number="1836"><div class="valid" valid="valid" title="valid: True, node: 1837, tag: div, level: 11" node_number="1837"><div class="valid" valid="valid" title="valid: True, node: 1838, tag: div, level: 12" node_number="1838"><div class="valid" valid="valid" title="valid: True, node: 1839, tag: div, level: 13" node_number="1839"><div class="valid" valid="valid" title="valid: True, node: 1840, tag: div, level: 14" node_number="1840"><h3 title="valid: False, node: 1841, tag: h3, level: 15" node_number="1841">Submit a Response to This Article</h3></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 1842, tag: div, level: 11" node_number="1842"> <div class="valid" valid="valid" title="valid: True, node: 1843, tag: div, level: 12" node_number="1843"> <h2 class="valid" valid="valid" title="valid: True, node: 1844, tag: h2, level: 13" node_number="1844">(0)eLetters</h2> </div> <p class="valid" valid="valid" title="valid: True, node: 1845, tag: p, level: 12" node_number="1845">eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> Log In to Submit a Response <p class="valid" valid="valid" title="valid: True, node: 1846, tag: p, level: 12" node_number="1846">No eLetters have been published for this article yet.</p> </div> </section> <div class="valid" valid="valid" title="valid: True, node: 1847, tag: div, level: 10" node_number="1847"><a class="valid" valid="valid" title="valid: True, node: 1848, tag: a, level: 11" node_number="1848">View Full Text</a><a class="valid" valid="valid" title="valid: True, node: 1849, tag: a, level: 11" node_number="1849">Download PDF</a></div> </div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1850, tag: div, level: 6" node_number="1850"><div class="valid" valid="valid" title="valid: True, node: 1851, tag: div, level: 7" node_number="1851"><div class="valid" valid="valid" title="valid: True, node: 1852, tag: div, level: 8" node_number="1852"><div class="valid" valid="valid" title="valid: True, node: 1853, tag: div, level: 9" node_number="1853"><section class="valid" valid="valid" title="valid: True, node: 1854, tag: section, level: 10" node_number="1854"><div class="valid" valid="valid" title="valid: True, node: 1855, tag: div, level: 11" node_number="1855"><h4 class="valid" valid="valid" title="valid: True, node: 1856, tag: h4, level: 12" node_number="1856"> Current Issue </h4><div class="valid" valid="valid" title="valid: True, node: 1857, tag: div, level: 12" node_number="1857"><div class="valid" valid="valid" title="valid: True, node: 1858, tag: div, level: 13" node_number="1858"> <div class="valid" valid="valid" title="valid: True, node: 1859, tag: div, level: 14" node_number="1859"><div title="valid: False, node: 1860, tag: div, level: 15" node_number="1860"><article title="valid: False, node: 1861, tag: article, level: 16" node_number="1861"><div title="valid: False, node: 1862, tag: div, level: 17" node_number="1862"><div title="valid: False, node: 1863, tag: div, level: 18" node_number="1863"><h3 title="valid: False, node: 1864, tag: h3, level: 19" node_number="1864"><a title="valid: False, node: 1865, tag: a, level: 20" node_number="1865">Cell-by-cell dissection of phloem development links a maturation gradient to cell specialization</a></h3><ul title="valid: False, node: 1866, tag: ul, level: 19" node_number="1866"><li title="valid: False, node: 1867, tag: li, level: 20" node_number="1867">By<ul title="valid: False, node: 1868, tag: ul, level: 21" node_number="1868"> <li title="valid: False, node: 1869, tag: li, level: 22" node_number="1869">Pawel Roszak</li> <li title="valid: False, node: 1870, tag: li, level: 22" node_number="1870">Jung-ok Heo</li> <li title="valid: False, node: 1871, tag: li, level: 22" node_number="1871">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1872, tag: article, level: 16" node_number="1872"><div title="valid: False, node: 1873, tag: div, level: 17" node_number="1873"><div title="valid: False, node: 1874, tag: div, level: 18" node_number="1874"><h3 title="valid: False, node: 1875, tag: h3, level: 19" node_number="1875">The energetics of uniquely human subsistence strategies</h3><ul title="valid: False, node: 1876, tag: ul, level: 19" node_number="1876"><li title="valid: False, node: 1877, tag: li, level: 20" node_number="1877">By<ul title="valid: False, node: 1878, tag: ul, level: 21" node_number="1878"> <li title="valid: False, node: 1879, tag: li, level: 22" node_number="1879">Thomas S. Kraft</li> <li title="valid: False, node: 1880, tag: li, level: 22" node_number="1880">Vivek V. Venkataraman</li> <li title="valid: False, node: 1881, tag: li, level: 22" node_number="1881">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1882, tag: article, level: 16" node_number="1882"><div title="valid: False, node: 1883, tag: div, level: 17" node_number="1883"><div title="valid: False, node: 1884, tag: div, level: 18" node_number="1884"><h3 title="valid: False, node: 1885, tag: h3, level: 19" node_number="1885">Early giant reveals faster evolution of large body size in ichthyosaurs than in cetaceans</h3><ul title="valid: False, node: 1886, tag: ul, level: 19" node_number="1886"><li title="valid: False, node: 1887, tag: li, level: 20" node_number="1887">By<ul title="valid: False, node: 1888, tag: ul, level: 21" node_number="1888"> <li title="valid: False, node: 1889, tag: li, level: 22" node_number="1889">P. Martin Sander</li> <li title="valid: False, node: 1890, tag: li, level: 22" node_number="1890">Eva Maria Griebeler</li> <li title="valid: False, node: 1891, tag: li, level: 22" node_number="1891">et al.</li> </ul> </li></ul></div></div></article></div><div title="valid: False, node: 1892, tag: div, level: 15" node_number="1892"><a title="valid: False, node: 1893, tag: a, level: 16" node_number="1893">Table of Contents</a></div></div> </div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1894, tag: section, level: 10" node_number="1894"> <h4 class="valid" valid="valid" title="valid: True, node: 1895, tag: h4, level: 11" node_number="1895">LATEST NEWS</h4> <div class="valid" valid="valid" title="valid: True, node: 1896, tag: div, level: 11" node_number="1896"> <div class="valid" valid="valid" title="valid: True, node: 1897, tag: div, level: 12" node_number="1897"><div class="valid" valid="valid" title="valid: True, node: 1898, tag: div, level: 13" node_number="1898"> <article class="valid" valid="valid" title="valid: True, node: 1899, tag: article, level: 14" node_number="1899"> <div title="valid: False, node: 1900, tag: div, level: 15" node_number="1900"> <div title="valid: False, node: 1901, tag: div, level: 16" node_number="1901"> News<time title="valid: False, node: 1902, tag: time, level: 17" node_number="1902">30 Dec 2021</time> </div> <div title="valid: False, node: 1903, tag: div, level: 16" node_number="1903"> Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1904, tag: article, level: 14" node_number="1904"> <div title="valid: False, node: 1905, tag: div, level: 15" node_number="1905"> <div title="valid: False, node: 1906, tag: div, level: 16" node_number="1906"> ScienceInsider<time title="valid: False, node: 1907, tag: time, level: 17" node_number="1907">29 Dec 2021</time> </div> <div title="valid: False, node: 1908, tag: div, level: 16" node_number="1908"> Once a &#8216;crazy idea,&#8217; patent-pooling nonprofit will help bring COVID-19 pills to world&#8217;s poor </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1909, tag: article, level: 14" node_number="1909"> <div title="valid: False, node: 1910, tag: div, level: 15" node_number="1910"> <div title="valid: False, node: 1911, tag: div, level: 16" node_number="1911"> ScienceInsider<time title="valid: False, node: 1912, tag: time, level: 17" node_number="1912">28 Dec 2021</time> </div> <div title="valid: False, node: 1913, tag: div, level: 16" node_number="1913"> The natural world loses two of its biggest advocates </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1914, tag: article, level: 14" node_number="1914"> <div title="valid: False, node: 1915, tag: div, level: 15" node_number="1915"> <div title="valid: False, node: 1916, tag: div, level: 16" node_number="1916"> ScienceInsider<time title="valid: False, node: 1917, tag: time, level: 17" node_number="1917">28 Dec 2021</time> </div> <div title="valid: False, node: 1918, tag: div, level: 16" node_number="1918"> <a title="valid: False, node: 1919, tag: a, level: 17" node_number="1919"> What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1920, tag: article, level: 14" node_number="1920"> <div title="valid: False, node: 1921, tag: div, level: 15" node_number="1921"> <div title="valid: False, node: 1922, tag: div, level: 16" node_number="1922"> ScienceInsider<time title="valid: False, node: 1923, tag: time, level: 17" node_number="1923">25 Dec 2021</time> </div> <div title="valid: False, node: 1924, tag: div, level: 16" node_number="1924"> NASA&#8217;s Webb telescope takes flight&#8212;a Christmas gift to astronomers everywhere </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1925, tag: article, level: 14" node_number="1925"> <div title="valid: False, node: 1926, tag: div, level: 15" node_number="1926"> <div title="valid: False, node: 1927, tag: div, level: 16" node_number="1927"> News<time title="valid: False, node: 1928, tag: time, level: 17" node_number="1928">23 Dec 2021</time> </div> <div title="valid: False, node: 1929, tag: div, level: 16" node_number="1929"> <a title="valid: False, node: 1930, tag: a, level: 17" node_number="1930"> More than a virus: Science&#8217;s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>